Change Healthcare (CHNG) 10-K 4 Jun 20 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2020	Jun. 01, 2020	Sep. 30, 2019
Document Type	10-K
Document Annual Report	true
Current Fiscal Year End Date	--03-31
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Transition Report	false
Entity File Number	001-38961
Entity Registrant Name	Change Healthcare Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-2152098
Entity Address, Address Line One	3055 Lebanon Pike
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Nashville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37214
City Area Code	615
Local Phone Number	932-3000
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		303,526,591
Entity Public Float			$ 597,490,716
Amendment Flag	false
Entity Central Index Key	0001756497
Document Fiscal Period Focus	FY
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement for the 2020 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.
Common Stock [Member]
Title of 12(b) Security	Common Stock, par value $.001 per share
Trading Symbol	CHNG
Security Exchange Name	NASDAQ
Tangible Equity Units [Member]
Title of 12(b) Security	6.00% Tangible Equity Units
Trading Symbol	CHNGU
Security Exchange Name	NASDAQ

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Total revenue	$ 196,792
Operating expenses
Sales, marketing, general and administrative	39,893	$ 1,159	$ 180
Cost of operations (exclusive of depreciation and amortization below)	71,435
Research and development	11,559
Customer postage	12,631
Depreciation and amortization	30,838
Accretion and changes in estimate with related parties, net	15,823
Tax Receivable Agreement charges	164,633
Goodwill impairment charge	561,164
Total operating expenses	907,976	1,159	180
Operating income (loss)	(711,184)	(1,159)	(180)
Non-operating (income) expense
Loss from Equity Method Investment in the Joint Venture	380,713	70,487	58,680
(Gain) Loss on sale of interests in the Joint Venture		(661)	(14)
Management fee income	(1,108)	(378)	(180)
Interest expense, net	16,652
(Gain) loss on other investments	(15,881)
Other, net	(709)
Total non-operating (income) expense	379,667	69,448	58,486
Income (loss) before income tax provision (benefit)	(1,090,851)	(70,607)	(58,666)
Income tax provision (benefit)	(143,254)	(18,595)	(119,621)
Net income (loss)	$ (947,597)	$ (52,012)	$ 60,955
Net income (loss) per share:
Basic	$ (6.92)	$ (0.69)	$ 0.81
Diluted	$ (6.92)	$ (0.69)	$ 0.78
Weighted average common shares outstanding:
Basic	136,996,624	75,513,130	75,590,613
Diluted	136,996,624	75,513,130	77,801,096
Solutions [Member]
Total revenue	$ 184,161
Postage [Member]
Total revenue	$ 12,631

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Consolidated Statements of Comprehensive Income (Loss) [Abstract]
Net income (loss)	$ (947,597)	$ (52,012)	$ 60,955
Other comprehensive income (loss):
Foreign currency translation adjustment	(5,519)	(2,833)	1,242
Changes in fair value of interest rate cap, net of taxes	981	(3,449)	1,606
Unrealized gain (loss) on available for sale debt securities of the Joint Venture, net of taxes	1,045
Realized gain (loss) on available for sale debt securities of the Joint Venture	(1,045)
Other comprehensive income (loss)	(4,538)	(6,282)	2,848
Total comprehensive income (loss)	$ (952,135)	$ (58,294)	$ 63,803

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Current assets:
Cash & cash equivalents	$ 410,405	$ 3,409
Accounts receivable, net of allowance for doubtful accounts	740,105
Contract assets	132,704
Due from Joint Venture		373
Prepaid expenses and other current assets	117,495
Income taxes receivable	472	1,781
Total current assets	1,401,181	5,563
Property and equipment, net	206,196
Goodwill	3,795,325
Intangible assets, net	4,365,806
Dividend receivable		81,264
Investment in the Joint Venture		1,211,996
Investment in business purchase option	146,500
Other noncurrent assets, net	192,372
Total assets	10,107,380	1,298,823
Current liabilities:
Accounts payable	68,169
Accrued expenses	390,294	176
Deferred revenues	302,313
Due to related parties, net	20,234
Current portion of long-term debt	278,779
Due to the Joint Venture		6,167
Total current liabilities	1,059,789	6,343
Long-term debt, excluding current portion	4,710,294
Deferred income tax liabilities	615,904	159,993
Tax receivable agreement obligations to related parties	177,826
Tax receivable agreement obligation	164,633
Other long-term liabilities	93,487
Total liabilities	6,821,933	166,336
Commitments and contingencies
Stockholders' Equity:
Preferred stock (par value, $.001), 900,000,000 and 0 shares authorized and no shares issued and outstanding at March 31, 2020 and 2019, respectively
Additional paid-in capital	4,222,580	1,153,509
Accumulated other comprehensive income (loss)	(7,372)	(3,256)
Accumultaed deficit	(930,064)	(17,841)
Total stockholders' equity	3,285,447	1,132,487
Total liabilities and stockholders' equity	10,107,380	1,298,823
Common Class X [Member]
Stockholders' Equity:
Common Stock
Common Stock [Member]
Stockholders' Equity:
Common Stock	303	75
Total stockholders' equity	$ 303	$ 75

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Mar. 31, 2019
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	900,000,000	0
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Class X [Member]
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	0	1
Common Stock, shares issued	0	0
Common Stock, shares outstanding	0	0
Common Stock [Member]
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	9,000,000,000	252,800,000
Common Stock, shares issued	303,428,142	75,474,654
Common Stock, shares outstanding	303,428,142	75,474,654

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Total
Balance at Mar. 31, 2017	$ 75	$ 1,114,771	$ (26,294)	$ (312)	$ 1,088,240
Balance, shares at Mar. 31, 2017	75,478,369
Equity compensation expense		24,700			24,700
Repurchase of the Company's common stock, net of taxes		(171)			(171)
Repurchase of the Company's common stock, net of taxes, shares	(8,974)
Issuance of the Company's common stock upon initial public offering, shares	279,723
Net income (loss)			60,955		60,955
Foreign currency translation adjustment				1,242	1,242
Changes in fair value of interest rate swap, net of taxes				1,606	1,606
Balance at Mar. 31, 2018	$ 75	1,139,300	34,661	2,536	1,176,572
Balance, shares at Mar. 31, 2018	75,749,118
Equity compensation expense		20,135			20,135
Repurchase of the Company's common stock, net of taxes		(5,926)			(5,926)
Repurchase of the Company's common stock, net of taxes, shares	(342,418)
Issuance of the Company's common stock upon initial public offering, shares	67,953
Net income (loss)			(52,012)		(52,012)
Foreign currency translation adjustment				(2,833)	(2,833)
Changes in fair value of interest rate swap, net of taxes				(3,449)	(3,449)
Balance at Mar. 31, 2019	$ 75	1,153,509	(17,841)	(3,256)	1,132,487
Balance, shares at Mar. 31, 2019	75,474,654
Cumulative effect of accounting change by the Joint Venture | ASU 2017-12 [Member]			(490)	490
Equity compensation expense		30,372			30,372
Issuance of the Company's common stock upon initial public offering	$ 49	608,630			608,679
Issuance of the Company's common stock upon initial public offering, shares	49,285,713
Effect of initial public offering issuance costs on Joint Venture equity		(4,160)			(4,160)
Issuance of tangible equity units		232,929			232,929
Unrealized gain (loss) on available for sale debt securities of the Joint Venture				1,045	1,045
Realized gain (loss) on available for sale debt securities of the Joint Venture				(1,045)	(1,045)
Issuance of the Company's common stock upon exercise of equity awards	$ 1	6,023			6,024
Issuance of the Company's common stock upon exercise of equity awards, shares	708,962
Net income (loss)			(947,597)		(947,597)
Foreign currency translation adjustment				(5,519)	(5,519)
Changes in fair value of interest rate swap, net of taxes				981	981
Issuance of the Company's common stock upon Merger	$ 176	2,194,484			2,194,660
Issuance of the Company's common stock upon Merger, shares	175,995,192
Conversion of tangible equity units	$ 2	(2)
Conversion of tangible equity units, shares	1,963,621
Other		795			795
Balance at Mar. 31, 2020	$ 303	$ 4,222,580	(930,064)	(7,372)	3,285,447
Balance, shares at Mar. 31, 2020	303,428,142
Cumulative effect of accounting change by the Joint Venture | ASC 606 [Member]			35,796		$ 35,796
Cumulative effect of accounting change by the Joint Venture | ASU 2018-02 [Member]			$ (422)	$ 422

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net income (loss)	$ (947,597)	$ (52,012)	$ 60,955
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Loss from Equity Method Investment in the Joint Venture	380,713	70,487	58,680
Depreciation and amortization	30,838
Accretion and changes in estimate, net	15,823
Tax receivable agreement charges	164,633
Equity compensation	1,701
Deferred income tax expense (benefit)	(143,822)	(18,595)	(119,621)
(Gain) Loss on Sale of Interests in the Joint Venture		(661)	(14)
(Gain) loss on other investments	(15,881)
Goodwill impairment charge	561,164
Amortization of debt discount and issuance costs	2,235
Other	(1,110)
Changes in operating assets and liabilities:
Accounts receivable	(21,211)
Prepaid expenses and other	(7,528)
Due from the Joint Venture	(2,516)	(72)	524
Income taxes receivable	1,309	14,047	(15,828)
Accounts payable	7,532
Accrued expenses and other liabilities	(195,207)	(125)	(524)
Deferred Revenue	11,304
Due to the Joint Venture	3,692	(9,661)	15,828
Net cash provided by (used in) operating activities	(153,928)	3,408
Cash flows from investing activities:
Proceeds from sale of interests in Joint Venture		6,503	171
Capitalized expenditures	(13,002)
Acquisitions, net of cash acquired	330,667
Investment in debt and equity securities of the Joint Venture	(278,875)
Proceeds from investments in debt securities of the Joint Venture	7,332
Investment in the Joint Venture	(610,784)
Net cash provided by (used in) investing activities	(564,662)	6,503	171
Cash flows from financing activities:
Proceeds from initial public offering, net of issuance costs	608,679
Proceeds from issuance of equity component of tangible equity units, net of issuance costs	232,929
Proceeds from issuance of debt component of tangible equity units	47,367
Payment of loan costs	(1,421)
Repayment of senior amortizing notes	(11,094)
Proceeds from draw on revolver	250,000
Payments to acquire common stock		(6,502)	(171)
Receipts (payments) on derivative instruments	(890)
Net cash provided by (used in) financing activities	1,125,570	(6,502)	(171)
Effect of exchange rate changes on cash and cash equivalents	16
Net increase (decrease) in cash, cash equivalents and restricted cash	406,996	3,409
Cash, cash equivalents and restricted cash at beginning of period	3,409
Cash, cash equivalents and restricted cash at end of period	410,405	3,409
Supplemental disclosures of cash flow information
Cash paid for interest	265,633
Cash paid for income taxes	(714)		15,828
Issuance of common stock upon exercise of equity awards:
Investment in the Joint Venture	5,077	1,297	5,306
Dividend receivable	(5,077)	(1,297)	(5,306)
Change Healthcare Inc. portion of the Joint Venture equity transactions:
Investment in the Joint Venture	13,902	(2,377)	10,898
Additional paid in capital	(11,133)	(6,043)	(7,427)
Accumulated other comprehensive income	(2,769)	$ 8,420	$ (3,471)
Capitalized Expenditures:
Property and equipment, net	5,295
Other noncurrent assets, net	14,169
Intangibles, net	2,855
Drafts and accounts payable	(9,843)
Accrued expenses	$ (12,476)

Nature of Business and Organiza

Nature of Business and Organization	12 Months Ended
	Mar. 31, 2020
Nature of Business and Organization [Abstract]
Nature of Business and Organization	1. Nature of Business and Organization Business Overview Change Healthcare Inc. (the “ Company”) is an independent healthcare technology platform that provides data and analytics-driven solutions to improve clinical, financial and patient engagement outcomes in the U.S. healthcare system. It offers a suite of software, analytics, technology-enabled services and network solutions that drive improved results in the complex workflows of healthcare system payers and providers. The Company’s solutions are designed to improve clinical decision-making, simplify billing, collection and payment processes and enable a better patient experience. Organization The Company, a Delaware corporation, was formed on June 22, 2016 to hold an equity investment in Change Healthcare LLC (the “Joint Venture”) a joint venture between the Company and McKesson Corporation (“McKesson”). The Transactions In June 2016, the Company, the Joint Venture, Change Healthcare Holdings, LLC, Change Healthcare Intermediate Holdings, LLC, Change Healthcare Performance, Inc. (formerly Change Healthcare, Inc.) (“Legacy CHC”) and its stockholders—including affiliates of The Blackstone Group, L.P. (“Blackstone”) and Hellman & Friedman LLC (“Hellman & Friedman”)—entered into an Agreement of Contribution and Sale (the “Contribution Agreement”) with McKesson Corporation (together with the Company, the “Members”). Under the terms of the Contribution Agreement, the parties agreed to form the Joint Venture, a joint venture that combined the majority of the McKesson Technology Solutions businesses excluding McKesson’s Enterprise Information Solutions business and RelayHealth Pharmacy Network (such contributed businesses, “Core MTS”), with substantially all of the assets and operations of Legacy CHC, but excluding Legacy CHC’s pharmacy claims switching and prescription routing businesses (such excluded business, the “eRx Network” and the businesses contributed by Legacy CHC, together with Core MTS, the “Contributed Businesses”). The creation of the Joint Venture, including the contribution of the Contributed Businesses and related transactions, is collectively referred to as the “Transactions” . The Transactions closed on March 1, 2017. Upon completion of the Transactions, the Company owned approximately 30% of the Joint Venture. Pursuant to the terms of the Contribution Agreement, the Legacy CHC stockholders, directly and indirectly, transferred ownership of substantially all of Legacy CHC to the Joint Venture in consideration of (a) the payment at the closing of the Transactions by the Joint Venture to Legacy CHC’s stockholders and certain participants in the Legacy CHC Amended and Restated 2009 Equity Incentive Plan (the “Legacy CHC Equity Plan”) of approximately $1,800,000 , stock in eRx Network Holdings, Inc., and the 2017 Tax Receivable Agreement (as described in Note 1 8 . Tax Receivable Agreements) and (b) the issuance to the Company of membership interests in the Joint Ventu re. In addition, McKesson caused Core MTS to be transferred to the Joint Venture in consideration of (a) the assumption and subsequent payment at the closing of the Transactions by the Joint Venture to McKesson of a promissory note in the amount of approximately $1,300,000 , (b) the issuance of membership interests in the Joint Venture and (c) an interest in a tax receivable agreement from the Joint Venture. In connection with the Transactions, the Joint Venture, through its subsidiaries, entered into new senior secured credit facilities, consisting of a Term Loan Facility in the amount of $5,100,000 and a Revolving Credit Facility in an aggregate principal amount of $500,000 , and issued $1,000,000 of 5.75% senior notes due 2025 . The proceeds were used to make all payments to the Legacy CHC stockholders, certain participants in the Legacy CHC Equity Plan and McKesson described above, to refinance certain of Legacy CHC’s existing indebtedness and to pay fees and expenses incurred in connection with the Transactions. Amendment of Certificate of Incorporation Effective June 26, 2019 and in contemplation of its initial public offering of common stock, the Company amended its certificate of incorporation to effect a 126.4 for 1 stock split for all previously issued shares of common stock, to increase the authorized number of common stock, and to authorize shares of preferred stock. Following this amendment, the authorized shares include 9,000,000,000 shares of common stock (par value $.001 per share), one share of Class X stock (par value $.001 per share), and 900,000,000 shares of preferred stock (par value $.001 per share). Effective upon the consummation of the Merger (see Note 2, Business Combinations ), the Class X stock is no longer available. All issued or outstanding shares or related share-based payment arrangement disclosures included herein have been retrospectively adjusted for the stock split. Initial Public Offering Effective July 1, 2019, the Company completed its initial public offering of 49,285,713 shares of common stock and a concurrent offering of 5,750,000 of tangible equity units (“TEUs”) for net proceeds of $608,679 and $278,875 , respectively. The proceeds of the offering of common stock were subsequently contributed to the Joint Venture in exchange for 49,285,713 additional units of the Joint Venture, which together with the Company’s existing holdings represent ed an approximate 41% interest in the Joint Venture immediately following the initial public offering . The proceeds of the offering of TEUs were used to acquire TEUs of the Joint Venture that substantially mirror the terms of the TEUs included in the offering. The Joint Venture, in turn, used the proceeds received from the Company to repay $805,000 of its indebtedness under the Term Loan Facility without penalty in July 2019. McKesson Exit On March 10, 2020 , McKesson completed a split-off of its interest in the Joint Venture through an exchange offer of its common stock for shares of PF2 SpinCo, Inc, a Delaware corporation and wholly owned subsidiary of McKesson (“SpinCo”). Immediately following consummation of the exchange offer, SpinCo was merged with and into the Company. As a result, McKesson no longer owns any voting or economic interest in the Joint Venture. See Note 2 , Business Combinations , for more information. COVID-19 Considerations On March 11, 2020, the World Health Organization declared the current coronavirus (“COVID-19”) outbreak to be a global pandemic. In response to this declaration and the rapid spread of COVID-19 within the U.S. , federal, state and local governments throughout the country have imposed varying degrees of restrictions on social and commercial activity to promote social distancing in an effort to slow the spread of the illness. These measures have led to weakened conditions in many sectors of the economy, including a decline in healthcare transaction volumes that are integral to the Company’s business. While COVID-19 had a limited impact on the Company’s results of operations for the year ended March 31, 2020, the Company expects the COVID-19 outbr eak to have an adverse impact on its financial results in future periods . As a result of this change in financial outlook, the Company recognized a non-cash impairment charge during the fourth quarter of the year-ended March 31, 2020, as detailed in Note 9, Goodwill and Intangible Assets . The Company is not presently aware of events or circumstances arising from COVID-19 that would require it to revise the carrying value of any other of its assets or liabilities, nor does the Company expect the impacts of COVID-19 to cause it to be unable to comply with its debt covenants or meet its other contractual obligations. 

Business Combinations

Business Combinations	12 Months Ended
	Mar. 31, 2020
Business Combinations [Abstract]
Business Combinations	2. Business Combinations The Merger On March 10, 2020 (the “Merger Effective Date”), pursuant to the Agreement and Plan of Merger, dated December 20, 2016 (the “Merger Agreement”), by and among the Company, McKesson and SpinCo, the Company combined with SpinCo in a two-step all-stock “Reverse Morris Trust” transaction that involved (i) a separation of SpinCo from McKesson pursuant to the Separation and Distribution Agreement, dated February 10, 2020 (the “Separation Agreement” and, the transactions contemplated by the Separation Agreement, the “Separation”), followed by (ii) the merger of SpinCo with and into the Company, with the Company as the surviving company (such merger, together with the other transactions contemplated by the Merger Agreement, the “Merger”). The Merger was consummated pursuant to the Merger Agreement and the Separation Agreement. On the Merger Effective Date, SpinCo merged with and into the Company, with the Company as the surviving company. As a result, the Joint Venture became a wholly owned subsidiary of the Company. Pursuant to the Merger Agreement, McKesson accepted 15,426,537 shares of its own common stock, par value $0.01 (the “McKesson Common Stock”) in exchange for all 175,995,192 issued and outstanding shares of SpinCo common stock, par value $0.001 per share (the “SpinCo Common Stock”). All shares of SpinCo Common Stock were then converted into an equal number of shares of common stock of the Company, par value $0.001 (the “Change Common Stock”), which the Company issued to the former holders of SpinCo Common Stock, together with cash in lieu of any fractional shares. Immediately after consummation of the Merger, approximately 58% of the outstanding Change Common Stock was held by pre-Merger holders of McKesson Common Stock and approximately 42% of the outstanding Change Common Stock was held by pre-Merger holders of Change Common Stock. Prior to the Merger, the Company accounted for its investment in the Joint Venture under the equity method of accounting. Therefore, the Company’s acquisition of control of the Joint Venture was accounted for as a business combination achieved in stages under the acquisition method, in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations. Accordingly, the Company remeasured its previously held equity interest in the Joint Venture to fair value by reference to the publicly traded price of the common shares issued to SpinCo shareholders in exchange for the remaining 58% equity interest in the Joint Venture. Upon remeasurement of its investment, the Company recognized a loss of $230,229 which is included in Loss from Equity Method Investment in the Joint Venture in the consolidated statement of operations. The loss represents the amount by which the carrying value of the Company’s investment in the Joint Venture exceeded the fair value of its 42% interest immediately prior to the Merger. The fair value s of the assets acquired and the liabilities assumed were determined based on information that is currently available to the Company. Additional information is being gathered to finalize the provisional measurements with respect to deferred taxes. Accordingly, the measurement of the deferred tax assets acquired and deferred tax liabilities assumed may change upon finalization of the Company’s valuations and completion of the purchase price allocation, both of which are expected to occur no later than one year from the acquisition date. The Company considers its accounting for the other assets acquired and liabilities assumed in the Merger to be complete. The following table summarizes the fair values of the identifiable assets and liabilities at the date of the acquisition.    Net Assets acquired  Cash $ 330,665  Accounts receivable, net of allowance for doubtful accounts of $22,059 718,895  Contract assets 132,704  Prepaid and other current assets 115,265  Investment in business purchase option 146,500  Property and equipment, net 206,751  Goodwill 4,360,648  Other noncurrent assets 169,539  Identified intangible assets:  Customer relationships (life 12 - 16 years) 3,056,000  Tradenames (life 18 years) 146,000  Technology-based intangible assets (life 6 - 12 years) 1,188,000  Drafts and accounts payable (60,637)  Accrued expenses (559,456)  Deferred revenues, current (292,528)  Current portion of long-term debt (28,969)  Other current liabilities (22,732)  Long-term debt, excluding current portion (4,713,565)  Deferred income tax liabilities (578,076)  Tax receivable agreement obligations with related parties (176,586)  Other long-term liabilities (102,675)  Net Assets acquired $ 4,035,743   Summary of purchase consideration:  Fair value of shares issued to SpinCo shareholders  ( 175,995,192 shares at $12.47 per share):  Common Stock, $0.001 par value $ 176  Additional paid-in capital 2,194,484  Fair value of Joint Venture equity interest previously held 1,589,040  Fair value of Joint Venture equity interest previously held through TEUs 216,764  Settlement of dividend receivable 42,778  Repayment of advances to member (7,499)  Purchase consideration $ 4,035,743  The goodwill recognized in the Merger is primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of the healthcare and information technology industries in which the Company operates. The goodwill is not expected to be deductible for tax purposes. Acquisition costs related to the Merger were not material for the year ended March 31, 2020. Supplemental Information The supplemental pro forma results below were calculated after applying the Company’s accounting policies and adjusting the results of the acquired Joint Venture businesses to reflect (i) the additional depreciation and amortization that would have been charged resulting from the fair value adjustments to property and equipment and intangible assets, (ii) the additional interest expense associated with the consolidation of the Joint Venture’s long-term borrowings, and (iii) the decrease to revenue resulting from the fair value adjustment of assumed deferred revenue obligations, assuming the acquisition occurred on April 1, 2018.    (Unaudited) Year ended March 31,  2020 2019  Results of acquired business since acquisition date of March 10, 2020:  Revenue $ 196,792 n/a  Net income (loss) $ 297 n/a   Supplemental pro forma data for combined entity:  Revenue $ 3,290,734 $ 3,133,907  Net income (loss) $ (228,234) $ (128,889)  Net income (loss) per share, basic and diluted $ (0.75) $ (0.43) 

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Mar. 31, 2020
Significant Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and include all subsidiaries and entities that are controlled by the Company. The results of operations for companies acquired are included in the consolidated financial statements from the effective date of acquisition. All intercompany accounts and transactions have been eliminated in the financial statements. Because of the significance of the Joint Venture to the Company’s financial position and results of operations, the Company is required to provide consolidated financial statements of the Joint Venture pursuant to Rule 3-09 of Regulation S-X. Accounting Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors and various other assumptions that the Company believes are necessary to consider in order to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of expenses and disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic, environmental and political factors and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment changes. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in the reported results of operations; and if material, the effects of changes in estimates are disclosed in the notes to the financial statements. Estimates and assumptions by management affect: the allowance for doubtful accounts; the fair value assigned to assets acquired and liabilities assumed in business combinations; tax receivable agreement obligations; the fair value of interest rate cap agreement obligations; measurement of the components of tangible equity units; contingent consideration; loss accruals; the carrying value of the Company’s investments; the carrying value of long-lived assets (including goodwill and intangible assets); the amortization period of long-lived assets (excluding goodwill); the carrying value, capitalization and amortization of software development costs; the provision and benefit for income taxes and related deferred tax accounts; certain accrued expenses; revenue recognition; contingencies; and the value attributed to equity awards; the provision and benefit for income taxes and related deferred tax accounts; certain accrued expenses. Business Combinations The Company recognizes the consideration transferred (i.e., purchase price) in a business combination, as well as the acquired business’ identifiable assets, liabilities and noncontrolling interests at their acquisition date fair value. The excess of the consideration transferred over the fair value of the identifiable assets, liabilities and noncontrolling interest, if any, is recorded as goodwill. Any excess of the fair value of the identifiable assets acquired and liabilities assumed over the consideration transferred, if any, is generally recognized within earnings as of the acquisition date. The fair value of the consideration transferred, assets, liabilities and noncontrolling interests is estimated based on one or a combination of income, costs or market approaches as determined based on the nature of the asset or liability and the level of inputs available to the Company (i.e., quoted prices in an active market, other observable inputs or unobservable inputs). To the extent that the Company’s initial accounting for a business combination is incomplete at the end of a reporting period, provisional amounts are reported for those items which are incomplete. Equity Method Investment in the Joint Venture Prior to the Merger, the Company accounted for its investment in the Joint Venture using the equity method. During that period, the Company evaluated its equity method investment for impairment whenever an event or change in circumstances occurred that had a potentially significant adverse impact on the carrying value of the investment. During the period from the inception of the Joint Venture through the date of the Merger, the Company did not identify any loss in the value of its investment that it deemed other than temporary, and therefore did not recognize any loss from impairment. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less to be cash equivalents. The Company’s cash and cash equivalents are deposited with several financial institutions. Deposits may exceed the amounts insured by the Federal Deposit Insurance Corporation in the U.S. and similar deposit insurance programs in other jurisdictions. The Company mitigates the risk of our short-term investment portfolio by depositing funds with reputable financial institutions and monitoring risk profiles. The Company’s cash balances from time to time include funds it manages for customers, the most significant of which relates to funds remitted to retail pharmacies. Such funds are not restricted; however, these funds are generally paid out in satisfaction of the processing obligations pursuant to the management contracts. At the time of receipt, the Company records a corresponding liability within accrued expenses on the accompanying consolidated balance sheets. Such liabilities are summarized as “Pass-through payments” within Note 11, Accrued Expenses . Allowance for Doubtful Accounts The allowance for doubtful accounts was $22,360 at March 31, 2020 and $0 at March 31, 2019 and all prior balance sheet dates. The allowance for doubtful accounts reflects the Company’s best estimate of losses inherent in the Company’s receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available evidence. The following table summarizes activity related to the allowance for doubtful accounts:     Year Ended Year Ended  March 31, March 31,  2020 2019  Balance at beginning of period $ — $ —  Acquisition in Merger 22,059 —  Provisions 905 —  Write-offs (604) —  Balance at end of period $ 22,360 $ — Capitalized Software Developed for Internal Use The Company provides services to many of its customers using software developed for internal use. The costs that are incurred to develop such software are expensed as incurred during the preliminary project stage and classified within research and development in the consolidated statements of operations. Once certain criteria have been met, direct costs incurred in developing or obtaining computer software are capitalized. Training and maintenance costs are expensed as incurred. Capitalized software costs are included in other noncurrent assets, net on the consolidated balance sheets and are generally amortized over the estimated useful life of three years . Capitalized Software Developed for Sale Development costs for software developed for sale to external customers are capitalized once a project has reached the point of technological feasibility. Completed projects are amortized after reaching the point of general availability using the straight-line method based on an estimated useful life of approximately three years . At each balance sheet date, or earlier if an indicator of an impairment exists, the Company evaluates the recoverability of unamortized capitalized software costs based on estimated future undiscounted revenues net of estimated related costs over the remaining amortization period. Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation, including that related to assets under capital lease, is computed using the straight-line method over the estimated useful lives of the related assets. Expenditures for maintenance, repair and renewals of minor items are expensed as incurred. Expenditures for repair and renewals that extend the useful life of an asset are capitalized. Goodwill and Intangible Assets Goodwill and intangible assets resulting from the Company’s acquisitions are accounted for using the acquisition method of accounting. Intangible assets with definite lives are amortized over their useful lives either on a straight-line basis or using an accelerated method, depending on the pattern that the Company expects the economic benefits of the assets to be consumed. Useful lives of the related assets generally are as follows:    Customer relationships 12 - 16 years Tradenames 18 years Technology-based intangible assets 6 - 12 years  The Company assesses its goodwill for impairment annually (as of January 1 of each year) or whenever significant indicators of impairment are present. The Company first assesses whether it can reach a more likely than not conclusion that goodwill is not impaired via qualitative analysis alone. To the extent such a conclusion cannot be reached based on a qualitative assessment alone, the Company, using the assistance of a valuation specialist as appropriate, compares the fair value of each reporting unit to its associated carrying value. The Company will generally recognize an impairment charge for the amount, if any, by which the carrying amount of the reporting unit exceeds its fair value. Long-Lived Assets Long-lived assets used in operations are reviewed for impairment whenever events or changes in circumstances indicate that carrying amounts may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. Long-lived assets held for sale are reported at the lower of cost or fair value less costs to sell. Derivatives Derivative financial instruments are used to manage the Company’s interest rate exposure. The Company does not enter into financial instruments for speculative purposes. Derivative financial instruments are accounted for and measured at fair value. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the forecasted transaction in the same period or periods during which the hedged transaction affects earnings (for example, in “interest expense” when the hedged transactions are interest cash flows associated with floating-rate debt). Receipts and payments under the derivative instruments are classified within cash flows from financing activities on the accompanying statements of cash flows. Tangible Equity Units In connection with the initial public offering, the Company completed an offering of TEUs. Each TEU comprises an amortizing note and purchase contract, both of which are freestanding instruments and separate units of account. The amortizing notes were issued at par and are classified as debt on the accompanying condensed consolidated balance sheet, with scheduled principal payments over the next twelve months reflected in current maturities of long-term debt. The purchase contracts are accounted for as prepaid forward contracts and classified as equity. The TEU proceeds and issuance costs were allocated to the amortizing notes and purchase contracts on a relative fair value basis. See Note 13, Tangible Equity Units for further discussion. Other Investments The proceeds of the offering of TEUs were used to acquire TEUs of the Joint Venture that substantially mirror the terms of the TEUs included in the offering. Under these mirrored arrangements, the Joint Venture is required to make cash payments or to transfer LLC Units to the Company concurrent with any cash payments or issuance of shares by the Company pursuant to the terms of its TEUs. Prior to the Merger, the Company accounted for these mirror arrangements as investments in debt and equity securities. The Company’s investment in debt securities were classified as “available-for-sale” and its investment in forward purchase contracts were considered equity securities measured at fair value. Changes in unrealized gains and losses for the Company’s debt securities were recognized as adjustments to other comprehensive income (loss) while changes in unrealized gains and losses for the Company’s investment in forward purchase contracts are recognized as adjustments to pretax income (loss). After the Merger, the Company’s investment in the TEUs of the Joint Venture is eliminated in the consolidated financial statements. See Note 22, Related Party Transactions , for a discussion regarding the Investment in business purchase option. Equity Compensation The Company measures stock-based compensation cost at the grant date based on the estimated fair value of the award and recognizes the expense over the requisite service period, typically on a straight-line basis. The Company recognizes stock-based compensation cost for awards with performance conditions if and when it concludes that it is probable that the performance conditions will be achieved. The fair value of equity awards is recognized as an asset or expense in the same period and in the same manner as if the Company had paid cash for the goods or services. The Company recognizes forfeitures as they occur. Prior to the Merger, these equity awards, as well as awards granted under the Company’s previous equity incentive plan, were granted to employees of the Company’s equity method investee, and therefore were subject to the accounting framework for awards granted to non-employees. Under this framework, the Company measured the compensation expense for equity awards based on the estimated fair value of such awards at the grant date, in a manner consistent with the recognition of expense for awards to employees. The recognized pre-Merger equity-based compensation is classified within loss from equity method investment in the Joint Venture on the consolidated statement of operations. However, as a result of a requirement that the Joint Venture issue an additional LLC Unit to the Company upon the exercise of each Company equity award (as described in Note 22, Related Party Transactions ), the Company recognized an offsetting amount (i.e., a deemed dividend) within the same caption on the consolidated statements of operations. Prior to the Merger, the Company recognized this deemed dividend as a receivable equal to the cumulative amount of stock compensation expense recognized by the Joint Venture for any outstanding equity awards. The dividend receivable was relieved upon exercise of the respective underlying equity awards. The Company’s dividend receivable from the Joint Venture was settled upon completion of the Merger. Revenue The Company recognizes revenue at an amount that reflects the consideration it expects to be entitled to in exchange for transferring goods or services to a customer, in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). See Note 4, Revenue Recognition , for additional information. Income Taxes The Company records deferred income taxes for the tax effect of differences between book and tax bases of its assets and liabilities, as well as differences relating to the timing of recognition of income and expenses. Deferred income taxes reflect the available net operating losses and the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of the future tax benefits related to deferred tax assets is dependent on many factors, including the Company’s past earnings history, expected future earnings, the character and jurisdiction of such earnings, reversing taxable temporary differences, unsettled circumstances that, if unfavorably resolved, would adversely affect utilization of its deferred tax assets, carryback and carryforward periods and tax strategies that could potentially enhance the likelihood of realization of a deferred tax asset. The Company recognizes tax benefits for uncertain tax positions at the time the Company concludes that the tax position, based solely on its technical merits, is more likely than not to be sustained upon examination. The benefit, if any, is measured as the largest amount of benefit, determined on a cumulative probability basis that is more likely than not to be realized upon ultimate settlement. Tax positions failing to qualify for initial recognition are recognized in the first subsequent interim period that they meet the more likely than not standard, upon resolution through negotiation or litigation with the taxing authority or on expiration of the statute of limitations. Warranties In the normal course of business, the Company provides warranties regarding the performance of software and products it sells. The Company’s liability under these warranties is to bring the product into compliance with previously agreed upon specifications. For software products, this may result in additional project costs, which are reflected in our estimates used for the percentage of completion method of accounting for software installations services within these contracts. In addition, most of the Company’s customers who purchase software and automation products also purchase annual maintenance agreements. Revenues from these maintenance agreements are recognized on a straight-line basis over the contract period and the cost of servicing product warranties is charged to expense when claims become estimable. As of March 31, 2020 and 2019, accrued warranty costs were immaterial. Classification of Distributions Received from the Joint Venture Prior to the Merger, the Company classifies distributions received from the Joint Venture in its consolidated statement of cash flows according to the nature of the distribution. Accounting Pronouncements Not Yet Adopted In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, as amended by ASU No. 2018-19, which requires that a financial asset (or group of financial assets) measured at amortized cost be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the reported amount. This update is scheduled to be effective for the Company beginning April 1, 2020. The Company is currently assessing the potential effects this update may have on its consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, which modifies the disclosure requirements for fair value measurements. ASU 2018-13 is effective for the Company beginning April 1, 2020. Early adoption is permitted for either the entire standard or only the provisions that eliminate or modify requirements. The Company is currently assessing the potential effects this update may have on its financial statement disclosures. In February 2016, the FASB issued ASU No. 2016-02, which generally requires that all lease obligations be recognized on the balance sheet at the present value of the remaining lease payments with a corresponding right of use asset (“ROU asset)”. As originally issued, the standard required that companies adopt the standard using the modified retrospective transition method and report a cumulative effect adjustment to the opening balance of retained earnings in the earliest comparative period presented. In July 2018, the FASB issued ASU No. 2018-11 which provides companies with the option to apply this cumulative effect adjustment to the opening balance of retained earnings in the period of adoption instead of the earliest comparative period presented. This update is effective for the Company beginning April 1, 2020, with early adoption permitted. The Company will utilize the modified retrospective approach upon adoption. While the Company is finalizing the assessment on the effect of adoption, the most significant impact is expected to relate to the recognition of new ROU assets and lease liabilities on the Company’s consolidated balance sheet for operating leases, as well as additional disclosures. Consequently, with adoption, the Company expects to recognize additional ROU assets and corresponding operating lease liabilities of between $110,000 and $125,000 . In August 2018, the FASB issued ASU No. 2018-15, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This update also requires that the effects of such capitalized costs be classified in the same respective caption of the statement of operations, balance sheet and cash flows as the underlying hosting arrangement. Upon adoption, a company may elect to either retrospectively restate each prior reporting period or apply the update prospectively to all implementation costs incurred after the effective date. This update is scheduled to be effective for the Company beginning April 1, 2020. The Company will adopt the new guidance prospectively and is assessing the potential effects this update may have on its consolidated financial statements. The Company does not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on the consolidated financial statements. Recently Adopted Accounting Pronouncements In April 2019, the Company adopted ASU No. 2018-16, which adds the Overnight Index Swap rate based on the Secured Overnight Financing Rate as a benchmark interest rate for hedging purposes. As the adoption of this update applies only to qualifying new or redesignated hedging relationships entered into following the date of adoption, its adoption had no immediate effect on the consolidated financial statements. In April 2019, the Company adopted ASU No. 2018-02, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 (“Tax Legislation”). The adoption of this update was not material and is limited to the separate disclosure in Note 26, Accumulated Other Comprehensive Income related to the reclassification of such stranded costs from accumulated comprehensive income (loss) to accumulated deficit. In April 2019, the Company adopted ASU No. 2018-07, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. Among other provisions, the measurement date for awards to nonemployees changed from the earlier of the date at which a commitment for performance by the counterparty is reached or the date at which performance is complete under the previous guidance to the grant date under this update. Because the Company’s equity-based compensation was previously subject to remeasurement at fair value each quarter under the previous authoritative literature, the effect of the adoption of this update had no material effect on the consolidated financial statements. In April 2019, the Company and the Joint Venture adopted ASC 606 on a modified retrospective basis. ASC 606 replaced most prior general and industry specific revenue recognition guidance with a principles-based comprehensive revenue recognition framework. Under this revised framework, a company recognizes revenue to depict the transfer of promised goods and services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. Prior to the Merger, the Company’s operations consisted principally of an investment in the Joint Venture, its financial statements reflected no revenue and, accordingly, the Company recognized no direct impact on its financial statements from the adoption of this update. However, upon adoption, the Joint Venture recognized a cumulative effect adjustment to its Members’ deficit. As a result of the impact of the adoption of ASC 606 to the Joint Venture’s Members’ deficit, the Company was required to recognize a proportionate amount of this cumulative effect adjustment to its April 1, 2019 retained earnings as well. The effect is disclosed within a separate caption of the accompanying consolidated statement of stockholders’ equity. The adoption of the new standard had an immaterial impact on the Company’s consolidated statement of cash flows for the fiscal year ended March 31, 2020. See Note 4, Revenue Recognition for more information. 

Revenue Recognition

Revenue Recognition	12 Months Ended
	Mar. 31, 2020
Revenue Recognition [Abstract]
Revenue Recognition	4. Revenue Recognition The Company generates most of its solutions revenue by using technology solutions (generally Software as a Service (“SaaS”)) to provide services to its customers that automate and simplify business and administrative functions for payers, providers, pharmacies, and channel partners and through the licensing of software, software systems (consisting of software, hardware and maintenance support) and content. The Company recognizes revenue when the customer obtains control of the good or service through the Company satisfying a performance obligation by transferring the promised good or service to the customer. Prior to the Merger, the Company’s principal operations were limited to its investment in the Joint Venture, and the Company therefore did not recognize revenue in its statement of operations. Principal Revenue Generating Products and Services Hosted solutions and SaaS - The Company enters into arrangements whereby the Company provides the customer access to a Company-owned software solution, which are generally marketed under annual and multi-year arrangements. The customer is only provided “access” (not a license) to the software application. In these arrangements, the customer does not purchase equipment nor does the customer take physical possession of the software. The related revenue is recognized ratably over the contracted term. For fixed fee arrangements, revenue recognition begins after set-up and implementation are complete. For per-transaction fee arrangements, revenue is recognized as transactions are processed beginning on the service start date. Revenue for hosted solutions and SaaS, which is included in solutions revenue, is generated by the Software and Analytics, Network Solutions, and Technology-Enabled Services segments. Transaction processing services - The Company provides transaction processing (such as claims processing) services to hospitals, pharmacies and health systems via a cloud-based (SaaS) platform. The promised service is to stand ready to process transactions for our customers over the contractual period on an as needed basis. The revenue related to these services is recognized over time as the transactions are processed, and the revenue is recognized over the individual days in which the services are performed. Revenue for these services is recognized as solutions revenue in the Software and Analytics, Network Solutions, and Technology-Enabled Services segments, with the exception of revenue related to postage that is generated through the delivery of certain of these services. Postage revenue is further discussed below and is separately presented on the consolidated statement of operations. Any fixed annual fees and implementation fees are recognized ratably over the contract period. Contingent fee services - The Company provides services to customers in which the transaction price is contingent on future occurrences, such as savings generated or amounts collected on behalf of its customers through the delivery of its services. In some cases, the Company performs services in advance of invoicing the customer, thereby creating a contract asset. Revenue in these arrangements is estimated and constrained until the Company determines that it is probable a significant revenue reversal will not occur, and variable consideration is allocated to the performance obligation for which the Company earns a contingent fee. The Company uses the expected value method when estimating variable consideration, as the Company has a large number of contracts with similar characteristics and considers a portfolio of data from other similar contracts to form its estimate of expected value. Revenue for contingent fee services, which is included in solutions revenue, is generated by the Software and Analytics and Technology-Enabled Services segments. Content license subscriptions and time-based software - The Company’s content license subscriptions and time-based software arrangements provide a license to use a software for a specified period of time. At the end of the contractual period, the customer either renews the license for an additional term or ceases to use the software. Software licenses are typically delivered to the customer with functionality that the customer can benefit from the software on its own or together with readily available resources. As contracts for these solutions generally do not price individual components separately, the Company allocates the transaction price to the license and ongoing support performance obligations based on standalone selling price, primarily determined by historical value relationships between licenses and ongoing support and updates. Revenue allocated to content license subscriptions and time-based software license agreements is generally recognized at the point-in-time of delivery of the license or the content update upon transfer of control of the underlying license to the customer. Generally, software implementation fees are recognized over the implementation period through an input measure of progress method. Revenue allocated to maintenance and support is recognized ratably over the period covered by the agreements, as passage of time represents a faithful depiction of the transfer of these services. In some cases, software arrangements provide licenses to several software applications that are highly integrated with the implementation services and software updates and cannot function separately. The bundle is a single performance obligation since the individually promised goods and services are not distinct in the context of the contract because the related implementation services significantly modify and customize the software and the updates provided to the integrated software solution are critical to the software’s utility. The related revenue is recognized on a straight-line basis, ratably over the contractual term due to the frequency and criticality of the updates throughout the license period . Revenue for content license subscriptions and time-based software, which is included in solutions revenue, is generated by the Software and Analytics segment. Perpetual software license s and software systems - The Company’s perpetual software arrangements provide a license for a customer to use software in perpetuity. Software licenses are typically delivered to the customer with functionality from which the customer can benefit from the license on its own or together with readily available resources. Perpetual software arrangements are recognized at the time of delivery or through an input measure of progress method over the installation period if the arrangements require significant production or modification or customization of the software. Contracts accounted for through an input measure of progress method are generally measured based on the ratio of labor hours incurred to date to total estimated labor hours to be incurred. Software implementation fees are recognized as the work is performed or under the input method for perpetual software. Hardware revenues are generally recognized upon delivery. Maintenance is recognized ratably over the term of the agreement as passage of time represents a faithful depiction of the transfer of these services. License, implementation, hardware and maintenance revenue for these arrangements, which is included in solutions revenue, is generated by the Software and Analytics segment. Professional services - The Company provides training and consulting services to its customers, and the services may be fixed fee or time and materials based. Consulting services that fall outside of the standard implementation services vary depending on the scope and complexity of the service requested by the customer. Consulting services are deemed to be capable of being distinct from other products and services, and the services are satisfied either at a point of time or over time based on delivery and are recognized as solutions revenue in the Software and Analytics and Technology-Enabled Services segments. Training services are usually provided as an optional service to enhance the customer’s experience with a software product or provides additional education surrounding the general topic of the solution. Training services are capable of being distinct from other products and services. The Company treats training services as a distinct performance obligation, and they are satisfied at a point of time and recognized as solutions revenue in the Software and Analytics and Technology-Enabled Services segments. Contract Balances The Company’s payment terms vary by customer and product type. For certain products or services, the Company requires upfront payments before control of the product or service has transferred to the customer. For other products and services, the Company invoices the customer in arrears after providing the products or services. In addition, for certain contingent fee services, customers are billed in arrears, typically based upon a percentage of collections the Company makes on the customer's behalf. Under the new revenue standard, the Company generally recognizes a contract asset when revenue is recognized in advance of invoicing on a customer contract, unless the right to payment for that revenue is unconditional (i.e. requiring no further performance and only the passage of time). If a right to payment is determined to meet the criteria to be considered 'unconditional', then the Company will recognize a receivable. Neither the Company nor the Joint Venture recognized any impairment losses on accounts receivable or contract assets during the year ended March 31, 2020. The Company records deferred revenues when billings or payments are received from customers in advance of its performance. Deferred revenue is generally recognized when transfer of control to customers occurs. The deferred revenue balance is driven by multiple factors, including the frequency of renewals, invoice timing, and invoice duration. As of March 31, 2020, the Company expects 94% of the deferred revenue balance to be recognized in one year or less . Prior to the Merger, the Company did not recognize revenue from contracts with customers, and therefore did not have deferred revenue on its balance sheet at March 31, 201 9. Upon completion of the Merger and consolidation of the Joint Venture, the Company assumed deferred revenue of $311,200 as part of purchase accounting. The Company recognized $25,601 of that deferred revenue balance during the year ended March 31, 2020 . Costs to Obtain or Fulfill a Contract Sales commissions and certain other incentive payments (e.g., bonuses that are contingent solely on obtaining a contract or a pool of contracts) are capitalized as incremental costs to obtain a contract. The Company typically does not offer commissions on contract renewals. Decremented commissions upon renewal (i.e., non-commensurate with initial commissions) are offered to the Company’s sales associates for certain customers and are i m m aterial. A ll commissions and other qualifying incentive payments capitalized are amortized over an expected period of benefit defined as the initial contract term plus anticipated renewals. In determining the appropriate period of benefit, the Company evaluate s both qualitative and quantitative factors such as the expected customer relationship period and technology obsolescence. In addition, prior to solution go-live, the Company incurs certain contract fulfillment costs primarily related to SaaS setup for our clients. These costs are capitalized to the extent they are directly related to a contract, are recoverable, and create a resource used to deliver the Company’s SaaS services. Capitalized costs to fulfill a contract are amortized over the expected period of benefit. In accounting for the Merger, the Company did not recognize an asset for costs to obtain or fulfill a contract that had been previously capitalized by the Joint Venture, but the Company began capitalizing only qualifying costs to obtain and fulfill a contract that were incurred after the date of the Merger. Consequently, the Company did not have a material balance of capitalized costs to obtain or fulfill a contract at March 31, 2020, nor did it recognize a material amount of amortization of such costs during the year ended March 31, 2020. Postage Revenues Postage revenues are the result of providing delivery services to customers in the Company's payment and communication solutions. Postage revenues are generally billed as a pass-through cost to the Company’s customers. The service is part of a combined performance obligation with the printing and handling services provided to the customer because the postage services are not distinct within the context of the contract. The Company presents Postage Revenue separately from Solutions Revenue on the consolidated statements of operations as doing so makes the financial statements more informative for the users. The revenue related to the combined performance obligation of the postage, printing, and handling service is recognized as the transactions are processed, and the revenue is recognized over the individual days in which the services are performed. Arrangements with Multiple Performance Obligations The Company engages in customer arrangements which may include multiple performance obligations, such as any combination of software, hardware, implementation, SaaS-based offerings, consulting services, or maintenance services. For such arrangements, the Company allocates revenues to each performance obligation on a relative standalone selling price basis. For substantially all such arrangements, a performance obligation’s standalone selling price is determined based on the directly observable prices charged to customers. When directly observable prices charged to customers are not available, other methods are used such as the adjusted market assessment approach, the expected cost plus a margin approach, or other approaches in cases where distinct performance obligations are not sold separately but instead sold at a bundled price. For performance obligations with historical pricing that is highly variable, the residual approach is used. Such instances primarily relate to the Company’s perpetual software arrangements in which the Company sells the same products to different customers for a broad range of amounts. Remaining Performance Obligations The aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts includes deferred revenue and other revenue yet to be recognized from non-cancellable contracts. As of March 31, 2020, the Company's total remaining performance obligations approximated $1,141,000 , of which approximately 55% is expected to be recognized over the next twelve months, and the remaining 45% thereafter . In this balance, the Company does not include the value of unsatisfied performance obligations related to those contracts for which it recognizes revenue at the amount for which it has the right to invoice for services performed. Additionally, this balance does not include revenue related to performance obligations that are part of a contract with an original expected duration of one year or less. Lastly, this balance does not include variable consideration allocated to the individual goods or services in a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. Examples includes variable fees associated with transaction processing and contingent fee services. Disaggregated Revenue Beginning in fiscal year 2021, the Company plans to report segment information consistent with the presentation of operating segments at the Joint Venture as it believes doing so best depicts how the nature, amount, timing and uncertainty of the Company’s revenue are affected by economic factors. Additionally, the Company plans to disaggregate revenue between revenue that is recognized over time and revenue that is recognized at a point in time. Given the short portion of the year during which the Company consolidated the results of the Joint Venture and recognized revenue in its financial statements, the Company does not consider disaggregation of the amount of revenue recognized in its consolidated statement of operations for the year ended March 31, 2020 to be meaningful. A full year disaggregation of revenues from contracts with customers is included in the accompany ing financial statements of the Joint Venture. Customer Incentives Certain customers, which include the Company’s channel partners, may receive cash-based incentives or rebates based on actual sales and achievement of a cumulative level of sales, which are accounted for as variable consideration. The Company considers these amounts to be consideration payable to the customer, and therefore, the Company estimates these amounts based on the expected amount to be provided to customers and reduces the transaction price accordingly. Practical Expedients and Exemptions The Company has elected to utilize either the right to invoice practical expedient or the series-based variable consideration allocation framework for most transaction processing services not subject to contingencies. The Company also has elected to exclude sales taxes and other similar taxes from the measurement of the transaction price in contracts with customers. Therefore, revenue is recognized net of such taxes. In certain customer arrangements with customers, the Company determined there are certain promised goods or services which are immaterial in the context of the contract from both a quantitative and qualitative perspective, and therefore, the goods and services are disregarded when assessing the performance obligations in the customer arrangement. The Company has elected to apply the significant financing practical expedient, and as a result, the Company will not adjust the promised amount of consideration in a customer contract for the effects of a significant financing component when the period of time between when the Company transfers a promised good or service to a customer and when the customer pays for the good or service will be one year or less. 

Concentration of Credit Risk

Concentration of Credit Risk	12 Months Ended
	Mar. 31, 2020
Concentration of Credit Risk [Abstract]
Concentration of Credit Risk	5. Concentration of Credit Risk The Company maintains its cash and cash equivalent balances in either insured depository accounts or money market mutual funds. The money market mutual funds are limited to investments in low-risk securities such as U.S. or government agency obligations, or repurchase agreements secured by such securities. 

Equity Method Investment in Cha

Equity Method Investment in Change Healthcare LLC	12 Months Ended
	Mar. 31, 2020
Equity Method Investment in Change Healthcare LLC [Abstract]
Equity Method Investment in Change Healthcare LLC	6. Equity Method Investment in Change Healthcare LLC Exchange of Equity Method Investments In connection with the Transactions, the Company exchanged its 45.615% investment in Legacy CHC for 30% of the membership units of the Joint Venture. The Joint Venture used proceeds from the issuance of debt referred to previously to acquire the remaining 54.385% of Legacy CHC. The Company has accounted for this exchange of investments as a non-monetary transaction at their respective carrying values. Prior to the Transactions, the investors of Legacy CHC accounted for their investments at fair value. As a result, the book basis and fair value of the Company’s investment in Legacy CHC were generally the same such that no gain was recognized as a result of the Transactions. The fair value of the Joint Venture was determined at March 1, 2017 using a combination of the income and the market valuation approaches. Under the income approach, a discounted cash flow model was used in which cash flows anticipated over several periods, plus a terminal value at the end of that time horizon, are discounted to their present value using an appropriate expected rate of return. The discount rate used for cash flows reflects capital market conditions and the specific risks associated with the business. Under the market approach, valuation multiples of reasonably similar publicly traded companies or guideline companies are applied to the operating data of the subject business to derive the estimated fair value. These valuation approaches are considered a Level 3 fair value measurement. Fair value determination requires complex assumptions and judgment by management in projecting future operating results, selecting guideline companies for comparisons, determining appropriate market value multiples, selecting the discount rate to measure the risks inherent in the future cash flows and assessing the business’s life cycle and the competitive trends impacting the business, including considering technical, legal, regulatory, or economic barriers to entry. Any material changes in key assumptions, including failure to meet business plans, deterioration in the financial market, an increase in interest rate or an increase in the cost of equity financing by market participants within the industry or other unanticipated events and circumstances, may affect such estimates. Additional Ownership Interest Following the initial public offering, the Company contributed the proceeds of the offering of common stock to the Joint Venture in exchange for 49,285,713 additional units of the Joint Venture, which represented approximately 11% of additional ownership interest. As a res ult of the additional ownership interest acquired, the Company measured additional basis differences at July 1, 2019 based on the fair value of the Joint Venture’s assets and liabilities as of the date of the initial public offering, and using valuation approaches substantially similar to those used as of the date of the Transactions. Equity Method Investment in the Joint Venture Prior to the Merger, the Company accounted for its investment in the Joint Venture using the equity method of accounting. During the period from April 1, 2019 to March 10 , 2020, and the years ended March 31, 2019 and 2018, the Company recorded a proportionate share of the loss from this investment of $380,713 , $70,487 , and $58,680 , respectively, which included transaction and integration expenses incurred by the Joint Venture and basis adjustments, including amortization expenses, associated with equity method intangible assets. The amount is in Loss from Equity Method Investment in the Joint Venture in the consolidated statements of operations. Following completion of the Merger, the Company consolidates the Joint Venture and no longer accounts for its ownership interest as an equity method investment. Summarized financial information of the Joint Venture is as follows:   Period of Year Ended Year Ended  April 1, 2019 to March 31, March 31,  Statement of Operations Data: March 10, 2020 2019 2018  Net revenue $ 3,092,875 $ 3,281,729 $ 3,298,843  Cost of operations (exclusive of depreciation and amortization) $ 1,263,244 $ 1,354,655 $ 1,407,893  Customer postage $ 215,448 $ 238,618 $ 274,397  Net income (loss) $ 123,771 $ 176,670 $ 192,442   March 10, March 31,  Balance Sheet Data (at period end): 2020 2019  Current assets $ 1,339,908 $ 980,463  Long-term assets $ 5,187,220 $ 5,223,675  Current liabilities $ 1,112,875 $ 889,783  Long-term liabilities $ 5,185,304 $ 6,219,141  Other Investments The Company invested in a unit purchase contract and a debt instrument of the Joint Venture on terms that substantially mirror the economics of the TEUs (see Note 1 3, Tangible Equity Units ). Prior to the Merger, the Company accounted for these mirror arrangements as investments in debt and equity securities. After the Merger, the Company’s investments in the TEUs of the Joint Venture are eliminated in consolidation. The following table presents a reconciliation of the activity related to the other investments :     Year Ended  March 31, 2020  Balance at beginning of period $ —  Acquisition of forward purchase contracts 232,928  Acquisition of available-for-sale debt securities 45,946  Receipt of payments on debt securities (7,332)  Change in fair value of forward purchase contracts 14,836  Change in fair value of debt securities 1,489  TEU conversions of forward purchase contracts (31,000)  Settlement of investment in forward purchase contracts (1) (216,764)  Elimination of investment in debt securities (2) (40,103)  Balance at end of period $ —  (1) Amount is included as part of the Merger purchase price. See Note 2, Business Combinations for additional information . (2) Amount is eliminated as part of consolidation. 

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Mar. 31, 2020
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	7. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets generally include items for which the Company has paid the related vendor or supplier in advance of receiving the related service. Prepaid expenses and other current assets consisted of the following:     March 31, March 31,  2020 2019  Prepaid expenses $ 73,354 $ —  Other current assets 44,141 —  Total prepaid expenses and other current assets $ 117,495 $ —  

Property and Equipment

Property and Equipment	12 Months Ended
	Mar. 31, 2020
Property and Equipment [Abstract]
Property and Equipment	8. Property and Equipment Property and equipment consisted of the following:     March 31, March 31,  2020 2019  Land $ 406 $ —  Buildings and leasehold improvements 51,460 —  Computer equipment 95,079 —  Production equipment 17,591 —  Office equipment, furniture and fixtures 31,302 —  Construction in process 13,318 —  Property and equipment, gross 209,156 —  Less accumulated depreciation (2,960) —  Property and equipment, net $ 206,196 $ — Depreciation expense was $2,960 , $0 , and $0 for the years ended March 31, 2020, 2019 and 2018, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets [Abstract]
Goodwill and Intangible Assets	9. Goodwill and Intangible Assets Goodwill The Company evaluates goodwill for impairment on an annual basis as of January 1 each year and at an interim date, if indicators of potential impairment exist. Goodwill impairment testing is conducted at the reporting unit level, which is generally defined as an operating segment or one level below an operating segment (also known as a component), for which discrete financial information is available and segment management regularly reviews the operating results of that reporting unit. As described in Note 24, Segment Reporting , management expects to view the Company’s operating results based on the same three reportable segments that currently comprise the Joint Venture: (a) Software & Analytics, (b) Network Solutions and (c) Technology-Enabled Services. Goodwill was recognized on March 10, 2020 as a result of the Merger in accordance with ASC 805 and allocated to the Company’s reporting units on a relative fair value basis. Subsequent to the Merger, the Company concluded a triggering event had occurred due to the expected impacts to its financial results arising out of the COVID-19 pandemic beginning in the first quarter of fiscal year 2021. Therefore, the Company performed a goodwill impairment test as of March 31, 2020 to compare the carrying value and fair value of the Company’s reporting units. The fair value of each reporting unit was determined using a combination of an income approach based on a discounted cash flow model and a market approach based on appropriate valuation multiples observed for the reporting unit’s guideline public companies. Fair value estimates result from a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions that have been deemed reasonable by management as of the measurement date. The estimates considered most impactful to the goodwill impairment test are the Company’s expectation of timing of a return to a normal level of healthcare activity , the discount rate used in the income approach, and the market multiples used in the market approach. If the timing of the return to a normal level of healthcare activity is later than expected, or if macroeconomic conditions worsen, additional impairment charges may be required . Fair value assessments of the reporting units are considered a Level 3 measurement due to the significance of unobservable inputs developed using company specific information. Based on the results of the interim impairment test, the Company recorded a non-cash pre-tax goodwill impairment charge of $561,164 as the Company determined that the carrying value of each of the three reporting units exceeded their estimated fair value. This charge is recorded under the caption Goodwill impairment charge in the consolidated statement of operations. The goodwill impairment was not deductible for income tax purposes. The following table presents the changes in the carrying amount of goodwill for the year ended March 31, 202 0:      Software and Analytics Network Solutions Technology-Enabled Services Total  Balance at March 31, 2019 $ — $ — $ — $ —  Acquisitions 1,901,116 1,944,701 514,831 4,360,648  Goodwill impairment (126,839) (298,870) (135,455) (561,164)  Effects of foreign currency (4,159) — — (4,159)  Balance at March 31, 2020 $ 1,770,118 — $ 1,645,831 — $ 379,376 — $ 3,795,325 Intangible Assets Intangible assets subject to amortization at March 31, 2020 consisted of the following:    Weighted Gross  Average Carrying Accumulated  Remaining Life Amount Amortization Net  Customer relationships 15.2 $ 3,056,000 $ (13,064) $ 3,042,936  Technology-based intangible assets 9.2 1,188,000 (10,290) 1,177,710  Tradenames 18.0 146,000 (840) 145,160  Total $ 4,390,000 $ (24,194) $ 4,365,806  The Company did not have any intangible assets subject to amortization as of March 31, 2019. Amortization expense was $24,194 , $0 and $0 for the years ended March 31, 2020, 2019 and 2018, respectively. Aggregate amortization expense for intangible assets future fiscal years is estimated to be:        2021 $ 441,268  2022 469,741  2023 421,556  2024 381,546  2025 349,177  Thereafter 2,302,518  Total $ 4,365,806 

Accrued Expenses

Accrued Expenses	12 Months Ended
	Mar. 31, 2020
Accrued Expenses [Abstract]
Accrued Expenses	10. Accrued Expenses Accrued expenses generally represent items for which the Company has received a service from a vendor in advance of being invoiced for that service. Accrued expenses consisted of the following:     March 31, March 31,  2020 2019  Customer deposits $ 37,357 $ —  Accrued compensation 113,959 —  Accrued outside services 28,822 —  Accrued insurance 14,293 —  Accrued income, sales and other taxes 10,129 176  Accrued interest 5,892 —  Interest rate cap agreements 28,131 —  Pass-through payments 29,518 —  Other accrued liabilities 122,193 —  Total accrued expenses $ 390,294 $ 176 

Long-Term Debt

Long-Term Debt	12 Months Ended
	Mar. 31, 2020
Long-Term Debt [Abstract]
Long-Term Debt	1 1 . Long-Term Debt The Company’s long-term indebtedness is comprised of a senior secured term loan facility (the “Term Loan Facility”), a revolving credit facility (the “Revolving Facility”; together with the Term Loan Facility, the “Senior Credit Facilities”), and 5.75% senior notes due 2025 (the “Senior Notes”). Long-term debt as of March 31, 2020 and 2019, consisted of the following:    March 31 March 31,  2020 2019  Senior Credit Facilities  $5,100,000 Term Loan Facility, due March 1, 2024 , net of unamortized discount of $125,793 and $0 at March 31, 2020 and 2019, respectively (effective interest rate of 4.42% ) $ 3,682,457 $ —  $785,000 Revolving Facility, expiring July 3, 2024 , and bearing interest at a variable interest rate (1) 250,000 —  Senior Notes  $1,000,000 5.75% Senior Notes due March 1, 2025 , net of unamortized discount of $2,228 and $0 at March 31, 2020 and 2019, respectively (effective interest rate of 5.80% ) 997,772 —  Tangible Equity Unit Senior Amortizing Note  $47,367 Senior Amortizing Notes due June 30, 2022 , net of unamortized discount of $842 and $0 at March 31, 2020 and 2019, respectively (effective interest rate of 7.44% ) 35,431 —  Other 23,413 —  Less current portion (278,779) —  Long-term debt $ 4,710,294 $ — (1) The weighted average interest rate at March 31, 2020 was 3.25% .  Senior Credit Facilities The Senior Credit Facilities provide the Company with the right at any time to request additional term loan tranches and/or term loan increases, increases in the revolving commitments and/or additional revolving credit facilities up to the sum of (i) (a) the greater of $1,080,000 or an amount equal to 100% of EBITDA for the most recently ended four consecutive fiscal quarters, plus (b) certain voluntary prepayments, repurchases, redemptions and other retirements of indebtedness and commitments under our Senior Credit Facilities, incremental equivalent debt, and refinancings thereof, plus (ii) an additional aggregate amount such that, after giving pro forma effect to such incurrence, (x) if such additional amounts are secured on a pari passu basis with the first lien obligations under our Senior Credit Facilities, our consolidated first lien net leverage ratio does not exceed 4.90 to 1.00, (y) if such additional amounts are secured on a junior lien basis to the first lien obligations under our Senior Credit Facilities, our consolidated secured net leverage ratio does not exceed 5.75 to 1.00 and (z) if such additional amounts are unsecured, either our consolidated total net leverage ratio does not exceed 6.00 to 1.00 or the Company could incur at least $1.00 of additional indebtedness under a consolidated interest coverage ratio test under our Senior Credit Facilities of 2.00 to 1.00. The lenders under the Senior Credit Facilities will not be under any obligation to provide any such incremental commitments or loans, which are uncommitted, and any such addition of or increase in commitments or loans will be subject to obtaining commitments and certain customary conditions precedent in the Company’s Senior Credit Facilities. The applicable margin for loans under the Term Loan Facility is subject to reduction from and after a Qualified IPO (as defined in the Senior Credit Facilities). Borrowings under the Senior Credit Facilities bear interest at a rate equal to either (i) LIBOR for the relevant interest period, adjusted for statutory reserve requirements (the Term Loan Facility is subject to a floor of 1.0% per annum and the Revolving Facility is subject to a floor of 0.0% per annum), plus an applicable margin or (ii) a base rate equal to the highest of (a) the rate of interest in effect as publicly announced by the administrative agent as its prime rate, (b) the federal funds effective rate plus 0.5% and (c) adjusted LIBOR for an interest period of one month plus 1.0% (the Term Loan Facility may be subject to a floor of 2.0% per annum), in each case, plus an applicable margin. The applicable margin under the Revolving Facility is subject to reduction after the completion of the Company’s first full fiscal quarter after the closing of its Senior Credit Facilities based upon its consolidated first lien net leverage ratio, as well as following a Qualified IPO. In July 2019, the Company amended its Revolving Facility, primarily to increase the capacity from $500,000 to $785,000 and to extend the maturity date to July 2, 2024. However, in the event the Term Loan Facility exceeds $1,100,000 on December 1, 2023 , amounts due, if any, under the Revolving Facility become due and payable on December 1, 2023 . In March 2020, the Company borrowed $250,000 under the Revolving Facility . The borrowings are classified as short-term based on the anticipated repayment date. The Revolving Facility has a total borrowing capacity of $785,000 less outstanding letters of credit which totaled $5,118 and $4,880 at March 31, 2020 and 2019, respectively. This leaves $529,882 and $495,120 available for borrowing as of March 31, 2020 and 2019, respectively. In addition to paying interest on outstanding principal under the Senior Credit Facilities, the Company is required to pay a commitment fee of 0.375% per annum to the lenders under the Revolving Facility in respect of the unutilized commitments thereunder. The Company must also pay customary letter of credit fees and an annual administrative agency fee. The Senior Credit Facilities requires the Company to prepay outstanding term loans, subject to certain exceptions, with: · 50% of the Parent Borrower’s (as defined in the Senior Credit Facilities) annual Excess Cash Flow (as defined in the Senior Credit Facilities) commencing with the first full fiscal year completed after the closing of the Senior Credit Facilities (percentage will be reduced to 25% and 0% if the Company achieves and maintains specified consolidated first lien net leverage ratios), subject to certain credits and exceptions; · 100% of the net cash proceeds of non-ordinary course asset sales or other dispositions of property, including insurance condemnation proceeds (percentage will be reduced to 50% , 25% and 0% if the Company achieves and maintains specified consolidated first lien net leverage ratios), subject to certain exceptions, in excess of a minimum amount threshold set forth in the Senior Credit Facilities and subject to our right to reinvest the proceeds; and · 100% of the net cash proceeds of any incurrence of debt by the borrowers or their restricted subsidiaries, other than proceeds from debt permitted to be incurred by the terms of the Senior Credit Facilities. The foregoing mandatory prepayments will be applied, subject to certain exceptions, to the term loans outstanding under the Senior Credit Facilities then outstanding as directed by the Parent Borrower. The Company may voluntarily repay outstanding loans or reduce outstanding commitments under the Senior Credit Facilities at any time without premium or penalty, subject to reimbursements of the lenders’ redeployment costs actually incurred in the case of a prepayment of LIBOR borrowings prior to the last day of the relevant interest period. The foregoing voluntary prepayments may be applied to the scheduled installments of principal of the Term Loan Facility in such order as directed by the Parent Borrower and applied to any class of loans under the Senior Credit Facilities as directed by the Parent Borrower. The Term Loan Facility amortizes in equal quarterly installments in aggregate annual amounts equal to 1.0% of the principal amount of the Term Loan Facility outstanding as of the date of the closing of the Senior Credit Facilities, with the balance being payable at maturity. Principal amounts outstanding under the Revolving Facility are due and payable in full at maturity. The Company does not have any remaining quarterly amortization payments. All obligations of the borrowers under the Senior Credit Facilities and under any swap agreements and cash management arrangements that are entered into are unconditionally guaranteed by all material wholly owned direct and indirect domestic restricted subsidiaries of the borrowers and by the direct parent of the Parent Borrower, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in adverse tax consequences. All obligations of the borrowers under the Senior Credit Facilities and under any swap agreements and cash management arrangements are secured, subject to permitted liens and other exceptions, by substantially all of the assets of the borrowers and each guarantor, including but not limited to: (i) a perfected pledge of all of the capital stock issued by the parent borrower and each direct wholly owned domestic restricted subsidiary of the borrowers or any subsidiary guarantor (subject to certain exceptions) and up to 65% of the capital stock issued and outstanding by each direct wholly owned foreign restricted subsidiary of the borrowers or any subsidiary guarantor (subject to certain exceptions) and (ii) perfected security interests in and mortgages on substantially all tangible and intangible personal property and material owned real property of the borrowers and the subsidiary guarantors (subject to certain exceptions and exclusions). As of March 31, 2020, the Company was in compliance with all of the applicable covenants under the Senior Credit Facilities. Senior Notes The Senior Notes bear interest at an annual rate of 5.75% with interest payable semi-annually on March 1 and September 1 of each year and mature on March 1, 2025 . The Company may redeem the Senior Notes, in whole or in part, at any time on or after March 1, 2020 at the applicable redemption price, plus accrued and unpaid interest. If the Company experiences specific kinds of changes in control, it must offer to purchase the Senior Notes at a price equal to 101% of the principal amount, plus accrued and unpaid interest. The Senior Notes are senior unsecured obligations and rank equally in right of payment with all of the Company’s existing and future indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness. The Company’s obligations under the Senior Notes are guaranteed on a senior basis by all of its existing and subsequently acquired or organized wholly owned U.S. restricted subsidiaries that guarantee the Senior Credit Facilities. The Senior Notes and the related guarantees are effectively subordinated to the Company’s existing and future secured obligations and that of its affiliate guarantors to the extent of the value of the collateral securing such obligations and are structurally subordinated to all existing and future indebtedness and other liabilities of any of the Company’s subsidiaries that do not guarantee the Senior Notes. As of March 31, 2020, the Company was in compliance with all of the applicable covenants under the Senior Notes. Tangible Equity Unit Senior Amortizing Note Refer to Note 13, Tangible Equity Units for information. Other From time to time, the Company enters into deferred financing arrangements with certain vendors. The obligations under such arrangements are recorded at the present value of the scheduled payments. Such future payments totaled approximately $21,454 at March 31, 2020. Aggregate Future Maturities The aggregate amounts of future maturities by fiscal year under long-term debt arrangements are as follows:    2021 $ 278,778  2022 25,432  2023 4,658  2024 3,808,682  2025 1,000,382  Thereafter —  Total $ 5,117,932 

Interest Rate Cap Agreements

Interest Rate Cap Agreements	12 Months Ended
	Mar. 31, 2020
Interest Rate Cap Agreements [Abstract]
Interest Rate Cap Agreements	12. Interest Rate Cap Agreements Risk Management Objective of Using Derivatives The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk, primarily by managing the amount, sources and duration of its debt funding and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage differences in the amount, timing and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings. Cash Flow Hedges of Interest Rate Risk The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate cap agreements as part of its interest rate risk management strategy. Payments and receipts related to interest rate cap agreements are included in cash flows from financing activities in the Company’s consolidated statements of cash flows. In March 2016 and 2017, Legacy CHC and the Joint Venture, respectively, executed annuitized interest rate cap agreements with a combined notional amount of $650,000 and $750,000 , respectively, to limit the exposure of the variable component of interest rates under the then existing term loan facility or future variable rate indebtedness, each beginning March 31, 2017 and expired March 31, 2020 . Due to the proximity of this maturity to the date of the Merger, these interest rate cap agreements were not redesignated as cash flow hedges by the Company. Instead, the Company recognized an immaterial amount of interest expense related to the change in fair value of these instruments in its consolidated statement of operations for the year ended March 31, 2020. In August 2018, the Joint Venture executed additional annuitized interest rate cap agreements with notional amounts of $500,000 , accreting to $1,500,000 to limit the exposure of the variable component of interest rates under the T erm L oan F acility or future variable rate indebtedness to a maximum of 1.0% . The interest rate cap agreement s became effective August 31, 2018 , accreted to $1,500,000 and expire December 31, 2021 . Upon completion of the Merger, these agreements were redesignated as cash flow hedges of the Company. In March 2020, the Company executed additional annuitized interest rate cap agreements with notional amounts totaling $1,000,000 to limit the exposure of the variable component of the interest rates under the Term Loan Facility or future variable rate indebtedness to a maximum of 1.0% . Each interest rate cap agreement became effective March 31, 2020 and expires March 31, 2024 . A t March 31, 2020, each of the Company ’s outstanding interest rate cap agreements were designated as cash flow hedge s of interest rate risk and was determined to be highly effective. Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. T he Company estimates that $1,203 will be reclassified as an increase to interest expense within one year. T he fair value of the Company’s derivative instruments at March 31, 2020 and 2019 is as follows :     Fair Values of Derivative Financial Instruments  Asset (Liability)  Derivative financial instruments designated as hedging instruments: Balance Sheet Location March 31, 2020 March 31, 2019  Interest rate cap agreements Prepaid and other current assets $ — $ —  Interest rate cap agreements Accrued expenses (28,131) —  Interest rate cap agreements Other long-term liabilities (19,277) —  $ (47,408) $ —   Effect of Derivative Instruments on the Statement of Operations The effect of the derivative instruments on the accompanying consolidated statements of operations for the years ended March 31, 2020, 2019 and 2018 is as follows :    Year Ended Year Ended Year Ended  Derivative financial instruments in cash flow hedging relationships: March 31, 2020 March 31, 2019 March 31, 2018  Gain/(loss) related to derivative financial instruments recognized in other comprehensive income (loss) $ (1,361) $ — $ —  Gain/ (loss) related to portion of derivative financial instruments reclassified from accumulated other comprehensive income (loss) to interest expense $ (22) $ — $ —  Credit Risk- R elated Contingent Features The Company has agreements with each of its derivative counterparties providing that if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender, then the Company also could be declared in default on its derivative obligations. As of March 31, 2020, the termination value of derivative financial instruments in a net liability position, which includes accrued interest but excludes any adjustment for nonperformance risk, was $51,020 . If the Company had breached any of these provisions at Ma r ch 31, 2020, the Company could have been required to settle its obligations under the agreements at this termination value. The Company does not offset any derivative financial instruments and the derivative financial instruments are not subject to collateral posting requirements. 

Tangible Equity Units

Tangible Equity Units	12 Months Ended
	Mar. 31, 2020
Tangible Equity Units [Abstract]
Tangible Equity Units	13. Tangible Equity Units In July 2019, the Company completed its offering of 5,750,000 TEUs. Total proceeds, net of underwriting discounts, were $278,875 . Each TEU, which has a stated amount of $50 , is comprised of a stock purchase contract and a senior amortizing note due June 30, 2022 . The Company allocated the proceeds from the issuance of the TEUs to equity and debt based on the relative fair values of the respective components of each TEU. The value allocated to the stock purchase contracts is reflected net of issuance costs in additional paid in capital. The value allocated to the senior amortizing notes is reflected in debt on the consolidated balance sheets, with payments expected in the next twelve months reflected in current maturities of long-term debt. Issuance costs, reflected as a reduction of the face amount of the amortizing notes, are being accreted to the face amount of the debt under the effective interest method. The aggregate values assigned upon issuance of the TEUs, based on the relative fair value of the respective components of each TEU, were as follows:    Equity Component Debt Component Total  Price per TEU $ 41.7622 $ 8.2378 $ 50.00  Gross proceeds 240,133 47,367 287,500  Issuance costs (7,204) (1,421) (8,625)  Net proceeds $ 232,929 $ 45,946 $ 278,875  Each senior amortizing note has an initial principal amount of $8.2378 and bears interest at 5.5% per year. On each March 30, June 30, September 30 and December 30, the Company pays equal quarterly cash installments of $0.7500 per amortizing note (except for the September 30, 2019 installment payment, which was $0.7417 per amortizing note). Each installment constitutes a payment of interest and partial payment of principal. Unless settled earlier, each purchase contract will automatically settle on June 30, 2022 . The Company will deliver between a minimum of 18,429,325 shares and a maximum of 22,115,075 shares of the Company’s common stock, subject to adjustment, based on the Applicable Market Value (as defined below) of the Company’s common stock as described below: · If the Applicable Market Value is greater than $15.60 per share, holders will receive 3.2051 shares of common stock per purchase contract. · If the Applicable Market Value is less than or equal to $15.60 per share but greater than or equal to $13.00 per share, the holder will receive a number of shares of the Company’s common stock per purchase contract equal to $50 , divided by the Applicable Market Value; and · If the Applicable Market Value is less than $13.00 per share, the holder will receive 3.8461 shares of common stock per purchase contract. The Applicable Market Value is defined as the arithmetic average of the volume weighted average price per share of the Company’s common stock over the twenty consecutive trading day period immediately preceding the balance sheet date, or June 30, 2022, for settlement of the stock purchase contracts. The TEUs have a dilutive effect on the Company’s net income (loss) per share. The 18,429,325 minimum shares to be issued are included in the calculation of basic net income (loss) per share. The difference between the minimum shares and the maximum shares are potentially dilutive securities, and accordingly, are included in the Company’s diluted net income (loss) per share on a pro rata basis to the extent the Applicable Market Value is higher than $13.00 but is less than $15.60 at period end. After the initial issuance date, the Company may elect to have the purchase contracts settled prior to the mandatory settlement date, June 30, 2022 . Upon settlement, each purchase contract will be settled for Joint Venture units equal to 3.2051 units per purchase contract. The following table summarizes TEU activity for the year ended March 31, 2020:     Tangible  Equity Units  Outstanding at beginning of year —  Issued 5,750,000  Conversions (612,655)  Outstanding at end of year 5,137,345  

Net Income (Loss) Per Share

Net Income (Loss) Per Share	12 Months Ended
	Mar. 31, 2020
Net Income (Loss) Per Share [Abstract]
Net Income (Loss) Per Share	1 4 . Net Income (Loss) Per Share The following table sets forth the computation of basic net income (loss) per share of common stock:       Year Ended Year Ended Year Ended  March 31, 2020 March 31, 2019 March 31, 2018  Basic net income (loss) per share:  Numerator:  Net income (loss) $ (947,597) $ (52,012) $ 60,955  Denominator:  Weighted average common shares outstanding 123,387,547 75,513,130 75,590,613  Minimum shares issuable under purchase contracts 13,609,077 — —  136,996,624 75,513,130 75,590,613  Basic net income (loss) per share $ (6.92) $ (0.69) $ 0.81   Diluted net income per share:  Numerator:  Net income (loss) $ (947,597) $ (52,012) $ 60,955  Denominator:  Number of shares used in basic computation 136,996,624 75,513,130 75,590,613  Weighted average effect of dilutive securities  Time-Vesting Options — — 2,051,346  Restricted Share Units — — 159,137  136,996,624 75,513,130 77,801,096  Diluted net income (loss) per share $ (6.92) $ (0.69) $ 0.78 Due to their antidilutive effect, the following securities have been excluded from diluted net income (loss) per share:    Year Ended Year Ended Year Ended  March 31, 2020 March 31, 2019 March 31, 2018  Dilutive shares issuable under purchase contracts 1,829,437 — —  Time-Vesting Options 1,259,594 1,869,456 4,570,624  Restricted Share Units 1,345,211 — —  Deferred Stock Units 20,371 — — 

Incentive Compensation Plans

Incentive Compensation Plans	12 Months Ended
	Mar. 31, 2020
Incentive Compensation Plans [Abstract]
Incentive Compensation Plans	 1 5 . I ncentive Compensation Plans Prior to the Merger, the Company provided equity awards to employees of the Joint Venture which were subject to the accounting framework for awards granted to non-employees. Under this framework, the Company recognized stock compensation expense within the Loss from Equity Method Investment in the Joint Venture caption on the consolidated statements of operations for its proportionate amount of stock compensation expense included in the operating results of the Joint Venture as well as the amount funded for the benefit of the McKesson member. However, due to requirements of the LLC Agreement, as described in Note 22, Related Party Transactions , the Company recognized a dividend receivable equal to the cumulative amount of stock compensation expense recognized by the Joint Venture for any outstanding equity awards with an offset to the Loss from Equity Method Investment in Joint Venture. As a result, no net equity compensation expense of the Joint Venture was recognized in the financial statements of the Company. Legacy CHC Equity Plan In connection with the Transactions, the Company assumed and amended the Legacy CHC Equity Plan. Pursuant to the amended Legacy CHC Equity Plan , 37.9 million shares of the Company’s common stock have been reserved for the issuance of equity awards to employees, directors and consultants of the Joint Venture and its affiliates. The Company grant ed equity-based awards of its common stock to certain employees, officers and directors of the Joint Venture under terms of awards that are described below. Grants under the Legacy CHC Equity Plan consist of one or a combination of time-vested and/or performance-based awards. In most circumstances, the shares issued upon exercise of the equity awards are subject to certain call rights by the Company in the event of termination of service of an award holder and put rights by the award holder or his/her beneficiary in the event of death or disability. The Company expects to repurchase shares of common stock held by former Joint Venture employees no earlier than six months following the issuance of such shares. Replacement Awards In connection with the Transactions, the Company was obligated to either assume obligations under Legacy CHC’s prior equity award plans or to issue substantially equivalent equity awards. The Company elected to issue replacement awards with vesting and exercisability terms generally identical to the awards which were replaced. Because the stock of eRx Network and the 2017 Tax Receivable Agreement were distributed to Legacy CHC stockholders immediately prior to the Transactions, certain participants in the Legacy CHC Equity Plan also received equity awards in eRx Network and the right to receive a cash payment related to a proportionate value of the 2017 Tax Receivable Agreement in connection with the Transactions. These replacement awards granted under the Legacy CHC Equity Plan consisted of one, or a combination of, time-vested awards and/or performance-based awards. Vested Awards : Vested awards consist of the following: (i) Tier I Time-Vesting Awards became immediately vested in connection with the Transactions, 54.4% of which were liquidated for cash upon the closing of the Transactions. The remaining 45.6% of such options were exchanged for vested options of the Company with exercise prices and expiration terms that correspond with those of the original grant to Legacy CHC Equity Plan participants (“Replacement Time-Vesting Options”). These Legacy CHC Equity Plan participants also received vested options in eRx Network with exercise prices equal to 25% of the fair value of the eRx Network stock and a cash payment related to the proportionate value of the 2017 Tax Receivable Agreement at the time of the Transactions. (ii) Tier II Time-Vesting Awards became immediately vested in connection with the Transactions but because the original exercise price of these awards was greater than the fair value of the stock at the time of the Transactions, none of the awards were liquidated and they were replaced with vested Replacement Time-Vesting Options with an exercise price equal to the original exercise price as reduced by the fair value of one share of eRx Network stock. (iii) 2.0x Exit-Vesting Awards became immediately vested in connection with the Transactions as a result of meeting the specified performance and market conditions outlined in the original award terms. As with the Tier I Time-Vesting Awards, 54.4% were liquidated for cash upon the closing of the Transactions. The remaining 45.6% of such options were exchanged for vested Replacement Time-Vesting Options with exercise prices and expiration terms that correspond with those of the original grant to the Legacy CHC Equity Plan participants. The Legacy CHC Equity Plan participants also received vested options in eRx Network with exercise prices equal to 25% of the fair value of the eRx Network stock and a cash payment related to the proportionate value of the 2017 Tax Receivable Agreement at the time of the Transactions. Unvested Awards : Certain awards granted by Legacy CHC contained conditions that were not satisfied at the time of the Transactions. These awards generally consisted of awards that vest subject to the employee’s continued employment through the date when Blackstone has sold at least 25% of the maximum number of Legacy CHC’s shares held by it (i.e. a liquidity event) and achieved specified rates of return that vary by award. In connection with the Transactions, these unvested equity awards were replaced with unvested restricted stock of the Company (“Replacement Exit-Vesting Restricted Stock”) with an aggregate intrinsic value and vesting conditions which were identical to the original Legacy CHC awards. Legacy CHC Equity Plan participants also received unvested restricted stock of eRx Network and a right, contingent upon vesting of the awards, to receive a future cash payment related to the proportionate value of the 2017 Tax Receivable Agreement at the time of the Transactions. Restricted Stock Units : Vesting of Legacy CHC restricted share units was not affected by the Transactions. 54.4% of the vested portion of such restricted share units were liquidated in connection with the Transactions and the remainder of the vested and unvested restricted share units were replaced with vested and unvested Company restricted share units (“Replacement Restricted Share Units”) with terms identical to the original awards. Legacy CHC Equity Plan participants also received vested and unvested restricted share units of eRx Network and a right to receive a future cash payment upon vesting related to the proportionate value of the 2017 Tax Receivable Agreement at the time of the Transactions. The total fair value of shares vested during the years ended March 31, 2020, 2019 and 2018 was $0 , $0 and $1,440 , respectively. The following table summarizes Replacement Time-Vesting Option activity for the year ended March 31, 2020:     Replacement Weighted Average Aggregate  Time-Vesting Weighted Average Remaining Intrinsic  Options Exercise Price Contractual Term Value  Outstanding at April 1, 2019 4,529,291 $ 11.76 4.4 $ 39,896  Exercised (708,969) 15.66 — 5,077  Forfeited (361,578) — — 74  Outstanding at March 31, 2020 3,458,744 $ 11.95 3.3 $ 4,083  Exercisable at March 31, 2020 3,458,744 $ 11.95 3.3 $ 4,083  The following table summarizes Replacement Exit-Vesting Restricted Stock activity for the year ended March 31, 2020:     Replacement Exit-Vesting  Restricted Stock  Unvested at April 1, 2019 1,261,599  Canceled (255,881)  Unvested at March 31, 2020 1,005,718 Time-Vesting Options Time-vesting options were granted with an exercise price equal to the fair value of the Company’s common stock on the date of grant and generally vest in equal 25% installments on the first through fourth anniversary of the designated vesting start date, subject to the award holders continued employment through such vesting date. The Company estimates the fair value of the time-vesting options using the Black-Scholes option pricing model. As of March 31, 2020, unrecognized expense related to the time-vesting options was $3,611 . This expense is expected to be recognized over a weighted average period of 1.3 years. Exit-Vesting Options Exit-vesting options were granted with an exercise price equal to the fair value of the Company’s common stock on the date of grant and vest, subject to the award holder’s continued employment through the vesting date, on the earlier to occur of (i) the date that affiliates of Blackstone sell 25% of the equity interests of the Joint Venture held by it on March 1, 2017 (the “Transaction Date”) at a specified weighted average price per share and McKesson distributes more than 50% of the equity interests of the Joint Venture held by it on the Transaction Date or (2) McKesson and affiliates of Blackstone collectively sell more than 25% of the aggregate equity interests held by McKesson and Blackstone on the Transaction Date at a specified weighted average price per share. In May 2018, the terms of the Exit-Vesting Options and Replacement Exit-Vesting Restricted Stock were modified to permit, in addition to existing vesting provisions, vesting to occur in three equal installments commencing on the earlier to occur of the date that (i) affiliates of Blackstone sell more than 25% of the equity interests of the Joint Venture held by it on March 1, 2017 (the “Transaction Date”) and McKesson distributes more than 50% of the equity interests of the Joint Venture held by it on the Transaction Date or (ii) McKesson and affiliates of Blackstone collectively sell more than 25% of the aggregate equity interests held by McKesson and Blackstone on the Transaction Date. No effect on compensation expense was recognized in connection with this modification as the vesting of the affected awards remained not probable following the modification. The following table summarized time-vesting and exit-vesting option activity for the year ended March 31, 2020:       Weighted Average  Weighted Average Remaining Aggregate  Awards Exercise Price Contractual Term Intrinsic Value  Time-Vesting Exit-Vesting Time-Vesting Exit-Vesting Time-Vesting Exit-Vesting Time-Vesting Exit-Vesting  Options Options Options Options Options Options Options Options  Outstanding at April 1, 2019 6,988,403 6,504,544 $ 18.99 $ 18.99 8.0 8.0 $ 11,058 $ 10,292  Forfeited (1,256,156) (1,250,440) 18.99 18.99 — — — —  Outstanding at March 31, 2020 5,732,247 5,254,104 18.99 18.99 7.6 7.6 — —  Exercisable at March 31, 2020 3,743,688 — $ 18.99 $ — 7.5 — $ — $ —  Valuation Assumptions The following table summarizes the weighted average fair value of awards using the Black-Scholes and Monte Carlo Simulation option pricing models, as appropriate, and the weighted average assumptions used to develop the fair value estimates under each of the valuation models for the years ended March 31, 2020 and 2019.    Replacement  Time-Vesting Exit-Vesting Exit-Vesting  Options Options Restricted Stock  Year Ended March 31, 2020:  Weighted average fair value $ 2.10 $ 0.08 $ 2.15  Expected dividend yield — % — % — %  Expected volatility 52.0 % 50.9 % 76.9 %  Risk-free interest rate 0.3 % 0.3 % 0.9 %  Expected term (years) 3.8 4.1 0.9   Year Ended March 31, 2019:  Weighted average fair value $ 9.78 $ 5.90 $ 12.80  Expected dividend yield — % — % — %  Expected volatility 52.5 % 52.9 % 62.2 %  Risk-free interest rate 2.2 % 2.2 % 2.3 %  Expected term (years) 4.5 5.1 1.9 · Expected dividend yield – Prior to the Merger, t he Company was subject to limitations on the payment of dividends under the LLC Agreement. An increase in the dividend yield will decrease compensation expense. · Expected volatility – Expected volatility is a measure of the amount by which the price of the equity instrument has fluctuated or is expected to fluctuate. The expected volatility was based on the levered median historical volatility of a group of guideline companies. An increase in the expected volatility will increase compensation expense. · Risk-free interest rate – This is the U.S. Treasury rate as of the measurement date having a term approximating the expected life of the award. An increase in the risk-free interest rate will increase compensation expense. · Expected term – This is the period of time over which the awards are expected to remain outstanding. The Company estimates the expected term as the mid-point between the actual or expected vesting date and the contractual term. An increase in the expected term will increase compensation expense. Omnibus Incentive Plan Effective as of the Company’s initial public offering, the Company adopted the Change Healthcare Inc. 2019 Omnibus Incentive Plan (the “Omnibus Incentive Plan”) pursuant to which 25.0 million shares of the Company’s common stock have been reserved for issuance to employees, directors and consultants of the Company, the Joint Venture and its affiliates. In connection with the Omnibus Incentive Plan, Change Healthcare Inc., during the year ended March 31, 2020, granted to the Company’s and the Joint Venture’s employees and directors one or a combination of time-vesting restricted stock units (RSUs), time-vesting deferred stock units, performance stock units, and cash settled restricted stock units under vesting terms that generally vary from one to four years from the date of grant. Each of these instruments are described below. Restricted Stock Units (“RSUs”) –The RSUs are subject to either a graded vesting schedule over four years, or a one or four year cliff vesting schedule, depending on the terms of the specific award. Upon vesting, the RSUs are exchanged for shares of the Company’s common stock. Performance Stock Units (“PSUs”) – The PSUs consist of two tranches, one for which the quantity of awards expected to vest varies based on the Joint Venture’s compound annual revenue growth rate over a three year period in comparison to a target percentage and one for which the quantity of awards expected to vest varies based on the Joint Venture’s compound annual Adjusted EBITDA growth rate over a three year period in comparison to a target percentage. The awards earned upon satisfaction of the performance conditions become vested on the fourth anniversary of the vesting commencement date of the award (i.e., continued service is required beyond the satisfaction of the performance condition prior to vesting). The Company recognizes compensation expense for the PSUs based on the number of awards that are considered probable to vest. Recognition of expense is based on the probability of achievement of performance targets and is periodically reevaluated. Cash Settled Restricted Stock Units (“CSRSUs”) – The CSRSUs are expected to vest ratably over three years. Upon vesting, however, the Company is required to pay cash in settlement of such CSRSUs based on their fair value at the date such CSRSUs vest. Prior to the Merger, the Company was reimbursed by the Joint Venture for any cash settlements. Deferred Stock Units (“DSUs”) – The DSUs vest 100% upon the one -year anniversary of the date of grant. Unlike the RSUs, the DSUs are exchanged for shares of the Company’s common stock only following the participant’s separation from service. The following table summarizes Omnibus Incentive Plan activity for the year ended March 31, 2020:     Cash Settled  Restricted Deferred Restricted Performance  Stock Units Stock Units Stock Units Stock Units  Outstanding at April 1, 2019 — — — —  Granted 4,846,058 45,704 597,006 1,079,621  Cancelled (377,969) — (119,445) (113,932)  Outstanding at March 31, 2020 4,468,089 45,704 477,561 965,689  During the year ended March 31, 2020, the Company recognized compensation expense of $1,701 . At March 31, 2020, aggregate unrecognized compensation expense related to awards granted under the Omnibus Incentive Plan was $89,182 . 

Retirement Plans and Other Post

Retirement Plans and Other Postretirement Benefits	12 Months Ended
	Mar. 31, 2020
Retirement Plans and Other Postretirement Benefits[Abstract]
Retirement Plans and Other Postretirement Benefits	1 6 . Retirement Plans and Other Postretirement Benefits Defined Contribution Plans Employees may participate in one of the Company’s 401k plans, which provide for matching contributions. Expenses related to these 401k plans were immaterial for the years ended March 31, 2020, 2019 and 2018. Deferred Compensation Plans Certain of the Company’s employees are eligible to participate in deferred compensation plans. Pursuant to these deferred compensation plans, certain executives and other highly compensated employees may defer a portion of their salaries and incentive compensation at their discretion. The following table summarizes the liabilities related to this plan at March 31, 2020 and 2019:    March 31, March 31,  Balance Sheet Location 2020 2019  Accrued expenses $ 1,772 $ —  Other long-term liabilities 15,880 —  Total deferred compensation $ 17,652 $ — Post-employment Benefits The Company generally offers post-employment benefits to its employees in the case of certain employee termination events consisting of severance and outplacement services. The extent of such benefits varies based on employee title and accumulates based on the respective employee’s years of service. Due to the episodic nature of severance benefit history at the Joint Venture and the inability to reasonably predict future termination events, no accrual for accumulating severance benefits is accrued until the point that the payment of a severance benefit is probable and can be reasonably estimated. As of March 31, 2020 and 2019, the Company recognized liabilities related to these benefits of $5,927 and $0 , respectively. 

Tax Receivable Agreements

Tax Receivable Agreements	12 Months Ended
	Mar. 31, 2020
Tax Receivable Agreements [Abstract]
Tax Receivable Agreements	1 7 . Tax Receivable Agreements Upon the consummation of the Merger, the Company assumed obligations related to certain tax receivable agreements (collectively, the “tax receivable agreements”) entered into by the Joint Venture with its current and former owners. Depending on whether the respective tax receivable agreements were assumed as part of the Merger or became effective after the Merger, the liabilities related to the tax receivable agreements are subject to differing accounting models as explained below. 2009 - 2011 Tax Receivable Agreements Under the 2009 - 2011 Tax Receivable Agreements assumed by the Company in connection with the Merger, the Company is obligated to make payments to certain of the former Legacy CHC stockholders, equal to 85% of the applicable cash savings that the Joint Venture expects to realize as a result of tax attributes arising from certain previous transactions. As a result of the covered change of control with respect to the tax receivable agreements that occurred in connection with the Transactions, payments the Joint Venture makes under the 2009 - 2011 Tax Receivable Agreements are required to be calculated using certain valuation assumptions, including that the Joint Venture will have sufficient taxable income to use the applicable tax attributes and that certain of such tax attributes will be used by the Joint Venture on a pro rata basis from the date of the Transactions (or in certain cases from the date of certain previous transactions) through the expiration of the applicable tax attribute. The 2009 - 2011 Tax Receivable Agreements was measured at its fair value as part of the Merger and is recognized at its initial fair value plus recognized accretion to date on the Company’s consolidated balance sheet. 2017 Tax Receivable Agreement The 2017 Tax Receivable Agreement generally provides for the payment by Change Healthcare Performance, Inc. (a subsidiary of the Company) to affiliates of Blackstone and Hellman & Friedman of 85% of the net cash tax savings realized (or, in certain circumstances, deemed to be realized) in periods ending on or after the Transactions as a result of certain net operating losses and certain other tax attributes of Change Healthcare Performance, Inc. as of the date of the Transactions. The 2017 Tax Receivable Agreement was measured at its fair value as part of the Merger and is recognized at its initial fair value plus recognized accretion to date on the Company’s consolidated balance sheet. Based on facts and circumstances at March 31, 2020, the Company estimates the aggregate payments due under these tax receivable agreements in future fiscal years to be as follows:    2009 - 2011 Tax Receivable Agreements 2017 Tax Receivable Agreement Total  2021 $ 18,714 $ 1,520 20,234  2022 20,113 2,281 22,394  2023 20,084 47,384 67,468  2024 19,358 26,551 45,909  2025 17,917 8,441 26,358  Thereafter 102,942 29,479 132,421  Gross expected payments 199,128 115,656 314,784  Less: Amounts representing discount (55,945) (60,779) (116,724)  Total tax receivable agreement obligations due to related parties 143,183 54,877 198,060  Less: Current portion due (included in due to related parties, net) (18,714) (1,520) (20,234)  Tax receivable agreement long-term obligations due to related parties $ 124,469 $ 53,357 $ 177,826  McKesson Tax Receivable Agreement In connection with the closing of the Transactions, the Joint Venture, the McK Members, McKesson and the Company entered into a tax receivable agreement (the “McKesson Tax Receivable Agreement”). The McKesson Tax Receivable Agreement generally requires payment to affiliates of McKesson (the “McKesson TRA Parties”) of 85% of certain cash tax savings realized (or, in certain circumstances, deemed to be realized) by the Company in periods ending on or after the date on which McKesson ceases to own at least 20% of the Joint Venture as a result of (i) certain amortizable tax basis in assets transferred to the Joint Venture at the Contribution Agreement Closing and (ii) imputed interest deductions and certain other tax attributes arising from payments under the McKesson Tax Receivable Agreement. Following the McKesson exit and based on anticipated amortization allocations McKesson advised, the Company recorded an obligation of $164,633 as of March 31, 2020 for the McKesson Tax Receivable estimated payments, which represents a loss contingency under ASC 450 and is included in the other long-term liabilities caption within the accompanying consolidated balance sheet. Future changes in this value will be reflected within pretax income or loss. Based on facts and circumstances at March 31, 2020, the Joint Venture estimates the aggregate payments due under the McKesson Tax Receivable Agreement in future fiscal years to be as follows:    McKesson Tax Receivable Agreement  2021 $ —  2022 128  2023 18,306  2024 19,905  2025 23,150  Thereafter 103,144  Gross expected payments 164,633  Less: Amounts representing discount —  Total tax receivable agreement obligation 164,633  Less: Current portion due (included in accrued expenses) —  Tax receivable agreement long-term obligation (included in other long-term liabilities) $ 164,633  The timing and/or amount of aggregate payments due may vary based on a number of factors, including the amount of net operating losses and income tax rates. 

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2020
Income Taxes [Abstract]
Income Taxes	18. Income Taxes The income tax provision (benefit) for the years ended March 31, 2020, 2019, and 2018 was as follows:     Year Ended Year Ended Year Ended  March 31, 2020 March 31, 2019 March 31, 2018  Current:  Federal $ — $ — $ —  State 568 — —  Current income tax provision (benefit) 568 — —  Deferred:  Federal (113,523) (15,468) (116,563)  State (30,299) (3,127) (3,058)  Deferred income tax provision (benefit) (143,822) (18,595) (119,621)  Total income tax provision (benefit) $ (143,254) $ (18,595) $ (119,621)  Effective Tax Rate The reconciliation between the federal statutory rate and the effective income tax rate is as follows:    Year Ended Year Ended Year Ended  March 31, 2020 March 31, 2019 March 31, 2018  Statutory U.S. federal tax rate 21.0 % 21.0 % 31.5 %  State income taxes (net of federal benefit) 2.1 3.5 3.6  Remeasurement of deferred tax assets and liabilities arising from the Tax Legislation — — 166.9  Change in fair value of equity based awards (1.2) 1.0 —  Look through accounting policy election 2.1  Research and development credit 0.2 1.6 2.4  Goodwill impairment charge (10.8)  Other (0.3) (0.8) (0.5)  Effective income tax rate 13.1 % 26.3 % 203.9 %  Deferred Tax Assets and Liabilities For the years ended March 31, 2019 and earlier, the Company recorded its deferred tax assets and liabilities with respect to its investment in the Joint Venture under the outside basis approach. As a result of the Merger, the Company elected to begin recording those deferred tax assets and liabilities under the look through approach. As a result, the change in the deferred tax assets and liabilities in the year ended March 31, 2020 reflects the impact of both the Company’s change in accounting for its investment in the Joint Venture to the look through approach as well as the application of the guidance in ASC 805 for a business combination achieved in stages as described in Note 2, Business Combinations . The change from the outside basis approach to the look through approach resulted in the reduction of the Company’s deferred tax liability associated with its investment in the Joint Venture by $28,576 . Significant components of the Company’s deferred tax assets (liabilities) were as follows :     March 31, March 31,  2020 2019  Investment in the Joint Venture $ — $ (190,448)  Depreciation and amortization (1,034,407) —  Accounts receivable 5,793 —  Fair value of interest rate cap agreements 14,011 —  Accruals and reserves 15,680 —  Net operating losses 348,329 19,958  Debt discount and interest (9,661) —  Equity compensation 18,560 —  Valuation allowance (29,350) —  Tax receivable agreements obligations to related parties 68,900 —  163(j) Business interest expense limitation 23,842 7,711  Tax credits 16,629 2,786  Accounting method change (ASC 606 adoption) (31,886) —  Residual deferred tax asset 12,072 —  Other (3,696) —  Net deferred tax assets (liabilities) $ (585,184) $ (159,993)  Reported as:  Non-current deferred tax assets 30,720 —  Non-current deferred tax liabilities (615,904) (159,993)  Net deferred tax assets (liabilities) $ (585,184) $ (159,993) At March 31, 2020, the Company and its subsidiaries had net operating loss carryforwards for federal, state and foreign income tax purposes of $1,174,862 , $1,833,161 , and $15,260 , respectively, which expire from 2026 through 2040 , 2020 through 2040 and 2028 through 2037 , respectively. A portion of net operating loss carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods due to “change of ownership” provisions of the Internal Revenue Code and similar state provisions. However, we do not believe that the limitation will impact the Company’s ability to utilize the net operating loss carryforwards. At March 31, 2020, the Company and its subsidiaries had research and development (R&D) tax credit carryforwards for federal and state income tax purposes of $16,302 and $413 , respectively. The federal credits expire from 2038 through 2040 , while $116 of the state credits have an indefinite carryforward period and $197 of the state credits expire from 2033 through 2035 . The Company believes that it is more likely than not that the benefit from certain state and foreign net operating loss carryforwards and a residual deferred tax asset recorded in the look through approach will not be realized. In recognition of this risk, the Company has provided a valuation allowance of $17,279 on the deferred tax assets related to these state and foreign net operating loss carryforwards and a valuation allowance of $12,701 on the residual deferred tax asset . If recognized, the tax benefits related to any reversal of the valuation allowance on deferred tax assets as of March 31, 2020, will be accounted for as a reduction of income tax expense of $26,403 . Unrecognized Tax Benefits The federal, state, and foreign net operating loss carryforwards and R&D and tax credits within the income tax returns filed included unrecognized tax benefits. The deferred tax assets recognized for those net operating losses and R&D credits are presented net of these unrecognized tax benefits. A reconciliation of unrecognized tax benefits is as follows:    Year Ended Year Ended  March 31, 2020 March 31, 2019  Beginning unrecognized benefit $ 863 $ —  Decreases from prior period tax positions (2) —  Increases from prior period tax positions — 432  Increases from current period tax positions 769 431  Increases from acquisition 54,547 —  Ending unrecognized benefit $ 56,177 $ 863 If the above unrecognized tax benefits were recognized, $46,672 would affect the effective income tax rate. The Company recognizes interest income and expense (if any) related to income taxes as a component of income tax expense. The Company recognized interest and penalties of $138 , $0 , and $0 for the year s ended March 31, 202 0, 2019 and 2018, respectively . The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. The U.S. federal and state income tax returns for certain subsidiaries of the Company remain subject to examination by the Internal Revenue Service for the tax years 2012 and beyond ( i.e., periods prior to the Transactions) . With respect to state and local jurisdictions and international countries, the Company and its subsidiaries are typically subject to examination for a number of years after the income tax returns have been filed. Although the outcome of tax audits is always uncertain, the Company believes that adequate amounts of tax, interest and penalties have been provided for in the consolidated financial statements for any adjustments that may be incurred due to state, local or foreign audits. Tax Legislation Updates On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted. Included in the CARES Act are numerous income tax provisions including changes to the n et o perating l oss rules and the business interest expense deduction rules under Code Section 163(j). The Company anticipates benefiting from the changes to the business interest expense deduction rules which temporarily increase the amount of interest expense that businesses are allowed to deduct on their tax returns by increasing the 30% Adjusted Taxable Income limitation to 50% for corporations for tax years 2019 and 202 0 . Such benefit resulted in an increase in the amount of deductible interest available to the Company. However, this did not result in any immediate change to the Company’s tax position given the amount of net operating losses currently available. In addition, the CARES Act accelerates the remaining alternative minimum tax (“AMT”) credit refund allowances resulting in taxpayers being able to immediately claim a refund in full for any AMT credit carryforwards, which should provide the Company with the accelerated receipt of its AMT credit refund of $869 .

Commitments

Commitments	12 Months Ended
	Mar. 31, 2020
Commitments [Abstract]
Commitments	19. Commitments Lease Commitments The Company leases its offices and other facilities under operating lease agreements that expire at various dates through 2029 . The Company recognizes lease expense on a straight-line basis, including predetermined fixed escalations, over the initial lease term including reasonably assured renewal periods from the time that the Company controls the leased property. Total rent expense for all operating leases was $3,048 , $0 and $0 for the years ended March 31, 2020, 2019, and 2018, respectively. Other Commitments In February 2018, the Joint Venture, through one its wholly-owned subsidiaries, entered into a Master Services Agreement (the “Agreement”) with Wipro, LLC and Wipro Limited (jointly, “Wipro”). The term of the Agreement is ten years, with the Company having three one -year renewal options. The Company initially committed to purchase services from Wipro through the initial ten -year term of the Agreement (the “Minimum Commitment”) in an aggregate amount of $1 billion ; the Minimum Commitment was subsequently adjusted in March 2020 to $975 million . Under the Agreement, Wipro will globally provide the Company with professional services for information technology (including infrastructure, application development and maintenance), business process outsourcing, call center services and similar services. As the Company orders specific services under the Agreement , the parties will execute Statements of Work describing the specific scope of the services to be performed by Wipro. The amount of the Minimum Commitment may be reduced on the occurrence of certain events, some of which also provide the Company the right to terminate the Agreement. If the Company has not fully satisfied the Minimum Commitment (as reduced) by the end of the initial ten -year term, it is required to pay Wipro 25% of the shortfall. In connection with the Agreement, the Company expects to incur significant severance costs related to the transition of services currently performed by the Company to Wipro. However, pending execution of future Statements of Work, the Company cannot reliably estimate the timing or amount of such future severance costs. Accordingly, the consolidated balance sheet reflects no accrual for such costs associated with the Agreement. Minimum Commitments Future minimum commitments by fiscal year as of March 31, 2020 consisted of the following:    Payments by Period  Total 2021 2022 2023 2024 2025 Thereafter  Operating lease obligations $ 141,010 $ 40,476 $ 34,750 $ 23,761 $ 15,393 $ 10,780 $ 15,850  Contingent consideration obligation 3,000 3,000 — — — — —  Purchase obligations and other 1,162,529 126,900 174,516 174,516 173,805 173,805 338,987  Total contractual obligations $ 1,306,539 $ 170,376 $ 209,266 $ 198,277 $ 189,198 $ 184,585 $ 354,837 (1) The Company expects to receive $1,562 of minimum rentals in the future under noncancelable subleases. 

Legal Proceedings

Legal Proceedings	12 Months Ended
	Mar. 31, 2020
Legal Proceedings [Abstract]
Legal Proceedings	20 . Legal Proceedings The Company is subject to various claims with customers and vendors, pending and potential legal actions for damages, investigations relating to governmental laws and regulators and other matters arising out of the normal conduct of its business. Government Subpoenas and Investigations From time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests also can lead to the assertion of claims or the commencement of civil or criminal proceedings against the Company and other members of the health care industry, as well as to settlements. Other Matters In the ordinary course of business, the Company is involved in various claims and legal proceedings. While the ultimate resolution of these matters has yet to be determined, the Company does not believe that it is reasonably possible that their outcomes will have a material adverse effect on the Company’s consolidated financial position, results of operations, or liquidity. 

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Mar. 31, 2020
Stockholders' Equity [Abstract]
Stockholders' Equity	2 1 . Stockholders’ Equity Under the amended certificate of incorporation and until the Merger, the Company was authorized to issue 9,000,000,001 shares of stock consisting of 9,000,000,000 shares of common stock (“Common Stock”) and one share of Class X stock (“Class X Stock”), each with a par value of $0.001 per share. Each holder of Common Stock is entitled to one vote for each share of Common Stock held with respect to matters on which stockholders are generally entitled to vote. The share of Class X Stock was issuable to McKesson only in the event that the Company breached the terms of the Agreement and Plan of Merger between the Company and McKesson dated December 20, 2016 and only during the period following a qualified initial public offering and prior to a McKesson exit. In the event of issuance of Class X Stock, the holder would have received the right to appoint an additional director to the Company’s board of directors. As of March 31, 2020 and 2019, the Company has a total of 303,428,142 and 75,474,654 shares of Common Stock outstanding, respectively, and no Class X Stock outstanding. Furthermore , as a result of the Merger, the Class X Stock is no longer available for issuance as McKesson no longer has an ownership interest in the Joint Venture. 

Related Party Transactions

Related Party Transactions	12 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	2 2 . Related Party Transactions Registration Rights Agreement The Joint Venture, certain subsidiaries of the Joint Venture, McKesson and the Company are party to a registration rights agreement providing each of McKesson and the Legacy CHC Stockholders party thereto with customary demand and piggyback registration rights with respect to the Company’s common stock. These registration rights include the rights to register shares of the Company in an initial public offering, the rights to register shares of the Company during certain specified time windows and the rights to freely register shares of the Company after such specified time windows. Advances Received from the Joint Venture Under the terms of the LLC Agreement, the Joint Venture was required to periodically advance to its members amounts necessary to fund their respective tax obligations on an interim basis, subject to recoupment in the event that such advances exceed the final tax obligations of the respective Members for such year. Once the final tax obligations of each of the Members was determined for such year, the Joint Venture was obligated to formally distribute such amounts to the respective Members. To the extent that the amounts to be distributed were subject to interim advances, additional cash was distributed only to the extent that the interim advances were insufficient to fund the respective Member’s final tax obligation. Distributions up to the amount of interim advances result ed in full settlement of any advances to the respective Member. The Company received advances of $625 during the year ended March 31, 2020, repaid $9,869 of previous advances during the year ended March 31, 2019 and received advances of $15,828 during the year ended March 31, 2018. Prior to the Merger, s uch amounts were classified within Due to the Joint Venture on the consolidated balance sheets. Dilution Under the terms of the LLC Agreement, the Company and the Joint Venture agreed to cooperate to ensure a 1 :1 ratio of Company shares outstanding to units of the Joint Venture held by the Company for as long as the McKesson members hold units of the Joint Venture. Specifically, the parties agreed that: · In the event that the Company issues additional shares, the Joint Venture is required to issue a corresponding number of units to the Company. · Any net proceeds received by the Company with respect to a Company share must be concurrently contributed to the Joint Venture. · Any stock split or combination of other equity restructuring involving Company shares must be concurrent with an equivalent unit split or other equity restructuring of the Joint Venture. · The Company may not redeem, repurchase or otherwise acquire any Company shares unless substantially simultaneously the Joint Venture redeems, repurchases, or otherwise acquires from the Company an equal number of units for the same price per security. · The Joint Venture may not redeem, repurchase or otherwise acquire any units held by the Company unless substantially simultaneously the Company redeems, repurchases, or otherwise acquires an equal number of Company shares for the same price per security. Services Provided to the Company by the Joint Venture Prior to the Merger, t he Company generally ha d no substantive independent assets or operations apart from its investment in the Joint Venture. As a result, the Company receive d certain services from the Joint Venture and its employees for which the Joint Venture was not reimbursed. These services include the utilization of office space and a portion of the salaries of the Company’s officers who are considered employees of the Joint Venture. In addition, the Joint Venture was responsible for funding certain costs incurred in connection with the Company’s contemplated initial public offering and the Merger. Accordingly, the consolidated statements of operations reflect no expense related to these services through the date of the Merger for the year ended March 31, 2020 and for the full years ended March 31, 2019 and 2018. Management Fees Under the terms of the LLC Agreement, the Joint Venture was required to fund the cost of preparing for and executing an initial registration statement. Such costs may include legal, accounting and other professional service fees. To the extent that these fees are incurred for the benefit of the Joint Venture and funded by the Joint Venture, they are excluded from the Company’s financial statements. For other costs that are incurred by the Company for its benefit but funded by the Joint Venture, the reimbursement of such costs has been presented in the consolidated statements of operations as Management fees. Letter Agreement The Company, the Joint Venture, McKesson and certain of McKesson’s affiliates entered into a letter agreement relating to the Contribution Agreement (the “Letter Agreement”). The Letter Agreement addresse d miscellaneous tax-related matters, including (i) technical clarifications and modifications to the manner in which the Joint Venture allocates certain items of taxable income, loss and deduction among, and calculates and makes required tax distributions to, its members, (ii) the sharing of certain contingent tax benefits and expenses not addressed by the McKesson Tax Receivable Agreement or the tax matters agreement that the Company enter ed into with McKesson in connection with a spin-off or split-off transaction (or a combination of the foregoing) that McKesson could , at its election, initiate and complete that would result, among other things, in the acquisition by the Company of all of McKesson’s LLC Units and the issuance by the Company to McKesson and/or McKesson’s securityholders of an equal number of shares of its common stock and (iii) procedures applicable in the case of certain tax proceedings. In particular, pursuant to the terms of the Letter Agreement, McKesson was permitted to adjust the manner in which depreciation or amortization deductions in respect of assets transferred to the Joint Venture at the closing of the Transactions are allocated among the Company, McKesson and certain of McKesson’s affiliates. If McKesson chos e to allocate an amount of deductions to the Company in excess of a specified minimum threshold, the Company was required to make cash payments to McKesson equal to 100% of the tax savings of the Company attributable to such excess deductions for any tax period ending prior to the date on which McKesson cease d to own at least 20% of the outstanding LLC Units of the Joint Venture, after which the terms of the McKesson Tax Receivable Agreement w ould control. Effective with the consummation of the Merger, McKesson no longer holds an ownership interest in the Joint Venture and the matters addressed by the Letter Agreement are governed by the terms of McKesson Tax Receivable Agreement. eRx Network Option Agreement Prior to the Transactions, the equity interests for entities representing the eRx Network were distributed to the former Legacy CHC stockholders, and in connection therewith a Legacy CHC subsidiary and the Legacy CHC Stockholders entered into an option agreement for a subsidiary of the Joint Venture to acquire the eRx Network (the “Option Agreement”). Under the terms of the Option Agreement, the option to acquire the eRx Network will only become exercisable at any such time that McKesson owns (directly or indirectly), in the aggregate, less than 5% of the outstanding Units of the Joint Venture. Such option will expire, unexercised or unexercisable, on the fifth anniversary of the Transactions. Under the Option Agreement, upon exercise of the option, a Legacy CHC subsidiary will be required to pay an exercise price of $1.00 plus a fixed multiple of the incremental increase (if any) in the EBITDA (as defined in the Option Agreement) of the eRx Network for the trailing 12 months preceding the exercise of the option over a baseline level of such EBITDA. Upon completion of the Merger, the Option became exercisable. As a result, the Option Agreement was recognized as an Investment in business purchase option acquired as part of the purchase price allocation described in Note 2, Business Combinations . The value of the option was determined using a Monte Carlo simulation that utilizes assumptions with regard to future cash flows, which were then discounted to present value using an appropriate discount rate, and no adjustment to the carrying value of the option occurred between the Merger Effective Date and March 31, 2020. As of March 31, 2020, the option had not been exercised, but the Company subsequently exercised the option and completed its acquisition of eRx Network in May 2020. See Note 26, Subsequent Events , for additional information. 

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Mar. 31, 2020
Fair Value Measurements [Abstract]
Fair Value Measurements	2 3 . Fair Value Measurements Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company’s assets and liabilities that are measured at fair value on a recurring basis consist of derivative financial instruments and contingent consideration obligations and prior to the Merger, a freestanding derivative . The following table below summarize these items , aggregated by the level in the fair value hierarchy within which those measurements fall , as of March 31, 2020 and 2019:    Quoted in Significant  Balance at Markets Significant Other Unobservable  March 31, Identical Observable Inputs Inputs  Description 2020 (Level 1) (Level 2) (Level 3)  Interest rate cap agreements $ (47,408) $ — $ (47,408) $ —  Contingent consideration obligation (3,000) — — (3,000)  Total $ (50,408) $ — $ (47,408) $ (3,000)     Quoted in Significant  Balance at Markets Significant Other Unobservable  March 31, Identical Observable Inputs Inputs  Description 2019 (Level 1) (Level 2) (Level 3)  Freestanding derivative $ 81,264 $ — $ — $ 81,264  Total $ 81,264 $ — $ — $ 81,264  Derivative Financial Instruments The valuation of the Company’s derivative financial instruments is determined using widely accepted valuation techniques, including a discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivative, including the period to maturity, and uses observable market-based inputs, including interest rate curves. The fair value of the interest rate cap agreements are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments) using the overnight index swap rate as the discount rate. The Company incorporates credit valuation adjustments to appropriately reflect both its own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. In adjusting the fair value of its derivative contracts for the effect of nonperformance risk, the Company considered the impact of netting and any applicable credit enhancements and measures the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio. Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments utilize Level 3 inputs to evaluate the likelihood of default by itself and its counterparties. As of March 31, 2020, the Company determined that the credit valuation adjustments are not significant to the overall valuation of its derivatives. As a result, the derivative valuations are classified in Level 2 of the fair value hierarchy. Contingent Consideration The valuation of the Company’s contingent consideration obligations was determined using a discounted cash flow method that involved a M onte C arlo simulation. This analysis reflects the contractual terms of the purchase agreements (i.e., minimum and maximum payments, length of earn-out periods, manner of calculating amounts due, etc.) and utilizes assumptions with regard to future cash flows that were determined using a M onte C arlo simulation which were then discounted to present value using an appropriate discount rate. Significant increases with respect to assumptions as to future revenue would have resulted in a higher fair value measurement while an increase in the discount rate would have resulted in a lower fair value measurement. Freestanding Derivative Prior to the Merger, the Company was entitled to receive an additional LLC Unit for each share of stock issued by the Company. In the case of equity-based awards, the requirement to receive an additional LLC Unit upon exercise of such awards represented a freestanding derivative. Because the fair value measurement of this derivative involved significant unobservable inputs, the most significant of which in the value of the Company’s stock, the Company determined that it represented a Level 3 fair value measurement. Because the freestanding derivative was directly related to the Company’s equity-based compensation awards, the valuation of the derivative was determined with the valuation of the underlying equity-based awards. Changes in the value of the derivative are generally expected to fluctuate with changes in the value of the Company’s stock. As the dividend receivable was initially received in connection with the contribution of assets to the Joint Venture, the initial fair value was treated as a component of the Company’s contribution of assets and receipt of its Investment in the Joint Venture . During the years ended March 31, 20 20 and 201 9 , the Company recognized changes in the Dividend Receivable as a component of Loss from Equity Method Investment in the Joint Venture. The result is that no net equity-based compensation related to employees of the Joint Venture wa s recognized in the financial statements of the Company prior to the Merger . Following the adoption of FASB ASU No. 2018-07, however, the measurement of equity-based compensation generally becomes fixed at the date of grant such that the fair value of the dividend receivable wa s no longer correlated with the amount of equity compensation recognized. As a result, following the adoption of FASB ASU No. 2018-07, the Loss from Equity Method Investment in the Joint Venture wa s subject to variability associated with changes in the fair value of the equity-based awards. This freestanding derivative was settled as a result of the Merger and the fair value was included as part of the total purchase price of the transaction . The fair value of the freestanding derivative at March 31, 2020 and 2019 was $0 and $81,264 , respectively. This was presented within Dividend r eceivable on the consolidated balance sheets. The following table presents a reconciliation of the fair value of the freestanding derivative for which the Company uses significant unobservable inputs:    Year Ended Year Ended  March 31, 2020 March 31, 2019  Balance at beginning of period $ 81,264 $ 59,116  Increase in fair value based on ASC 505 equity-based compensation — 20,135  Settlements due to exercise of awards (5,077) (1,297)  Change in fair value of equity-based awards (33,409) 3,310  Settlement as component of Merger purchase price (42,778) —  Balance at end of period $ — $ 81,264  Assets and Liabilities Measured at Fair Value upon Initial Recognition The carrying amount and the estimated fair value of financial instruments held by the Company as of March 31, 2020 and 2019 were as follows :   March 31, 2020 March 31, 2019  Carrying Amount Fair Value Carrying Amount Fair Value  Cash and cash equivalents $ 410,405 $ 410,405 $ 3,409 $ 3,409  Accounts receivable $ 740,105 $ 740,105 $ — $ —  Investment in business purchase option $ 146,500 $ 146,500 $ — $ —  Senior Credit Facilities (Level 2) $ 3,682,457 $ 3,452,687 $ — $ —  Senior Notes (Level 2) $ 997,772 $ 950,000 $ — $ —  Debt component of tangible equity units (Level 2) $ 35,431 $ 34,806 $ — $ —  Additionally, the assets acquired and liabilities assumed as part of the Merger were recorded at fair value upon initial recognition. See Note 2, Business Combinations , for additional information. As described in Note 9, Goodwill and Intangible Assets , f air value assessments of the reporting unit s used in the Company’s impairment analysis are considered a Level 3 measurement due to the significance of unobservable inputs developed using company specific information. Investments in Businesses In December 2018, the Joint Venture purchased $15,000 of preferred shares of a health care company and $500 of shares in a related company holding certain intellectual property, each of which is classified within Other noncurrent assets, net on the accompanying consolidated balance sheets. Because this investment has no readily determinable fair value, the Joint Venture measures this investment at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.  

Segment Reporting

Segment Reporting	12 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Segment Reporting	24. Segment Reporting Beginning in fiscal year 2021, management expects to view the Company’s operating results based on the same three reportable segments that currently comprise the Joint Venture: (a) Software & Analytics, (b) Network Solutions and (c) Technology-Enabled Services. Prior to the Merger, the Company had minimal operations outside of its investment in the Joint Venture, and its standalone operating results were not utilized by management to make operating decisions, assess performance, or allocate resources. The Company’s chief operating decision maker (“CODM”) and management team, which is the same CODM and management team as of the Joint Venture, did not request or review financial results of the consolidated Company for the period from the date of the Merger through March 31, 2020. Management instead considers the results of its reportable segments for the year end ed March 31, 2020 to be best summarized in Note 26, Segment Reporting of the Joint Venture’s consolidated financial statements, which are included as Exhibit 99.1 to the Company’s Form 10-K. 

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	12 Months Ended
	Mar. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Abstract]
Accumulated Other Comprehensive Income (Loss)	2 5 . Accumulated Other Comprehensive Income (Loss) The following is a summary of the accumulated other comprehensive income (loss) activity for the years ended March 31, 2020, 2019 and 2018. Prior to the Merger, the activity in accumulated other comprehensive income (loss) reflects the Company’s proportionate share of the Joint Venture’s accumulated other comprehensive income (loss), net of taxes .    Foreign Accumulated  Available Currency Other  For Sale Translation Cash Flow Comprehensive  Debt Security Adjustment Hedge Income (Loss)  Balance at March 31, 2017 $ — $ 26 $ (338) $ (312)  Change associated with foreign currency translation — 1,242 — 1,242  Change associated with current period hedging (net of taxes of $623 ) — — 1,267 1,267  Reclassification into earnings — — 339 339  Balance at March 31, 2018 $ — $ 1,268 $ 1,268 $ 2,536   Cumulative effect of accounting change by the Joint Venture-ASU 2017-12 — — 490 490  Change associated with foreign currency translation — (2,833) — (2,833)  Change associated with current period hedging (net of taxes of $2,139 ) — — (1,671) (1,671)  Reclassification into earnings — — (1,778) (1,778)  Balance at March 31, 2019 $ — $ (1,565) $ (1,691) $ (3,256)   Cumulative effect of accounting change of the Joint Venture-ASU 2018-02 — — 422 422  Unrealized gain (loss) on available for sale debt securities of the Joint Venture 1,045 — — 1,045  Realized gain (loss) on available for sale debt securities of the Joint Venture (1,045) — — (1,045)  Change associated with foreign currency translation — (5,519) — (5,519)  Change associated with current period hedging (net of taxes of $607 ) — — 981 981  Reclassification into earnings — — — —  Balance at March 31, 2020 $ — $ (7,084) $ (288) $ (7,372) Effective April 1, 2018, the Joint Venture adopted ASU No. 2017-12, which significantly changed the framework by which hedge accounting is recognized, presented and disclosed in the Joint Venture’s financial statements. The adoption of this update by the Joint Venture resulted in a reclassification between accumulated other comprehensive income (loss) and accumulated earnings (deficit). Effective April 1, 2019, the Joint Venture adopted ASU No. 2018-02, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017. The adoption of this update resulted in a reclassification between accumulative other comprehensive income (loss) and accumulated earnings (deficit). 

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	2 6 . Subsequent Events Senior Note Issuance On April 21, 2020, the Company issued $325,000 of 5.75% unsecured senior notes due 2025 (“Senior Notes”) at 100% of their principal amount. The Senior Notes were issued as part of the same series as the $1,000,000 of 5.75% senior notes due 2025 issued in February 2017. Connected Analytics Divestiture On May 1, 2020, the Company completed the sale of its Connected Analytics business for total consideration of $55,000 , subject to a customary working capital adjustment, including a $25,000 note receivable from the buyer. eRx Network Option On May 1, 2020, the Company exercised its option to purchase and completed the acquisition of eRx Network, a leading provider in comprehensive, innovative and secure data-driven solutions for pharmacies. The Company acquired 100% of the ownership interest for a purchase price of $212,900 plus cash on the balance sheet. The Company expects to account for this transaction as a business combination. The initial accounting, including the identification and allocation of consideration to assets acquired and liabilities assumed, is not complete given the proximity of the acquisition to the financial statement filing date. PDX Acquisition On June 1, 2020, the Company completed the purchase of PDX, Inc. (“PDX”), a company focused on delivering patient centric and innovative technologies for pharmacies and health systems. The Company acquired 100% of the ownership interest for a purchase price of $208,000 , and the Company expects to account for this transaction as a business combination. The initial accounting, including the identification and allocation of consideration to assets acquired and liabilities assumed, is not complete given the proximity of the acquisition to the financial statement filing date. 

Quarterly Financial Information

Quarterly Financial Information	12 Months Ended
	Mar. 31, 2020
Quarterly Financial Information [Abstract]
Quarterly Financial Information	27. Quarterly Financial Information (unaudited) Selected quarterly financial information is as follows:    Total Revenue Income (Loss) Before Income Tax Net Income (Loss) Basic Net Income (Loss) Per Unit Diluted Net Income (Loss) Per Unit  Quarter Ended:  June 30, 2019 $ — $ (39,701) $ (37,517) $ (0.50) $ (0.50)  September 30, 2019 — (107,555) (93,935) (0.66) (0.66)  December 31, 2019 — 65,975 50,735 0.35 0.35  March 31, 2020 (1) 196,792 (1,009,571) (866,881) (4.65) (4.65)    Total Revenue Income (Loss) Before Income Tax Net Income (Loss) Basic Net Income (Loss) Per Unit Diluted Net Income (Loss) Per Unit  Quarter Ended:  June 30, 2018 $ — $ (22,302) (17,501) $ (0.23) $ (0.23)  September 30, 2018 — (25,374) (18,591) (0.25) (0.25)  December 31, 2018 — (17,468) (12,388) (0.16) (0.16)  March 31, 2019 — 65,144 48,480 (0.05) (0.05)  (1) Results for the quarter ended March 31, 2020 were impact ed by the Merger and recognition of a goodwill impairment charge . See Note 2 , Business Combinations and Note 9, Goodwill and Intangible Assets , for additional information.   

Significant Accounting Polici_2

Significant Accounting Policies (Policy)	12 Months Ended
	Mar. 31, 2020
Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and include all subsidiaries and entities that are controlled by the Company. The results of operations for companies acquired are included in the consolidated financial statements from the effective date of acquisition. All intercompany accounts and transactions have been eliminated in the financial statements. Because of the significance of the Joint Venture to the Company’s financial position and results of operations, the Company is required to provide consolidated financial statements of the Joint Venture pursuant to Rule 3-09 of Regulation S-X.
Accounting Estimates	Accounting Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors and various other assumptions that the Company believes are necessary to consider in order to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of expenses and disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic, environmental and political factors and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment changes. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in the reported results of operations; and if material, the effects of changes in estimates are disclosed in the notes to the financial statements. Estimates and assumptions by management affect: the allowance for doubtful accounts; the fair value assigned to assets acquired and liabilities assumed in business combinations; tax receivable agreement obligations; the fair value of interest rate cap agreement obligations; measurement of the components of tangible equity units; contingent consideration; loss accruals; the carrying value of the Company’s investments; the carrying value of long-lived assets (including goodwill and intangible assets); the amortization period of long-lived assets (excluding goodwill); the carrying value, capitalization and amortization of software development costs; the provision and benefit for income taxes and related deferred tax accounts; certain accrued expenses; revenue recognition; contingencies; and the value attributed to equity awards; the provision and benefit for income taxes and related deferred tax accounts; certain accrued expenses.
Business Combinations	Business Combinations The Company recognizes the consideration transferred (i.e., purchase price) in a business combination, as well as the acquired business’ identifiable assets, liabilities and noncontrolling interests at their acquisition date fair value. The excess of the consideration transferred over the fair value of the identifiable assets, liabilities and noncontrolling interest, if any, is recorded as goodwill. Any excess of the fair value of the identifiable assets acquired and liabilities assumed over the consideration transferred, if any, is generally recognized within earnings as of the acquisition date. The fair value of the consideration transferred, assets, liabilities and noncontrolling interests is estimated based on one or a combination of income, costs or market approaches as determined based on the nature of the asset or liability and the level of inputs available to the Company (i.e., quoted prices in an active market, other observable inputs or unobservable inputs). To the extent that the Company’s initial accounting for a business combination is incomplete at the end of a reporting period, provisional amounts are reported for those items which are incomplete.
Equity Method Investment in the Joint Venture	Equity Method Investment in the Joint Venture Prior to the Merger, the Company accounted for its investment in the Joint Venture using the equity method. During that period, the Company evaluated its equity method investment for impairment whenever an event or change in circumstances occurred that had a potentially significant adverse impact on the carrying value of the investment. During the period from the inception of the Joint Venture through the date of the Merger, the Company did not identify any loss in the value of its investment that it deemed other than temporary, and therefore did not recognize any loss from impairment.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less to be cash equivalents. The Company’s cash and cash equivalents are deposited with several financial institutions. Deposits may exceed the amounts insured by the Federal Deposit Insurance Corporation in the U.S. and similar deposit insurance programs in other jurisdictions. The Company mitigates the risk of our short-term investment portfolio by depositing funds with reputable financial institutions and monitoring risk profiles. The Company’s cash balances from time to time include funds it manages for customers, the most significant of which relates to funds remitted to retail pharmacies. Such funds are not restricted; however, these funds are generally paid out in satisfaction of the processing obligations pursuant to the management contracts. At the time of receipt, the Company records a corresponding liability within accrued expenses on the accompanying consolidated balance sheets. Such liabilities are summarized as “Pass-through payments” within Note 11, Accrued Expenses .
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts The allowance for doubtful accounts was $22,360 at March 31, 2020 and $0 at March 31, 2019 and all prior balance sheet dates. The allowance for doubtful accounts reflects the Company’s best estimate of losses inherent in the Company’s receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available evidence. The following table summarizes activity related to the allowance for doubtful accounts:     Year Ended Year Ended  March 31, March 31,  2020 2019  Balance at beginning of period $ — $ —  Acquisition in Merger 22,059 —  Provisions 905 —  Write-offs (604) —  Balance at end of period $ 22,360 $ — 
Capitalized Software Developed for Internal Use	Capitalized Software Developed for Internal Use The Company provides services to many of its customers using software developed for internal use. The costs that are incurred to develop such software are expensed as incurred during the preliminary project stage and classified within research and development in the consolidated statements of operations. Once certain criteria have been met, direct costs incurred in developing or obtaining computer software are capitalized. Training and maintenance costs are expensed as incurred. Capitalized software costs are included in other noncurrent assets, net on the consolidated balance sheets and are generally amortized over the estimated useful life of three years .
Capitalized Software Developed for Sale	Capitalized Software Developed for Sale Development costs for software developed for sale to external customers are capitalized once a project has reached the point of technological feasibility. Completed projects are amortized after reaching the point of general availability using the straight-line method based on an estimated useful life of approximately three years . At each balance sheet date, or earlier if an indicator of an impairment exists, the Company evaluates the recoverability of unamortized capitalized software costs based on estimated future undiscounted revenues net of estimated related costs over the remaining amortization period.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation, including that related to assets under capital lease, is computed using the straight-line method over the estimated useful lives of the related assets. Expenditures for maintenance, repair and renewals of minor items are expensed as incurred. Expenditures for repair and renewals that extend the useful life of an asset are capitalized.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill and intangible assets resulting from the Company’s acquisitions are accounted for using the acquisition method of accounting. Intangible assets with definite lives are amortized over their useful lives either on a straight-line basis or using an accelerated method, depending on the pattern that the Company expects the economic benefits of the assets to be consumed. Useful lives of the related assets generally are as follows:    Customer relationships 12 - 16 years Tradenames 18 years Technology-based intangible assets 6 - 12 years  The Company assesses its goodwill for impairment annually (as of January 1 of each year) or whenever significant indicators of impairment are present. The Company first assesses whether it can reach a more likely than not conclusion that goodwill is not impaired via qualitative analysis alone. To the extent such a conclusion cannot be reached based on a qualitative assessment alone, the Company, using the assistance of a valuation specialist as appropriate, compares the fair value of each reporting unit to its associated carrying value. The Company will generally recognize an impairment charge for the amount, if any, by which the carrying amount of the reporting unit exceeds its fair value.
Long-Lived Assets	Long-Lived Assets Long-lived assets used in operations are reviewed for impairment whenever events or changes in circumstances indicate that carrying amounts may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. Long-lived assets held for sale are reported at the lower of cost or fair value less costs to sell.
Derivatives	Derivatives Derivative financial instruments are used to manage the Company’s interest rate exposure. The Company does not enter into financial instruments for speculative purposes. Derivative financial instruments are accounted for and measured at fair value. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the forecasted transaction in the same period or periods during which the hedged transaction affects earnings (for example, in “interest expense” when the hedged transactions are interest cash flows associated with floating-rate debt). Receipts and payments under the derivative instruments are classified within cash flows from financing activities on the accompanying statements of cash flows.
Tangible Equity Units	Tangible Equity Units In connection with the initial public offering, the Company completed an offering of TEUs. Each TEU comprises an amortizing note and purchase contract, both of which are freestanding instruments and separate units of account. The amortizing notes were issued at par and are classified as debt on the accompanying condensed consolidated balance sheet, with scheduled principal payments over the next twelve months reflected in current maturities of long-term debt. The purchase contracts are accounted for as prepaid forward contracts and classified as equity. The TEU proceeds and issuance costs were allocated to the amortizing notes and purchase contracts on a relative fair value basis. See Note 13, Tangible Equity Units for further discussion.
Other Investments	Other Investments The proceeds of the offering of TEUs were used to acquire TEUs of the Joint Venture that substantially mirror the terms of the TEUs included in the offering. Under these mirrored arrangements, the Joint Venture is required to make cash payments or to transfer LLC Units to the Company concurrent with any cash payments or issuance of shares by the Company pursuant to the terms of its TEUs. Prior to the Merger, the Company accounted for these mirror arrangements as investments in debt and equity securities. The Company’s investment in debt securities were classified as “available-for-sale” and its investment in forward purchase contracts were considered equity securities measured at fair value. Changes in unrealized gains and losses for the Company’s debt securities were recognized as adjustments to other comprehensive income (loss) while changes in unrealized gains and losses for the Company’s investment in forward purchase contracts are recognized as adjustments to pretax income (loss). After the Merger, the Company’s investment in the TEUs of the Joint Venture is eliminated in the consolidated financial statements. See Note 22, Related Party Transactions , for a discussion regarding the Investment in business purchase option.
Equity Compensation	Equity Compensation The Company measures stock-based compensation cost at the grant date based on the estimated fair value of the award and recognizes the expense over the requisite service period, typically on a straight-line basis. The Company recognizes stock-based compensation cost for awards with performance conditions if and when it concludes that it is probable that the performance conditions will be achieved. The fair value of equity awards is recognized as an asset or expense in the same period and in the same manner as if the Company had paid cash for the goods or services. The Company recognizes forfeitures as they occur. Prior to the Merger, these equity awards, as well as awards granted under the Company’s previous equity incentive plan, were granted to employees of the Company’s equity method investee, and therefore were subject to the accounting framework for awards granted to non-employees. Under this framework, the Company measured the compensation expense for equity awards based on the estimated fair value of such awards at the grant date, in a manner consistent with the recognition of expense for awards to employees. The recognized pre-Merger equity-based compensation is classified within loss from equity method investment in the Joint Venture on the consolidated statement of operations. However, as a result of a requirement that the Joint Venture issue an additional LLC Unit to the Company upon the exercise of each Company equity award (as described in Note 22, Related Party Transactions ), the Company recognized an offsetting amount (i.e., a deemed dividend) within the same caption on the consolidated statements of operations. Prior to the Merger, the Company recognized this deemed dividend as a receivable equal to the cumulative amount of stock compensation expense recognized by the Joint Venture for any outstanding equity awards. The dividend receivable was relieved upon exercise of the respective underlying equity awards. The Company’s dividend receivable from the Joint Venture was settled upon completion of the Merger.
Revenue	Revenue The Company recognizes revenue at an amount that reflects the consideration it expects to be entitled to in exchange for transferring goods or services to a customer, in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). See Note 4, Revenue Recognition , for additional information.
Income Taxes	Income Taxes The Company records deferred income taxes for the tax effect of differences between book and tax bases of its assets and liabilities, as well as differences relating to the timing of recognition of income and expenses. Deferred income taxes reflect the available net operating losses and the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of the future tax benefits related to deferred tax assets is dependent on many factors, including the Company’s past earnings history, expected future earnings, the character and jurisdiction of such earnings, reversing taxable temporary differences, unsettled circumstances that, if unfavorably resolved, would adversely affect utilization of its deferred tax assets, carryback and carryforward periods and tax strategies that could potentially enhance the likelihood of realization of a deferred tax asset. The Company recognizes tax benefits for uncertain tax positions at the time the Company concludes that the tax position, based solely on its technical merits, is more likely than not to be sustained upon examination. The benefit, if any, is measured as the largest amount of benefit, determined on a cumulative probability basis that is more likely than not to be realized upon ultimate settlement. Tax positions failing to qualify for initial recognition are recognized in the first subsequent interim period that they meet the more likely than not standard, upon resolution through negotiation or litigation with the taxing authority or on expiration of the statute of limitations.
Warranties	Warranties In the normal course of business, the Company provides warranties regarding the performance of software and products it sells. The Company’s liability under these warranties is to bring the product into compliance with previously agreed upon specifications. For software products, this may result in additional project costs, which are reflected in our estimates used for the percentage of completion method of accounting for software installations services within these contracts. In addition, most of the Company’s customers who purchase software and automation products also purchase annual maintenance agreements. Revenues from these maintenance agreements are recognized on a straight-line basis over the contract period and the cost of servicing product warranties is charged to expense when claims become estimable. As of March 31, 2020 and 2019, accrued warranty costs were immaterial.
Classification of Distributions Received from the Joint Venture	Classification of Distributions Received from the Joint Venture Prior to the Merger, the Company classifies distributions received from the Joint Venture in its consolidated statement of cash flows according to the nature of the distribution.
Accounting Pronouncements Not Yet Adopted and Recently Adopted Accounting Pronouncements	Accounting Pronouncements Not Yet Adopted In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, as amended by ASU No. 2018-19, which requires that a financial asset (or group of financial assets) measured at amortized cost be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the reported amount. This update is scheduled to be effective for the Company beginning April 1, 2020. The Company is currently assessing the potential effects this update may have on its consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, which modifies the disclosure requirements for fair value measurements. ASU 2018-13 is effective for the Company beginning April 1, 2020. Early adoption is permitted for either the entire standard or only the provisions that eliminate or modify requirements. The Company is currently assessing the potential effects this update may have on its financial statement disclosures. In February 2016, the FASB issued ASU No. 2016-02, which generally requires that all lease obligations be recognized on the balance sheet at the present value of the remaining lease payments with a corresponding right of use asset (“ROU asset)”. As originally issued, the standard required that companies adopt the standard using the modified retrospective transition method and report a cumulative effect adjustment to the opening balance of retained earnings in the earliest comparative period presented. In July 2018, the FASB issued ASU No. 2018-11 which provides companies with the option to apply this cumulative effect adjustment to the opening balance of retained earnings in the period of adoption instead of the earliest comparative period presented. This update is effective for the Company beginning April 1, 2020, with early adoption permitted. The Company will utilize the modified retrospective approach upon adoption. While the Company is finalizing the assessment on the effect of adoption, the most significant impact is expected to relate to the recognition of new ROU assets and lease liabilities on the Company’s consolidated balance sheet for operating leases, as well as additional disclosures. Consequently, with adoption, the Company expects to recognize additional ROU assets and corresponding operating lease liabilities of between $110,000 and $125,000 . In August 2018, the FASB issued ASU No. 2018-15, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This update also requires that the effects of such capitalized costs be classified in the same respective caption of the statement of operations, balance sheet and cash flows as the underlying hosting arrangement. Upon adoption, a company may elect to either retrospectively restate each prior reporting period or apply the update prospectively to all implementation costs incurred after the effective date. This update is scheduled to be effective for the Company beginning April 1, 2020. The Company will adopt the new guidance prospectively and is assessing the potential effects this update may have on its consolidated financial statements. The Company does not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on the consolidated financial statements. Recently Adopted Accounting Pronouncements In April 2019, the Company adopted ASU No. 2018-16, which adds the Overnight Index Swap rate based on the Secured Overnight Financing Rate as a benchmark interest rate for hedging purposes. As the adoption of this update applies only to qualifying new or redesignated hedging relationships entered into following the date of adoption, its adoption had no immediate effect on the consolidated financial statements. In April 2019, the Company adopted ASU No. 2018-02, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 (“Tax Legislation”). The adoption of this update was not material and is limited to the separate disclosure in Note 26, Accumulated Other Comprehensive Income related to the reclassification of such stranded costs from accumulated comprehensive income (loss) to accumulated deficit. In April 2019, the Company adopted ASU No. 2018-07, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. Among other provisions, the measurement date for awards to nonemployees changed from the earlier of the date at which a commitment for performance by the counterparty is reached or the date at which performance is complete under the previous guidance to the grant date under this update. Because the Company’s equity-based compensation was previously subject to remeasurement at fair value each quarter under the previous authoritative literature, the effect of the adoption of this update had no material effect on the consolidated financial statements. In April 2019, the Company and the Joint Venture adopted ASC 606 on a modified retrospective basis. ASC 606 replaced most prior general and industry specific revenue recognition guidance with a principles-based comprehensive revenue recognition framework. Under this revised framework, a company recognizes revenue to depict the transfer of promised goods and services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. Prior to the Merger, the Company’s operations consisted principally of an investment in the Joint Venture, its financial statements reflected no revenue and, accordingly, the Company recognized no direct impact on its financial statements from the adoption of this update. However, upon adoption, the Joint Venture recognized a cumulative effect adjustment to its Members’ deficit. As a result of the impact of the adoption of ASC 606 to the Joint Venture’s Members’ deficit, the Company was required to recognize a proportionate amount of this cumulative effect adjustment to its April 1, 2019 retained earnings as well. The effect is disclosed within a separate caption of the accompanying consolidated statement of stockholders’ equity. The adoption of the new standard had an immaterial impact on the Company’s consolidated statement of cash flows for the fiscal year ended March 31, 2020. See Note 4, Revenue Recognition for more information.

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Mar. 31, 2020
Business Combinations [Abstract]
Summary of Provisional Fair Values of Identifiable Assets and Liabilities	  Net Assets acquired  Cash $ 330,665  Accounts receivable, net of allowance for doubtful accounts of $22,059 718,895  Contract assets 132,704  Prepaid and other current assets 115,265  Investment in business purchase option 146,500  Property and equipment, net 206,751  Goodwill 4,360,648  Other noncurrent assets 169,539  Identified intangible assets:  Customer relationships (life 12 - 16 years) 3,056,000  Tradenames (life 18 years) 146,000  Technology-based intangible assets (life 6 - 12 years) 1,188,000  Drafts and accounts payable (60,637)  Accrued expenses (559,456)  Deferred revenues, current (292,528)  Current portion of long-term debt (28,969)  Other current liabilities (22,732)  Long-term debt, excluding current portion (4,713,565)  Deferred income tax liabilities (578,076)  Tax receivable agreement obligations with related parties (176,586)  Other long-term liabilities (102,675)  Net Assets acquired $ 4,035,743   Summary of purchase consideration:  Fair value of shares issued to SpinCo shareholders  ( 175,995,192 shares at $12.47 per share):  Common Stock, $0.001 par value $ 176  Additional paid-in capital 2,194,484  Fair value of Joint Venture equity interest previously held 1,589,040  Fair value of Joint Venture equity interest previously held through TEUs 216,764  Settlement of dividend receivable 42,778  Repayment of advances to member (7,499)  Purchase consideration $ 4,035,743 
Supplemental Pro Forma Results	  (Unaudited) Year ended March 31,  2020 2019  Results of acquired business since acquisition date of March 10, 2020:  Revenue $ 196,792 n/a  Net income (loss) $ 297 n/a   Supplemental pro forma data for combined entity:  Revenue $ 3,290,734 $ 3,133,907  Net income (loss) $ (228,234) $ (128,889)  Net income (loss) per share, basic and diluted $ (0.75) $ (0.43) 

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2020
Significant Accounting Policies [Abstract]
Summary of Activity Related to Allowance for Doubtful Accounts	    Year Ended Year Ended  March 31, March 31,  2020 2019  Balance at beginning of period $ — $ —  Acquisition in Merger 22,059 —  Provisions 905 —  Write-offs (604) —  Balance at end of period $ 22,360 $ — 
Schedule of Finite-Lived Intangible Assets Useful Lives	   Customer relationships 12 - 16 years Tradenames 18 years Technology-based intangible assets 6 - 12 years  

Equity Method Investment in C_2

Equity Method Investment in Change Healthcare LLC (Tables)	12 Months Ended
	Mar. 31, 2020
Equity Method Investment in Change Healthcare LLC [Abstract]
Summarized Financial Information of the Joint Venture	  Period of Year Ended Year Ended  April 1, 2019 to March 31, March 31,  Statement of Operations Data: March 10, 2020 2019 2018  Net revenue $ 3,092,875 $ 3,281,729 $ 3,298,843  Cost of operations (exclusive of depreciation and amortization) $ 1,263,244 $ 1,354,655 $ 1,407,893  Customer postage $ 215,448 $ 238,618 $ 274,397  Net income (loss) $ 123,771 $ 176,670 $ 192,442   March 10, March 31,  Balance Sheet Data (at period end): 2020 2019  Current assets $ 1,339,908 $ 980,463  Long-term assets $ 5,187,220 $ 5,223,675  Current liabilities $ 1,112,875 $ 889,783  Long-term liabilities $ 5,185,304 $ 6,219,141 
Reconciliation of Other Investments	  Year Ended  March 31, 2020  Balance at beginning of period $ —  Acquisition of forward purchase contracts 232,928  Acquisition of available-for-sale debt securities 45,946  Receipt of payments on debt securities (7,332)  Change in fair value of forward purchase contracts 14,836  Change in fair value of debt securities 1,489  TEU conversions of forward purchase contracts (31,000)  Settlement of investment in forward purchase contracts (1) (216,764)  Elimination of investment in debt securities (2) (40,103)  Balance at end of period $ —  (1) Amount is included as part of the Merger purchase price. See Note 2, Business Combinations for additional information . (2) Amount is eliminated as part of consolidation.

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Mar. 31, 2020
Prepaid Expenses and Other Current Assets [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	   March 31, March 31,  2020 2019  Prepaid expenses $ 73,354 $ —  Other current assets 44,141 —  Total prepaid expenses and other current assets $ 117,495 $ — 

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Mar. 31, 2020
Property and Equipment [Abstract]
Schedule of Property and Equipment	   March 31, March 31,  2020 2019  Land $ 406 $ —  Buildings and leasehold improvements 51,460 —  Computer equipment 95,079 —  Production equipment 17,591 —  Office equipment, furniture and fixtures 31,302 —  Construction in process 13,318 —  Property and equipment, gross 209,156 —  Less accumulated depreciation (2,960) —  Property and equipment, net $ 206,196 $ — 

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets [Abstract]
Schedule of Goodwill	   Software and Analytics Network Solutions Technology-Enabled Services Total  Balance at March 31, 2019 $ — $ — $ — $ —  Acquisitions 1,901,116 1,944,701 514,831 4,360,648  Goodwill impairment (126,839) (298,870) (135,455) (561,164)  Effects of foreign currency (4,159) — — (4,159)  Balance at March 31, 2020 $ 1,770,118 — $ 1,645,831 — $ 379,376 — $ 3,795,325 
Schedule of Intangible Assets	  Weighted Gross  Average Carrying Accumulated  Remaining Life Amount Amortization Net  Customer relationships 15.2 $ 3,056,000 $ (13,064) $ 3,042,936  Technology-based intangible assets 9.2 1,188,000 (10,290) 1,177,710  Tradenames 18.0 146,000 (840) 145,160  Total $ 4,390,000 $ (24,194) $ 4,365,806 
Schedule of Aggregate Amortization Expense	   2021 $ 441,268  2022 469,741  2023 421,556  2024 381,546  2025 349,177  Thereafter 2,302,518  Total $ 4,365,806 

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Mar. 31, 2020
Accrued Expenses [Abstract]
Schedule of Accrued Expenses	  March 31, March 31,  2020 2019  Customer deposits $ 37,357 $ —  Accrued compensation 113,959 —  Accrued outside services 28,822 —  Accrued insurance 14,293 —  Accrued income, sales and other taxes 10,129 176  Accrued interest 5,892 —  Interest rate cap agreements 28,131 —  Pass-through payments 29,518 —  Other accrued liabilities 122,193 —  Total accrued expenses $ 390,294 $ 176 

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Mar. 31, 2020
Long-Term Debt [Abstract]
Schedule of Long-Term Debt	  March 31 March 31,  2020 2019  Senior Credit Facilities  $5,100,000 Term Loan Facility, due March 1, 2024 , net of unamortized discount of $125,793 and $0 at March 31, 2020 and 2019, respectively (effective interest rate of 4.42% ) $ 3,682,457 $ —  $785,000 Revolving Facility, expiring July 3, 2024 , and bearing interest at a variable interest rate (1) 250,000 —  Senior Notes  $1,000,000 5.75% Senior Notes due March 1, 2025 , net of unamortized discount of $2,228 and $0 at March 31, 2020 and 2019, respectively (effective interest rate of 5.80% ) 997,772 —  Tangible Equity Unit Senior Amortizing Note  $47,367 Senior Amortizing Notes due June 30, 2022 , net of unamortized discount of $842 and $0 at March 31, 2020 and 2019, respectively (effective interest rate of 7.44% ) 35,431 —  Other 23,413 —  Less current portion (278,779) —  Long-term debt $ 4,710,294 $ — (1) The weighted average interest rate at March 31, 2020 was 3.25% . 
Schedule of Future Maturities	  2021 $ 278,778  2022 25,432  2023 4,658  2024 3,808,682  2025 1,000,382  Thereafter —  Total $ 5,117,932 

Interest Rate Cap Agreements (T

Interest Rate Cap Agreements (Tables)	12 Months Ended
	Mar. 31, 2020
Interest Rate Cap Agreements [Abstract]
Schedule of Fair Value of Derivative Instruments	  Fair Values of Derivative Financial Instruments  Asset (Liability)  Derivative financial instruments designated as hedging instruments: Balance Sheet Location March 31, 2020 March 31, 2019  Interest rate cap agreements Prepaid and other current assets $ — $ —  Interest rate cap agreements Accrued expenses (28,131) —  Interest rate cap agreements Other long-term liabilities (19,277) —  $ (47,408) $ — 
Schedule of Effect of Derivative Instruments on Statement of Operations	  Year Ended Year Ended Year Ended  Derivative financial instruments in cash flow hedging relationships: March 31, 2020 March 31, 2019 March 31, 2018  Gain/(loss) related to derivative financial instruments recognized in other comprehensive income (loss) $ (1,361) $ — $ —  Gain/ (loss) related to portion of derivative financial instruments reclassified from accumulated other comprehensive income (loss) to interest expense $ (22) $ — $ — 

Tangible Equity Units (Tables)

Tangible Equity Units (Tables)	12 Months Ended
	Mar. 31, 2020
Tangible Equity Units [Abstract]
Schedule of Aggregate Values Assigned upon Issuance of Tangible Equity Units	  Equity Component Debt Component Total  Price per TEU $ 41.7622 $ 8.2378 $ 50.00  Gross proceeds 240,133 47,367 287,500  Issuance costs (7,204) (1,421) (8,625)  Net proceeds $ 232,929 $ 45,946 $ 278,875 
Schedule of Tangible Equity Units Activity	  Tangible  Equity Units  Outstanding at beginning of year —  Issued 5,750,000  Conversions (612,655)  Outstanding at end of year 5,137,345 

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	12 Months Ended
	Mar. 31, 2020
Net Income (Loss) Per Share [Abstract]
Computation of Basic Net Income (Loss) Per Share of Common Stock	   Year Ended Year Ended Year Ended  March 31, 2020 March 31, 2019 March 31, 2018  Basic net income (loss) per share:  Numerator:  Net income (loss) $ (947,597) $ (52,012) $ 60,955  Denominator:  Weighted average common shares outstanding 123,387,547 75,513,130 75,590,613  Minimum shares issuable under purchase contracts 13,609,077 — —  136,996,624 75,513,130 75,590,613  Basic net income (loss) per share $ (6.92) $ (0.69) $ 0.81   Diluted net income per share:  Numerator:  Net income (loss) $ (947,597) $ (52,012) $ 60,955  Denominator:  Number of shares used in basic computation 136,996,624 75,513,130 75,590,613  Weighted average effect of dilutive securities  Time-Vesting Options — — 2,051,346  Restricted Share Units — — 159,137  136,996,624 75,513,130 77,801,096  Diluted net income (loss) per share $ (6.92) $ (0.69) $ 0.78 
Antidilutive Securities Excluded from Diluted Net Income (Loss) Per Share	  Year Ended Year Ended Year Ended  March 31, 2020 March 31, 2019 March 31, 2018  Dilutive shares issuable under purchase contracts 1,829,437 — —  Time-Vesting Options 1,259,594 1,869,456 4,570,624  Restricted Share Units 1,345,211 — —  Deferred Stock Units 20,371 — — 

Incentive Compensation Plans (T

Incentive Compensation Plans (Tables)	12 Months Ended
	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Valuation Assumptions	  Replacement  Time-Vesting Exit-Vesting Exit-Vesting  Options Options Restricted Stock  Year Ended March 31, 2020:  Weighted average fair value $ 2.10 $ 0.08 $ 2.15  Expected dividend yield — % — % — %  Expected volatility 52.0 % 50.9 % 76.9 %  Risk-free interest rate 0.3 % 0.3 % 0.9 %  Expected term (years) 3.8 4.1 0.9   Year Ended March 31, 2019:  Weighted average fair value $ 9.78 $ 5.90 $ 12.80  Expected dividend yield — % — % — %  Expected volatility 52.5 % 52.9 % 62.2 %  Risk-free interest rate 2.2 % 2.2 % 2.3 %  Expected term (years) 4.5 5.1 1.9 
Schedule of Omnibus Incentive Plan Activity	  Cash Settled  Restricted Deferred Restricted Performance  Stock Units Stock Units Stock Units Stock Units  Outstanding at April 1, 2019 — — — —  Granted 4,846,058 45,704 597,006 1,079,621  Cancelled (377,969) — (119,445) (113,932)  Outstanding at March 31, 2020 4,468,089 45,704 477,561 965,689 
Replacement Time-Vesting Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Option Activity	   Replacement Weighted Average Aggregate  Time-Vesting Weighted Average Remaining Intrinsic  Options Exercise Price Contractual Term Value  Outstanding at April 1, 2019 4,529,291 $ 11.76 4.4 $ 39,896  Exercised (708,969) 15.66 — 5,077  Forfeited (361,578) — — 74  Outstanding at March 31, 2020 3,458,744 $ 11.95 3.3 $ 4,083  Exercisable at March 31, 2020 3,458,744 $ 11.95 3.3 $ 4,083 
Replacement Exit-Vesting Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Replacement Exit-Vesting Restricted Stock Activity	   Replacement Exit-Vesting  Restricted Stock  Unvested at April 1, 2019 1,261,599  Canceled (255,881)  Unvested at March 31, 2020 1,005,718 
Time-Vesting and Exit-Vesting Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Option Activity	   Weighted Average  Weighted Average Remaining Aggregate  Awards Exercise Price Contractual Term Intrinsic Value  Time-Vesting Exit-Vesting Time-Vesting Exit-Vesting Time-Vesting Exit-Vesting Time-Vesting Exit-Vesting  Options Options Options Options Options Options Options Options  Outstanding at April 1, 2019 6,988,403 6,504,544 $ 18.99 $ 18.99 8.0 8.0 $ 11,058 $ 10,292  Forfeited (1,256,156) (1,250,440) 18.99 18.99 — — — —  Outstanding at March 31, 2020 5,732,247 5,254,104 18.99 18.99 7.6 7.6 — —  Exercisable at March 31, 2020 3,743,688 — $ 18.99 $ — 7.5 — $ — $ — 

Retirement Plans and Other Po_2

Retirement Plans and Other Postretirement Benefits (Tables)	12 Months Ended
	Mar. 31, 2020
Retirement Plans and Other Postretirement Benefits[Abstract]
Summary of Liabilities Related to Deferred Compensation Plan	  March 31, March 31,  Balance Sheet Location 2020 2019  Accrued expenses $ 1,772 $ —  Other long-term liabilities 15,880 —  Total deferred compensation $ 17,652 $ — 

Tax Receivable Agreements (Tabl

Tax Receivable Agreements (Tables)	12 Months Ended
	Mar. 31, 2020
Related Party Transaction [Line Items]
Aggregate Payments Due Under Tax Receivable Agreements	  2009 - 2011 Tax Receivable Agreements 2017 Tax Receivable Agreement Total  2021 $ 18,714 $ 1,520 20,234  2022 20,113 2,281 22,394  2023 20,084 47,384 67,468  2024 19,358 26,551 45,909  2025 17,917 8,441 26,358  Thereafter 102,942 29,479 132,421  Gross expected payments 199,128 115,656 314,784  Less: Amounts representing discount (55,945) (60,779) (116,724)  Total tax receivable agreement obligations due to related parties 143,183 54,877 198,060  Less: Current portion due (included in due to related parties, net) (18,714) (1,520) (20,234)  Tax receivable agreement long-term obligations due to related parties $ 124,469 $ 53,357 $ 177,826  
McKesson Tax Receivable Agreement [Member]
Related Party Transaction [Line Items]
Aggregate Payments Due Under Tax Receivable Agreements	  McKesson Tax Receivable Agreement  2021 $ —  2022 128  2023 18,306  2024 19,905  2025 23,150  Thereafter 103,144  Gross expected payments 164,633  Less: Amounts representing discount —  Total tax receivable agreement obligation 164,633  Less: Current portion due (included in accrued expenses) —  Tax receivable agreement long-term obligation (included in other long-term liabilities) $ 164,633 

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2020
Income Taxes [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	  Year Ended Year Ended Year Ended  March 31, 2020 March 31, 2019 March 31, 2018  Current:  Federal $ — $ — $ —  State 568 — —  Current income tax provision (benefit) 568 — —  Deferred:  Federal (113,523) (15,468) (116,563)  State (30,299) (3,127) (3,058)  Deferred income tax provision (benefit) (143,822) (18,595) (119,621)  Total income tax provision (benefit) $ (143,254) $ (18,595) $ (119,621) 
Schedule of Effective Income Tax Rate Reconciliation	  Year Ended Year Ended Year Ended  March 31, 2020 March 31, 2019 March 31, 2018  Statutory U.S. federal tax rate 21.0 % 21.0 % 31.5 %  State income taxes (net of federal benefit) 2.1 3.5 3.6  Remeasurement of deferred tax assets and liabilities arising from the Tax Legislation — — 166.9  Change in fair value of equity based awards (1.2) 1.0 —  Look through accounting policy election 2.1  Research and development credit 0.2 1.6 2.4  Goodwill impairment charge (10.8)  Other (0.3) (0.8) (0.5)  Effective income tax rate 13.1 % 26.3 % 203.9 % 
Schedule of Deferred Tax Assets (Liabilities)	  March 31, March 31,  2020 2019  Investment in the Joint Venture $ — $ (190,448)  Depreciation and amortization (1,034,407) —  Accounts receivable 5,793 —  Fair value of interest rate cap agreements 14,011 —  Accruals and reserves 15,680 —  Net operating losses 348,329 19,958  Debt discount and interest (9,661) —  Equity compensation 18,560 —  Valuation allowance (29,350) —  Tax receivable agreements obligations to related parties 68,900 —  163(j) Business interest expense limitation 23,842 7,711  Tax credits 16,629 2,786  Accounting method change (ASC 606 adoption) (31,886) —  Residual deferred tax asset 12,072 —  Other (3,696) —  Net deferred tax assets (liabilities) $ (585,184) $ (159,993)  Reported as:  Non-current deferred tax assets 30,720 —  Non-current deferred tax liabilities (615,904) (159,993)  Net deferred tax assets (liabilities) $ (585,184) $ (159,993) 
Reconciliation of Unrecognized Tax Benefits	  Year Ended Year Ended  March 31, 2020 March 31, 2019  Beginning unrecognized benefit $ 863 $ —  Decreases from prior period tax positions (2) —  Increases from prior period tax positions — 432  Increases from current period tax positions 769 431  Increases from acquisition 54,547 —  Ending unrecognized benefit $ 56,177 $ 863 

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Mar. 31, 2020
Commitments [Abstract]
Schedule of Future Minimum Commitments	   Payments by Period  Total 2021 2022 2023 2024 2025 Thereafter  Operating lease obligations $ 141,010 $ 40,476 $ 34,750 $ 23,761 $ 15,393 $ 10,780 $ 15,850  Contingent consideration obligation 3,000 3,000 — — — — —  Purchase obligations and other 1,162,529 126,900 174,516 174,516 173,805 173,805 338,987  Total contractual obligations $ 1,306,539 $ 170,376 $ 209,266 $ 198,277 $ 189,198 $ 184,585 $ 354,837 (1) The Company expects to receive $1,562 of minimum rentals in the future under noncancelable subleases.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Mar. 31, 2020
Fair Value Measurements [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	    Quoted in Significant  Balance at Markets Significant Other Unobservable  March 31, Identical Observable Inputs Inputs  Description 2020 (Level 1) (Level 2) (Level 3)  Interest rate cap agreements $ (47,408) $ — $ (47,408) $ —  Contingent consideration obligation (3,000) — — (3,000)  Total $ (50,408) $ — $ (47,408) $ (3,000)     Quoted in Significant  Balance at Markets Significant Other Unobservable  March 31, Identical Observable Inputs Inputs  Description 2019 (Level 1) (Level 2) (Level 3)  Freestanding derivative $ 81,264 $ — $ — $ 81,264  Total $ 81,264 $ — $ — $ 81,264 
Reconciliation of Fair Value Derivative Using Unobservable Inputs	  Year Ended Year Ended  March 31, 2020 March 31, 2019  Balance at beginning of period $ 81,264 $ 59,116  Increase in fair value based on ASC 505 equity-based compensation — 20,135  Settlements due to exercise of awards (5,077) (1,297)  Change in fair value of equity-based awards (33,409) 3,310  Settlement as component of Merger purchase price (42,778) —  Balance at end of period $ — $ 81,264 
Carrying Amount and Estimated Fair Value of Financial Instruments	  March 31, 2020 March 31, 2019  Carrying Amount Fair Value Carrying Amount Fair Value  Cash and cash equivalents $ 410,405 $ 410,405 $ 3,409 $ 3,409  Accounts receivable $ 740,105 $ 740,105 $ — $ —  Investment in business purchase option $ 146,500 $ 146,500 $ — $ —  Senior Credit Facilities (Level 2) $ 3,682,457 $ 3,452,687 $ — $ —  Senior Notes (Level 2) $ 997,772 $ 950,000 $ — $ —  Debt component of tangible equity units (Level 2) $ 35,431 $ 34,806 $ — $ — 

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Mar. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Abstract]
Summary of Accumulated Other Comprehensive Income (Loss)	  Foreign Accumulated  Available Currency Other  For Sale Translation Cash Flow Comprehensive  Debt Security Adjustment Hedge Income (Loss)  Balance at March 31, 2017 $ — $ 26 $ (338) $ (312)  Change associated with foreign currency translation — 1,242 — 1,242  Change associated with current period hedging (net of taxes of $623 ) — — 1,267 1,267  Reclassification into earnings — — 339 339  Balance at March 31, 2018 $ — $ 1,268 $ 1,268 $ 2,536   Cumulative effect of accounting change by the Joint Venture-ASU 2017-12 — — 490 490  Change associated with foreign currency translation — (2,833) — (2,833)  Change associated with current period hedging (net of taxes of $2,139 ) — — (1,671) (1,671)  Reclassification into earnings — — (1,778) (1,778)  Balance at March 31, 2019 $ — $ (1,565) $ (1,691) $ (3,256)   Cumulative effect of accounting change of the Joint Venture-ASU 2018-02 — — 422 422  Unrealized gain (loss) on available for sale debt securities of the Joint Venture 1,045 — — 1,045  Realized gain (loss) on available for sale debt securities of the Joint Venture (1,045) — — (1,045)  Change associated with foreign currency translation — (5,519) — (5,519)  Change associated with current period hedging (net of taxes of $607 ) — — 981 981  Reclassification into earnings — — — —  Balance at March 31, 2020 $ — $ (7,084) $ (288) $ (7,372) 

Quarterly Financial Informati_2

Quarterly Financial Information (Tables)	12 Months Ended
	Mar. 31, 2020
Quarterly Financial Information [Abstract]
Schedule of Quarterly Financial Information	 Total Revenue Income (Loss) Before Income Tax Net Income (Loss) Basic Net Income (Loss) Per Unit Diluted Net Income (Loss) Per Unit  Quarter Ended:  June 30, 2019 $ — $ (39,701) $ (37,517) $ (0.50) $ (0.50)  September 30, 2019 — (107,555) (93,935) (0.66) (0.66)  December 31, 2019 — 65,975 50,735 0.35 0.35  March 31, 2020 (1) 196,792 (1,009,571) (866,881) (4.65) (4.65)    Total Revenue Income (Loss) Before Income Tax Net Income (Loss) Basic Net Income (Loss) Per Unit Diluted Net Income (Loss) Per Unit  Quarter Ended:  June 30, 2018 $ — $ (22,302) (17,501) $ (0.23) $ (0.23)  September 30, 2018 — (25,374) (18,591) (0.25) (0.25)  December 31, 2018 — (17,468) (12,388) (0.16) (0.16)  March 31, 2019 — 65,144 48,480 (0.05) (0.05)  (1) Results for the quarter ended March 31, 2020 were impact ed by the Merger and recognition of a goodwill impairment charge . See Note 2 , Business Combinations and Note 9, Goodwill and Intangible Assets , for additional information.

Nature of Business and Organi_2

Nature of Business and Organization (Narrative) (Details)	Mar. 10, 2020USD ($)$ / shares	Jul. 01, 2019USD ($)shares	Jun. 26, 2019$ / sharesshares	Mar. 01, 2017USD ($)	Jul. 31, 2019USD ($)shares	Mar. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2019$ / sharesshares	Mar. 31, 2018shares
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Ownership percentage				30.00%
Consideration transferred	$ 176,000
Stock split conversion ratio			126.4
Common Stock, shares authorized | shares			9,000,000,001
Common Stock, par value | $ / shares	$ 0.001		$ 0.001
Preferred stock, shares authorized | shares			900,000,000			900,000,000	0
Preferred stock, par value | $ / shares			$ 0.001			$ 0.001	$ 0.001
Share offering | shares		49,285,713
Proceeds from initial public offering		$ 608,679,000				$ 608,679,000
Senior Notes due March 1, 2025 [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Debt instrument, face amount						$ 1,000,000,000
Stated interest rate						5.75%
Maturity date						Mar. 1, 2025
Common Class X [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Common Stock, shares authorized | shares			1			0	1
Common Stock, par value | $ / shares			$ 0.001			$ 0.001	$ 0.001
Tangible Equity Units [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Tangible equity unit offering | shares		5,750,000			5,750,000	5,750,000
Proceeds from tangible equity units		$ 278,875,000			$ 278,875,000	$ 278,875,000
Joint Venture [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Ownership percentage		41.00%
Consideration transferred				$ 1,800,000,000
Promissory note payable				1,300,000,000
Shares received from Joint Venture | shares		49,285,713				49,285,713
Joint Venture [Member] | Senior Notes due March 1, 2025 [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Debt instrument, face amount				$ 1,000,000,000
Stated interest rate				5.75%
Maturity date						Mar. 1, 2025
Common Stock [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Common Stock, shares authorized | shares			9,000,000,000			9,000,000,000	252,800,000
Common Stock, par value | $ / shares			$ 0.001			$ 0.001	$ 0.001
Share offering | shares						49,285,713	67,953	279,723
Term Loan Facility [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Debt instrument, face amount						$ 5,100,000,000
Maturity date						Mar. 1, 2024
Term Loan Facility [Member] | Joint Venture [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Debt instrument, face amount				$ 5,100,000,000
Repayment of debt					$ 805,000,000
Revolving Credit Facility [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Debt instrument, face amount						$ 785,000,000
Maturity date						Jul. 3, 2024
Revolving Credit Facility [Member] | Joint Venture [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Debt instrument, face amount				$ 500,000,000

Business Combinations (Narrativ

Business Combinations (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 10, 2020	Jul. 01, 2019	Mar. 01, 2017	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018	Jun. 26, 2019
Business Acquisition [Line Items]
Common Stock, par value	$ 0.001						$ 0.001
Number of shares of equity interests issued	175,995,192
Ownership percentage			30.00%
Loss from Equity Method Investment in the Joint Venture				$ 380,713	$ 70,487	$ 58,680
Joint Venture [Member]
Business Acquisition [Line Items]
Ownership percentage acquired in exchange				30.00%
Ownership percentage		41.00%
Joint Venture [Member] | Prior to Merger [Member]
Business Acquisition [Line Items]
Percentage of remaining equity interest being acquired	58.00%
Loss from Equity Method Investment in the Joint Venture	$ 230,229
McKesson Common Stock [Member]
Business Acquisition [Line Items]
Common Stock, par value	$ 0.01
Number of shares of equity interests issued	15,426,537
McKesson Common Stock [Member] | McKesson Corporation [Member]
Business Acquisition [Line Items]
Ownership percentage acquired in exchange	58.00%
SpinCo Common Stock [Member]
Business Acquisition [Line Items]
Common Stock, par value	$ 0.001
Number of shares of equity interests issued	175,995,192
Change Common Stock [Member]
Business Acquisition [Line Items]
Common Stock, par value	$ 0.001
Change Common Stock [Member] | SpinCo [Member]
Business Acquisition [Line Items]
Ownership percentage	42.00%

Business Combinations (Summary

Business Combinations (Summary of Provisional Fair Values of Identifiable Assets and Liabilities) (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 10, 2020	Mar. 31, 2020	Jun. 26, 2019
Business Acquisition [Line Items]
Cash	$ 330,665
Accounts receivable, net of allowance for doubtful accounts of $22,360	718,895
Prepaid and other current assets	115,265
Contract assets	132,704
Investment in business purchase option	146,500
Property and equipment, net	206,751
Goodwill	4,360,648
Other noncurrent assets	169,539
Drafts and accounts payable	(60,637)
Accrued expenses	(559,456)
Deferred revenues, current	(292,528)
Current portion of long-term debt	(28,969)
Other current liabilities	(22,732)
Long-term debt, excluding current portion	(4,713,565)
Deferred income tax liabilities	(578,076)
Tax receivable agreement with related parties	(176,586)
Other long-term liabilities	(102,675)
Net Assets acquired	4,035,743
Accounts receivable, allownace for doubtful accounts	22,059
Fair value of shares issued to SpinCo shareholders (175,995,192 shares at $12.47 per share): Common Stock, $0.001 par value	176
Additional paid-in capital	2,194,484
Fair value of Joint Venture equity interest previously held	1,589,040
Fair value of Joint Venture equity interest previously held through TEUs	216,764
Settlement of dividend receivable	42,778
Repayment of advances to member	(7,499)
Purchase consideration	$ 4,035,743
Fair value of shares issued to SpinCo shareholders , shares	175,995,192
Fair value of shares issued to SpinCo shareholders, share price	$ 12.47
Common Stock, par value	$ 0.001		$ 0.001
Customer Relationships [Member]
Business Acquisition [Line Items]
Identified intangible assets	$ 3,056,000
Customer Relationships [Member] | Minimum [Member]
Business Acquisition [Line Items]
Useful life	12 years	12 years
Customer Relationships [Member] | Maximum [Member]
Business Acquisition [Line Items]
Useful life	16 years	16 years
Tradenames [Member]
Business Acquisition [Line Items]
Identified intangible assets	$ 146,000
Useful life	18 years	18 years
Technology-Based Intangible Assets [Member]
Business Acquisition [Line Items]
Identified intangible assets	$ 1,188,000
Technology-Based Intangible Assets [Member] | Minimum [Member]
Business Acquisition [Line Items]
Useful life	6 years	6 years
Technology-Based Intangible Assets [Member] | Maximum [Member]
Business Acquisition [Line Items]
Useful life	12 years	12 years

Business Combinations (Suppleme

Business Combinations (Supplemental Pro Forma Results) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2020	Mar. 31, 2019
Business Acquisition [Line Items]
Revenue		$ 3,290,734	$ 3,133,907
Net income (loss)		$ (228,234)	$ (128,889)
Net income (loss) per share, basic and diluted		$ (0.75)	$ (0.43)
Since Acquisition Date of March 10, 2020 [Member]
Business Acquisition [Line Items]
Revenue	$ 196,792
Net income (loss)	$ 297

Significant Accounting Polici_4

Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Apr. 01, 2020	Mar. 31, 2019	Mar. 31, 2018
Significant Accounting Policies [Line Items]
Equity method investment, impairment loss	$ 0
Allowance for doubtful accounts	$ 22,360
Forecast [Member]
Significant Accounting Policies [Line Items]
ROU assets		$ 110,000
Operating lease liability		$ 125,000
Capitalized Software Developed for Internal Use [Member]
Significant Accounting Policies [Line Items]
Useful life	3 years
Capitalized Software Developed for Sale [Member]
Significant Accounting Policies [Line Items]
Useful life	3 years

Significant Accounting Polici_5

Significant Accounting Policies (Summary of Activity Related to Allowance for Doubtful Accounts) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Significant Accounting Policies [Abstract]
Balance at beginning of period
Acquisition in Merger	22,059
Provisions	905
Write-offs	(604)
Balance at end of period	$ 22,360

Significant Accounting Polici_6

Significant Accounting Policies (Schedule of Finite-Lived Intangible Assets Useful Lives) (Details)	Mar. 10, 2020	Mar. 31, 2020
Customer Relationships [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	12 years	12 years
Customer Relationships [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	16 years	16 years
Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	18 years	18 years
Technology-Based Intangible Assets [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	6 years	6 years
Technology-Based Intangible Assets [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	12 years	12 years

Revenue Recognition (Narrative)

Revenue Recognition (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 10, 2020
Revenue Recognition [Abstract]
Percentage of deferred revenue balance expected to be recognized in one year or less	94.00%
Deferred revenue	$ 25,601	$ 0
Deferred revenues assumed			$ 311,200
Deferred revenue, revenue recognized		$ 0
Remaining performance obligation	$ 1,141,000

Revenue Recognition (Remaining

Revenue Recognition (Remaining Performance Obligation - Narrative) (Details)	Mar. 31, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, expected satisfaction, period	12 months
Remaining performance obligation, percentage	55.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, expected satisfaction, period	1 year
Remaining performance obligation, percentage	45.00%

Equity Method Investment in C_3

Equity Method Investment in Change Healthcare LLC (Narrative) (Details) - USD ($) $ in Thousands	Jul. 01, 2019	Mar. 01, 2017	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Schedule of Equity Method Investments [Line Items]
Ownership percentage		30.00%
Legacy CHC [Member]
Schedule of Equity Method Investments [Line Items]
Percentage investment exchanged for membership interest in Joint Venture			45.615%
Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage acquired in exchange			30.00%
Ownership percentage	41.00%
Shares received from Joint Venture	49,285,713		49,285,713
Additional ownership percentage acquired			11.00%
Write-off of basis differences within Loss from Equity Method Investment in the Joint Venture			$ 380,713	$ 70,487	$ 58,680
Joint Venture [Member] | Legacy CHC [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage			54.385%

Equity Method Investment in C_4

Equity Method Investment in Change Healthcare LLC (Summarized Financial Information of the Joint Venture) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Equity Method Investment in Change Healthcare LLC [Abstract]
Net revenue	$ 3,092,875	$ 3,281,729	$ 3,298,843
Cost of operations (exclusive of depreciation and amortization)	1,263,244	1,354,655	1,407,893
Customer postage	215,448	238,618	274,397
Net income (loss)	123,771	176,670	$ 192,442
Current assets	1,339,908	980,463
Long-term assets	5,187,220	5,223,675
Current liabilities	1,112,875	889,783
Long-term liabilities	$ 5,185,304	$ 6,219,141

Equity Method Investment in C_5

Equity Method Investment in Change Healthcare LLC (Reconciliation of Other Investments) (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2020USD ($)
Marketable Securities [Line Items]
Balance
Balance
Forward Contracts [Member]
Marketable Securities [Line Items]
Acquisition	232,928
Change in fair value	14,836
TEU conversions of forward purchase contracts	(31,000)
Settlement of investment in forward purchase contracts	(216,764)	[1]
Debt Securities [Member]
Marketable Securities [Line Items]
Acquisition	45,946
Receipt of payments on debt securities	(7,332)
Change in fair value	1,489
Elimination of investment in debt securities	$ (40,103)	[2]
[1]	Amount is included as part of the Merger purchase price. See Note 2, Business Combinations for additional information.
[2]	Amount is eliminated as part of consolidation.

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Schedule of Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid expenses	$ 73,354
Other current assets	44,141
Total prepaid expenses and other current assets	$ 117,495

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 209,156
Less accumulated depreciation	(2,960)
Property and equipment, net	206,196
Depreciation expense	2,960	0	$ 0
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	406
Buildings and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	51,460
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	95,079
Production Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	17,591
Office Equipment, Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	31,302
Construction in Process [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 13,318

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Narrative) (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2020USD ($)item	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)
Goodwill and Intangible Assets [Abstract]
Number of reportable segments | item	3
Goodwill impairment charge	$ 561,164
Amortization expense	$ 24,194	$ 0	$ 0

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Schedule of Goodwill) (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2020USD ($)
Goodwill [Line Items]
Balance at March 31, 2019
Acquisitions	4,360,648
Goodwill impairment	(561,164)
Effects of foreign currency	(4,159)
Balance at March 31, 2020	3,795,325
Software and Analytics [Member]
Goodwill [Line Items]
Balance at March 31, 2019
Acquisitions	1,901,116
Goodwill impairment	(126,839)
Effects of foreign currency	(4,159)
Balance at March 31, 2020	1,770,118
Network Solutions [Member]
Goodwill [Line Items]
Balance at March 31, 2019
Acquisitions	1,944,701
Goodwill impairment	(298,870)
Effects of foreign currency
Balance at March 31, 2020	1,645,831
Technolgy-Enabled Services [Member]
Goodwill [Line Items]
Balance at March 31, 2019
Acquisitions	514,831
Goodwill impairment	(135,455)
Effects of foreign currency
Balance at March 31, 2020	$ 379,376

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($) $ in Thousands	Mar. 10, 2020	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		$ 4,390,000
Accumulated Amortization		(24,194)	$ 0	$ 0
Net		4,365,806
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		3,056,000
Accumulated Amortization		(13,064)
Net		$ 3,042,936
Customer Relationships [Member] | Weighted Average [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Life		15 years 2 months 12 days
Technology-Based Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		$ 1,188,000
Accumulated Amortization		(10,290)
Net		$ 1,177,710
Technology-Based Intangible Assets [Member] | Weighted Average [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Life		9 years 2 months 12 days
Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Life	18 years	18 years
Gross Carrying Amount		$ 146,000
Accumulated Amortization		(840)
Net		$ 145,160
Tradenames [Member] | Weighted Average [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Remaining Life		18 years

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets (Schedule of Aggregate Amortization Expense) (Details) $ in Thousands	Mar. 31, 2020USD ($)
Goodwill and Intangible Assets [Abstract]
2021	$ 441,268
2022	469,741
2023	421,556
2024	381,546
2025	349,177
Thereafter	2,302,518
Net	$ 4,365,806

Accrued Expenses (Schedule of A

Accrued Expenses (Schedule of Accued Expenses) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Accrued Expenses [Abstract]
Customer deposits	$ 37,357
Accrued compensation	113,959
Accrued outside services	28,822
Accrued insurance	14,293
Accrued income, sales and other taxes	10,129	$ 176
Accrued interest	5,892
Interest rate cap agreements	28,131
Pass-through payments	29,518
Other accrued liabilities	122,193
Total accrued expenses	$ 390,294	$ 176

Long-Term Debt (Long-Term Debt

Long-Term Debt (Long-Term Debt - Narrative) (Details) - Senior Notes due March 1, 2025 [Member]	12 Months Ended
	Mar. 31, 2020
Debt Instrument [Line Items]
Stated interest rate	5.75%
Maturity date	Mar. 1, 2025

Long-Term Debt (Senior Credit F

Long-Term Debt (Senior Credit Facilities - Narrative) (Details)	12 Months Ended
	Mar. 31, 2020USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)
Debt Instrument [Line Items]
Letters of credit	$ 5,118,000		$ 4,880,000
Senior Credit Facilities [Member]
Debt Instrument [Line Items]
Right to request additional sums, maximum amount	$ 1,080,000,000
Right to request additional sums, maximum percentage amount equal to EBITDA	100.00%
Additional indebtedness incurred if leverage ratio exceeded	$ 1
Consolidated interest coverage ratio	2
Percentage of Parent borrower's annual excess cash flows required to be exempt from requirement to prepay outstanding term loans	50.00%
Percentage of net cash proceeds of non-ordinary course asset sales or other dispositions of property required to be exempt from requirement to prepay outstanding term loans	100.00%
Percentage of net cash proceeds of any incurrence of debt by borrowers other than proceeds from debt permitted under the terms required to be exempt from requirement to prepay outstanding term loans	100.00%
Maximum percentage of capital stock of wholly owned foreign restricted subsidiary pledged	65.00%
Senior Credit Facilities [Member] | Specified Consolidated First Lien Net Leverage Ratios Achieved and Maintained Second Fiscal Year [Member]
Debt Instrument [Line Items]
Leverage ratio	4.90
Percentage of Parent borrower's annual excess cash flows required to be exempt from requirement to prepay outstanding term loans	25.00%
Percentage of net cash proceeds of non-ordinary course asset sales or other dispositions of property required to be exempt from requirement to prepay outstanding term loans	50.00%
Senior Credit Facilities [Member] | Specified Consolidated First Lien Net Leverage Ratios Achieved and Maintained Third Fiscal Year [Member]
Debt Instrument [Line Items]
Leverage ratio	5.75
Percentage of Parent borrower's annual excess cash flows required to be exempt from requirement to prepay outstanding term loans	0.00%
Percentage of net cash proceeds of non-ordinary course asset sales or other dispositions of property required to be exempt from requirement to prepay outstanding term loans	25.00%
Senior Credit Facilities [Member] | Specified Consolidated First Lien Net Leverage Ratios Achieved and Maintained Forth Fiscal Year [Member]
Debt Instrument [Line Items]
Leverage ratio	6
Percentage of net cash proceeds of non-ordinary course asset sales or other dispositions of property required to be exempt from requirement to prepay outstanding term loans	0.00%
Senior Credit Facilities [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Basis spread	1.00%
Senior Credit Facilities [Member] | Fed Funds Effective Rate Overnight Index Swap Rate [Member]
Debt Instrument [Line Items]
Basis spread	0.50%
Term Loan Facility [Member]
Debt Instrument [Line Items]
Floor rate	1.00%
Maturity date	Mar. 1, 2024
Date used to determine amount that, if exceeded, would require amounts due under Revolving Facility to be paid	Dec. 1, 2023
Amount, if exceeded, that would require amounts due under Revolving Facility to be paid	$ 1,100,000,000
Date amounts due under Revolving Facility are required to be paid if Term Loan amount is exceeded	Dec. 1, 2023
Percentage of principal amount amortized in equal quarterly installments	1.00%
Term Loan Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Floor rate	2.00%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Floor rate	0.00%
Maximum borrowing capacity	$ 785,000,000	$ 500,000,000
Maturity date	Jul. 3, 2024
Borrowings	$ 250,000,000
Current borrowing capacity	785,000,000
Remaining borrowing capacity	$ 529,882,000		$ 495,120,000
Commitment fee percentage	0.375%

Long-Term Debt (Senior Notes -

Long-Term Debt (Senior Notes - Narrative) (Details) - Senior Notes due March 1, 2025 [Member]	12 Months Ended
	Mar. 31, 2020
Debt Instrument [Line Items]
Stated interest rate	5.75%
Maturity date	Mar. 1, 2025
Redemption price percentage	101.00%

Long-Term Debt (Other - Narrati

Long-Term Debt (Other - Narrative) (Details) $ in Thousands	Mar. 31, 2020USD ($)
Debt Instrument [Line Items]
Long-term debt	$ 5,117,932
Deferred Financing Arrangements [Member]
Debt Instrument [Line Items]
Long-term debt	$ 21,454

Long-Term Debt (Schedule of Lon

Long-Term Debt (Schedule of Long-Term Debt) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Debt Instrument [Line Items]
Long-term debt	$ 5,117,932,000
Less current portion	(278,779,000)
Long-term debt, excluding current portion	4,710,294,000
Senior Notes due March 1, 2025 [Member]
Debt Instrument [Line Items]
Long-term debt	997,772,000
Debt instrument, face amount	$ 1,000,000,000
Stated interest rate	5.75%
Maturity date	Mar. 1, 2025
Unamortized doscount	$ 2,228,000	$ 0
Effective interest rate	5.80%
Senior Amortizing Notes due June 30, 2022 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 35,431,000
Debt instrument, face amount	$ 47,367,000
Maturity date	Jun. 30, 2022
Unamortized doscount	$ 842,000	0
Effective interest rate	7.44%
Other [Member]
Debt Instrument [Line Items]
Long-term debt	$ 23,413,000
Term Loan Facility [Member]
Debt Instrument [Line Items]
Long-term debt	3,682,457,000
Debt instrument, face amount	$ 5,100,000,000
Maturity date	Mar. 1, 2024
Unamortized doscount	$ 125,793,000	$ 0
Effective interest rate	4.42%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt	$ 250,000,000
Debt instrument, face amount	$ 785,000,000
Maturity date	Jul. 3, 2024
Weighted average interest rate	3.25%

Long-Term Debt (Schedule of Fut

Long-Term Debt (Schedule of Future Maturities) (Details) $ in Thousands	Mar. 31, 2020USD ($)
Long-Term Debt [Abstract]
2021	$ 278,778
2022	25,432
2023	4,658
2024	3,808,682
2025	1,000,382
Total	$ 5,117,932

Interest Rate Cap Agreements (N

Interest Rate Cap Agreements (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Aug. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Derivative [Line Items]
Reclassified as interest expense	$ 1,203
Fair value derivative net liability	51,020
Interest Rate Cap Agreements [Member]
Derivative [Line Items]
Notional amount	$ 1,000,000
Derivative, maturity date	Mar. 31, 2024
Effective date	Mar. 31, 2020
Interest Rate Cap Agreements [Member] | Maximum [Member]
Derivative [Line Items]
Variable rate	1.00%
Legacy CHC and Joint Venture [Member] | Interest Rate Cap Agreements [Member]
Derivative [Line Items]
Notional amount			$ 750,000	$ 650,000
Derivative, maturity date	Mar. 31, 2020
Effective date	Mar. 31, 2017
Joint Venture [Member] | Interest Rate Cap Agreements [Member]
Derivative [Line Items]
Notional amount		$ 1,500,000
Derivative, maturity date	Dec. 31, 2021
Effective date	Aug. 31, 2018
Joint Venture [Member] | Interest Rate Cap Agreements [Member] | Minimum [Member]
Derivative [Line Items]
Notional amount		500,000
Joint Venture [Member] | Interest Rate Cap Agreements [Member] | Maximum [Member]
Derivative [Line Items]
Notional amount		$ 1,500,000
Variable rate		1.00%

Interest Rate Cap Agreements (S

Interest Rate Cap Agreements (Schedule of Fair Value of Derivative Instruments) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Derivatives Fair Value [Line Items]
Prepaid expenses and other current assets	$ 117,495
Accrued expenses	(390,294)	(176)
Other long-term liabilities	(93,487)
Fair Values of Derivative Instruments Asset (Liability) Derivatives	(51,020)
Designated as Hedging Instrument [Member] | Interest Rate Cap Agreements [Member]
Derivatives Fair Value [Line Items]
Prepaid expenses and other current assets
Accrued expenses	(28,131)
Other long-term liabilities	(19,277)
Fair Values of Derivative Instruments Asset (Liability) Derivatives	$ (47,408)

Interest Rate Cap Agreements _2

Interest Rate Cap Agreements (Schedule of Effect of Derivative Instruments on Statement of Operations) (Details) - Cash Flow Hedging [Member] - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(loss) related to derivative financial instruments recognized in other comprehensive income (loss)	$ (1,361)
Gain/ (loss) related to portion of derivative financial instruments reclassified from accumulated other comprehensive income (loss) to interest expense	$ (22)

Tangible Equity Units (Narrativ

Tangible Equity Units (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 01, 2019	Jul. 31, 2019	Mar. 31, 2020	Sep. 30, 2019
Tangible Equity Units [Line Items]
Share offering	49,285,713
Conversion to shares			$ 3.2051
Senior Amortizing Note [Member]
Tangible Equity Units [Line Items]
Maturity date			Jun. 30, 2022
Initial principal amount			$ 8.2378
Stated interest rate			5.50%
Cash installment			$ 0.7500	$ 0.7417
Settlement date			Jun. 30, 2022
Minimum [Member]
Tangible Equity Units [Line Items]
Share offering			18,429,325
Maximum [Member]
Tangible Equity Units [Line Items]
Share offering			22,115,075
Applicable Market Value is greater than $15.60 per share [Member]
Tangible Equity Units [Line Items]
Share price			$ 15.60
Conversion to shares			3.2051
Applicable Market Value is less than or equal to $15.60 per share but greater than or equal to $13.00 per share [Member]
Tangible Equity Units [Line Items]
Conversion to shares			50
Applicable Market Value is less than or equal to $15.60 per share but greater than or equal to $13.00 per share [Member] | Minimum [Member]
Tangible Equity Units [Line Items]
Share price			13
Applicable Market Value is less than or equal to $15.60 per share but greater than or equal to $13.00 per share [Member] | Maximum [Member]
Tangible Equity Units [Line Items]
Share price			15.60
Applicable Market Value is less than $13.00 per share [Member]
Tangible Equity Units [Line Items]
Share price			13
Conversion to shares			$ 3.8461
Tangible Equity Units [Member]
Tangible Equity Units [Line Items]
Tangible equity unit offering	5,750,000	5,750,000	5,750,000
Total proceeds, net of issuance costs	$ 278,875	$ 278,875	$ 278,875
TEU price per share		$ 50	$ 50
Initial principal amount			$ 8.2378
Tangible Equity Units [Member] | Applicable Market Value is less than or equal to $15.60 per share but greater than or equal to $13.00 per share [Member] | Minimum [Member]
Tangible Equity Units [Line Items]
Share offering			18,429,325
Share price			$ 13
Tangible Equity Units [Member] | Applicable Market Value is less than or equal to $15.60 per share but greater than or equal to $13.00 per share [Member] | Maximum [Member]
Tangible Equity Units [Line Items]
Share price			$ 15.60

Tangible Equity Units (Schedule

Tangible Equity Units (Schedule of Aggregate Values Assigned upon Issuance of Tangible Equity Units) (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 01, 2019	Jul. 31, 2019	Mar. 31, 2020
Tangible Equity Units [Line Items]
Equity Component, Net proceeds			$ 232,929
Debt Component, Gross proceeds			$ 47,367
Tangible Equity Units [Member]
Tangible Equity Units [Line Items]
Equity Component, Price per TEU			$ 41.7622
Equity Component, Gross proceeds			$ 240,133
Equity Component, Issuance costs			(7,204)
Equity Component, Net proceeds			$ 232,929
Debt Component, Price per TEU			$ 8.2378
Debt Component, Gross proceeds			$ 47,367
Debt Component, Issuance costs			(1,421)
Debt Component, Net proceeds			$ 45,946
Total, Price per share		$ 50	$ 50
Total, Gross proceeds			$ 287,500
Total, Issuance costs			(8,625)
Total, Net proceeds	$ 278,875	$ 278,875	$ 278,875

Tangible Equity Units (Schedu_2

Tangible Equity Units (Schedule of Tangible Equity Units Activity) (Details) - Tangible Equity Units [Member] - shares	Jul. 01, 2019	Jul. 31, 2019	Mar. 31, 2020
Tangible Equity Units [Line Items]
Outstanding at beginning of year
Issued	5,750,000	5,750,000	5,750,000
Conversions			(612,655)
Outstanding at end of year			5,137,345

Net Income (Loss) Per Share (Co

Net Income (Loss) Per Share (Computation of Basic Net Income (Loss) Per Share of Common Stock) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Basic net income (loss) per share:
Net income (loss)	$ (866,881)	$ 50,735	$ (93,935)	$ (37,517)	$ 48,480	$ (12,388)	$ (18,591)	$ (17,501)	$ (947,597)	$ (52,012)	$ 60,955
Weighted average common shares outstanding									123,387,547	75,513,130	75,590,613
Minimum shares issuable under purchase contracts									13,609,077
Total weighted average common shares outstanding, basic									136,996,624	75,513,130	75,590,613
Basic net income (loss) per share	$ (4.65)	$ 0.35	$ (0.66)	$ (0.50)	$ (0.05)	$ (0.16)	$ (0.25)	$ (0.23)	$ (6.92)	$ (0.69)	$ 0.81
Diluted net income per share:
Net income (loss)	$ (866,881)	$ 50,735	$ (93,935)	$ (37,517)	$ 48,480	$ (12,388)	$ (18,591)	$ (17,501)	$ (947,597)	$ (52,012)	$ 60,955
Number of shares used in basic computation									136,996,624	75,513,130	75,590,613
Total weighted average common shares outstanding, diluted									136,996,624	75,513,130	77,801,096
Diluted net income (loss) per share	$ (4.65)	$ 0.35	$ (0.66)	$ (0.50)	$ (0.05)	$ (0.16)	$ (0.25)	$ (0.23)	$ (6.92)	$ (0.69)	$ 0.78
Time-Vesting Options [Member]
Diluted net income per share:
Weighted average effect of dilutive securities											2,051,346
Restricted Stock Units (RSUs) [Member]
Diluted net income per share:
Weighted average effect of dilutive securities											159,137

Net Income (Loss) Per Share (An

Net Income (Loss) Per Share (Antidilutive Securities Excluded from Diluted Net Income (Loss) Per Share) (Details) - shares	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Purchase Contracts [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net income (loss) per share	1,829,437
Time-Vesting Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net income (loss) per share	1,259,594	1,869,456	4,570,624
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net income (loss) per share	1,345,211
Deferred Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net income (loss) per share	20,371

Incentive Compensation Plans (N

Incentive Compensation Plans (Narrative) (Details)	12 Months Ended
	Mar. 31, 2020USD ($)itemshares	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)
Legacy CHC Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance | shares	37,900,000
Expected time period to repurchase shares from stock held by Joint Venture	6 months
Liquidity event, percentage threshold of shares sold	25.00%
Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance | shares	25,000,000
Granted in period | shares	1
Compensation expense	$ 1,701,000
Unrecognized compensation expense	$ 89,182,000
Time-Vesting Options [Member] | Legacy CHC Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of tranches | item	4
Unrecognized compensation expense	$ 3,611,000
Unrecognized compensation expense period for recognition	1 year 3 months 18 days
Time-Vesting Options [Member] | Legacy CHC Equity Plan [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of awards liquidated for cash	54.40%
Percentage of awards exchanged for vested options	45.60%
Awards received as, exercise price equal to percentage of fair value, percentage	25.00%
Vesting percentage	25.00%
Time-Vesting Options [Member] | Legacy CHC Equity Plan [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	25.00%
Time-Vesting Options [Member] | Legacy CHC Equity Plan [Member] | Share-based Payment Arrangement, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	25.00%
Time-Vesting Options [Member] | Legacy CHC Equity Plan [Member] | Share-based Payment Arrangement, Tranche Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	25.00%
Exit-Vesting Options [Member] | Legacy CHC Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of awards liquidated for cash	54.40%
Percentage of awards exchanged for vested options	45.60%
Awards received as, exercise price equal to percentage of fair value, percentage	25.00%
Number of tranches | item	3
Compensation expense		$ 0
Restricted Stock Units (RSUs) [Member] | Legacy CHC Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of awards liquidated for cash	54.40%
Fair value of shares vested	$ 0	$ 0	$ 1,440,000
Restricted Stock Units (RSUs) [Member] | Omnibus Incentive Plan [Member] | Graded Vesting Schedule [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Restricted Stock Units (RSUs) [Member] | Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Stock Units PSU [Member] | Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of tranches | item	2
Performance Stock Units PSU [Member] | Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Cash Settled Restricted Stock Units CSRSU [Member] | Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Deferred Stock Units DSU [Member] | Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Vesting percentage	100.00%
Joint Venture [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense	$ 0
Minimum [Member] | Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Minimum [Member] | Restricted Stock Units (RSUs) [Member] | Omnibus Incentive Plan [Member] | Cliff Vesting Schedule [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Maximum [Member] | Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Maximum [Member] | Restricted Stock Units (RSUs) [Member] | Omnibus Incentive Plan [Member] | Cliff Vesting Schedule [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Blackstone [Member] | Joint Venture [Member] | Exit-Vesting Options [Member] | Legacy CHC Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Liquidity event, percentage threshold of shares sold	25.00%
McKesson Corporation [Member] | Joint Venture [Member] | Exit-Vesting Options [Member] | Legacy CHC Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Liquidity event, percentage threshold of shares sold	50.00%
Blackstone And McKesson [Member] | Joint Venture [Member] | Exit-Vesting Options [Member] | Legacy CHC Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Liquidity event, percentage threshold of shares sold	25.00%

Incentive Compensation Plans (S

Incentive Compensation Plans (Schedule of Replacement Time-Vesting Option Activity) (Details) - Replacement Time-Vesting Options [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at April 1, 2019	4,529,291
Exercised	(708,969)
Forfeited	(361,578)
Outstanding at March 31, 2020	3,458,744	4,529,291
Exercisable at March 31, 2020	3,458,744
Weighted Average Exercise Price, Outstanding at April 1, 2019	$ 11.76
Weighted Average Exercise Price, Exercised	15.66
Weighted Average Exercise Price, Outstanding at March 31, 2020	11.95	$ 11.76
Weighted Average Exercise Price, Exercisable at March 31, 2020	$ 11.95
Weighted Average Remaining Contractual Term, Outstanding	3 years 3 months 18 days	4 years 4 months 24 days
Weighted Average Remaining Contractual Term, Exercisable at March 31, 2020	3 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding at April 1, 2019	$ 39,896
Aggregate Intrinsic Value, Exercised	5,077
Aggregate Intrinsic Value, Forfeited	74
Aggregate Intrinsic Value, Outstanding at March 31, 2020	4,083	$ 39,896
Aggregate Intrinsic Value, Exercisable at March 31, 2020	$ 4,083

Incentive Compensation Plans _2

Incentive Compensation Plans (Schedule of Replacement Exit-Vesting Restricted Stock Activity) (Details) - Replacement Exit-Vesting Restricted Stock [Member]	12 Months Ended
	Mar. 31, 2020shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at April 1, 2019	1,261,599
Canceled	(255,881)
Unvested at March 31, 2020	1,005,718

Incentive Compensation Plans _3

Incentive Compensation Plans (Summary of Time-Vesting amd Exit-Vesting Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Time-Vesting Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at April 1, 2019	6,988,403
Forfeited	(1,256,156)
Outstanding at March 31, 2020	5,732,247	6,988,403
Exercisable at March 31, 2020	3,743,688
Weighted Average Exercise Price, Outstanding at April 1, 2019	$ 18.99
Weighted Average Exercise Price, Forfeited	18.99
Weighted Average Exercise Price, Outstanding at March 31, 2020	18.99	$ 18.99
Weighted Average Exercise Price, Exercisable at March 31, 2020	$ 18.99
Weighted Average Remaining Contractual Term, Outstanding	7 years 7 months 6 days	8 years
Weighted Average Remaining Contractual Term, Exercisable at March 31, 2020	7 years 6 months
Aggregate Intrinsic Value, Outstanding at April 1, 2019	$ 11,058
Aggregate Intrinsic Value, Outstanding at March 31, 2020		$ 11,058
Exit-Vesting Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at April 1, 2019	6,504,544
Forfeited	(1,250,440)
Outstanding at March 31, 2020	5,254,104	6,504,544
Weighted Average Exercise Price, Outstanding at April 1, 2019	$ 18.99
Weighted Average Exercise Price, Forfeited	18.99
Weighted Average Exercise Price, Outstanding at March 31, 2020	$ 18.99	$ 18.99
Weighted Average Remaining Contractual Term, Outstanding	7 years 7 months 6 days	8 years
Aggregate Intrinsic Value, Outstanding at April 1, 2019	$ 10,292
Aggregate Intrinsic Value, Outstanding at March 31, 2020		$ 10,292

Incentive Compensation Plans _4

Incentive Compensation Plans (Summary of Valuation Assumptiona) (Details) - $ / shares	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Time-Vesting Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value	$ 2.10	$ 9.78
Expected volatility	52.00%	52.50%
Risk-free interest rate	0.30%	2.20%
Expected term (years)	3 years 9 months 18 days	4 years 6 months
Exit-Vesting Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value	$ 0.08	$ 5.90
Expected volatility	50.90%	52.90%
Risk-free interest rate	0.30%	2.20%
Expected term (years)	4 years 1 month 6 days	5 years 1 month 6 days
Replacement Exit-Vesting Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value	$ 2.15	$ 12.80
Expected volatility	76.90%	62.20%
Risk-free interest rate	0.90%	2.30%
Expected term (years)	10 months 24 days	1 year 10 months 24 days

Incentive Compensation Plans _5

Incentive Compensation Plans (Schedule of Omnibus Incentive Plan Activity) (Details)	12 Months Ended
	Mar. 31, 2020shares
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	4,846,058
Canceled	(377,969)
Outstanding at March 31, 2020	4,468,089
Deferred Stock Units DSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	45,704
Outstanding at March 31, 2020	45,704
Cash Settled Restricted Stock Units CSRSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	597,006
Canceled	(119,445)
Outstanding at March 31, 2020	477,561
Performance Stock Units PSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	1,079,621
Canceled	(113,932)
Outstanding at March 31, 2020	965,689

Retirement Plans and Other Po_3

Retirement Plans and Other Postretirement Benefits (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Post-Employment Benefits [Member]
Defined Contribution Plan Disclosure [Line Items]
Benefit obligation	$ 5,927	$ 0

Retirement Plans and Other Po_4

Retirement Plans and Other Postretirement Benefits (Summary of Liabilities Related to Deferred Compensation Plan) (Details) $ in Thousands	Mar. 31, 2020USD ($)
Retirement Plans and Other Postretirement Benefits[Abstract]
Accrued expenses	$ 1,772
Other long-term liabilities	15,880
Total deferred compensation	$ 17,652

Tax Receivable Agreements (Narr

Tax Receivable Agreements (Narrative) (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2020USD ($)
Tax Receivable Agreements 2009-2011 [Member]
Related Party Transaction [Line Items]
Net cash tax savings, percentage payment provided by agreement	85.00%
Tax Receivable Agreement 2017 [Member]
Related Party Transaction [Line Items]
Net cash tax savings, percentage payment provided by agreement	85.00%
McKesson Tax Receivable Agreement [Member]
Related Party Transaction [Line Items]
Net cash tax savings, percentage payment provided by agreement	85.00%
Loss contingecy	$ 164,633
McKesson Tax Receivable Agreement [Member] | Joint Venture [Member]
Related Party Transaction [Line Items]
Maximum percentage ownership allowed to receive net cash tax savings payment	20.00%

Tax Receivable Agreements (Aggr

Tax Receivable Agreements (Aggregate Payments Due Under Tax Receivable Agreements (Details) $ in Thousands	Mar. 31, 2020USD ($)
Related Party Transaction [Line Items]
2021	$ 20,234
2022	22,394
2023	67,468
2024	45,909
2025	26,358
Thereafter	132,421
Gross expected payments	314,784
Less: Amounts representing discount	(116,724)
Total tax receivable agreement obligations due to related parties	198,060
Less: Current portion due	(20,234)
Tax receivable agreement long-term obligations due to related parties	177,826
Tax Receivable Agreements 2009-2011 [Member]
Related Party Transaction [Line Items]
2021	18,714
2022	20,113
2023	20,084
2024	19,358
2025	17,917
Thereafter	102,942
Gross expected payments	199,128
Less: Amounts representing discount	(55,945)
Total tax receivable agreement obligations due to related parties	143,183
Less: Current portion due	(18,714)
Tax receivable agreement long-term obligations due to related parties	124,469
Tax Receivable Agreement 2017 [Member]
Related Party Transaction [Line Items]
2021	1,520
2022	2,281
2023	47,384
2024	26,551
2025	8,441
Thereafter	29,479
Gross expected payments	115,656
Less: Amounts representing discount	(60,779)
Total tax receivable agreement obligations due to related parties	54,877
Less: Current portion due	(1,520)
Tax receivable agreement long-term obligations due to related parties	$ 53,357

Tax Receivable Agreements (Ag_2

Tax Receivable Agreements (Aggregate Payments Due Under Tax Receivable Agreements - McKesson Tax Receivable Agreement) (Details) $ in Thousands	Mar. 31, 2020USD ($)
Related Party Transaction [Line Items]
2021	$ 20,234
2022	22,394
2023	67,468
2024	45,909
2025	26,358
Thereafter	132,421
Gross expected payments	314,784
Less: Amounts representing discount	(116,724)
Total tax receivable agreement obligations due to related parties	198,060
Less: Current portion due	(20,234)
Tax receivable agreement long-term obligations due to related parties	177,826
McKesson Tax Receivable Agreement [Member]
Related Party Transaction [Line Items]
2021
2022	128
2023	18,306
2024	19,905
2025	23,150
Thereafter	103,144
Gross expected payments	164,633
Less: Amounts representing discount
Total tax receivable agreement obligations due to related parties	164,633
Less: Current portion due
Tax receivable agreement long-term obligations due to related parties	$ 164,633

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Income Taxes [Line Items]
Deferred tax liability	$ 615,904	$ 159,993
Valuation allowance	29,350
Reduction to income tax expense if benefits from net operating loss carryforwards are realized	26,403
Unrecognized tax benefits that would affect the effective tax rate	46,672
Interest and penalties	138	$ 0	$ 0
Accelerated receipt of AMT credit refund amount	869
Residual Deferred Tax Asset [Member]
Income Taxes [Line Items]
Valuation allowance	12,701
Federal [Member]
Income Taxes [Line Items]
Operating loss carryforwards	1,174,862
Federal [Member] | Research and Development Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Tax credit carryforwards	16,302
State [Member]
Income Taxes [Line Items]
Operating loss carryforwards	1,833,161
State [Member] | Research and Development Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Tax credit carryforwards	413
State [Member] | Research and Development Tax Credit Carryforward [Member] | Indefinite Carryforward [Member]
Income Taxes [Line Items]
Tax credit carryforwards	116
State [Member] | Research and Development Tax Credit Carryforward [Member] | Expire from 2033 through 2034 [Member]
Income Taxes [Line Items]
Tax credit carryforwards	197
Foreign [Member]
Income Taxes [Line Items]
Operating loss carryforwards	15,260
State and Foreign [Member]
Income Taxes [Line Items]
Valuation allowance	17,279
Accounting Standards Update 2017-01 [Member]
Income Taxes [Line Items]
Deferred tax liability	$ (28,576)
Minimum [Member] | Federal [Member]
Income Taxes [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2026
Minimum [Member] | Federal [Member] | Research and Development Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Tax credit carryforwards, expiration date	Dec. 31, 2038
Minimum [Member] | State [Member]
Income Taxes [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2020
Minimum [Member] | State [Member] | Research and Development Tax Credit Carryforward [Member] | Expire from 2033 through 2034 [Member]
Income Taxes [Line Items]
Tax credit carryforwards, expiration date	Dec. 31, 2033
Minimum [Member] | Foreign [Member]
Income Taxes [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2028
Maximum [Member] | Federal [Member]
Income Taxes [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2040
Maximum [Member] | Federal [Member] | Research and Development Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Tax credit carryforwards, expiration date	Dec. 31, 2040
Maximum [Member] | State [Member]
Income Taxes [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2040
Maximum [Member] | State [Member] | Research and Development Tax Credit Carryforward [Member] | Expire from 2033 through 2034 [Member]
Income Taxes [Line Items]
Tax credit carryforwards, expiration date	Dec. 31, 2035
Maximum [Member] | Foreign [Member]
Income Taxes [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2037

Income Taxes (Schedule of Compo

Income Taxes (Schedule of Components of Income Tax Expense (Benefit)) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Current:
Federal
State	568
Current income tax provision (benefit)	568
Deferred:
Federal	(113,523)	(15,468)	(116,563)
State	(30,299)	(3,127)	(3,058)
Deferred income tax provision (benefit)	(143,822)	(18,595)	(119,621)
Total income tax provision (benefit)	$ (143,254)	$ (18,595)	$ (119,621)

Income Taxes (Schedule of Effec

Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Income Taxes [Abstract]
Statutory U.S. federal tax rate	21.00%	21.00%	31.50%
State income taxes (net of federal benefit)	2.10%	3.50%	3.60%
Remeasurement of deferred tax assets and liabilities arising from the Tax Legislation			166.90%
Change in fair value of equity based awards	(1.20%)	1.00%
Look through accounting policy election	2.10%
Research and development credit	0.20%	1.60%	2.40%
Goodwill impairment charge	(10.80%)
Other	(0.30%)	(0.80%)	(0.50%)
Effective income tax rate	13.10%	26.30%	203.90%

Income Taxes (Schedule of Defer

Income Taxes (Schedule of Deferred Tax Assets (Liabilities)) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Income Taxes [Abstract]
Investment in the Joint Venture		$ (190,448)
Depreciation and amortization	$ (1,034,407)
Accounts receivable	5,793
Fair value of interest rate cap agreements	14,011
Accruals and reserves	15,680
Net operating losses	348,329	19,958
Debt discount and interest	(9,661)
Equity compensation	18,560
Valuation allowance	(29,350)
Tax receivable agreements obligation to related parties	68,900
163(j) Business interest expense limitation	23,842	7,711
Tax credits	16,629	2,786
Accounting method change (ASC 606 adoption)	(31,886)
Residual deferred tax assets	12,072
Other	(3,696)
Net deferred tax assets (liabilities)	(585,184)	(159,993)
Reported as:
Non-current deferred tax assets	30,720
Non-current deferred tax liabilities	(615,904)	(159,993)
Net deferred tax assets (liabilities)	$ (585,184)	$ (159,993)

Income Taxes (Reconciliation of

Income Taxes (Reconciliation of Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Taxes [Abstract]
Beginning unrecognized benefit	$ 863
Decreases from prior period tax positions	(2)
Increases from prior period tax positions		432
Increases from current period tax positions	769	431
Increases from acquisition	54,547
Ending unrecognized benefit	$ 56,177	$ 863

Commitments (Narrative) (Detail

Commitments (Narrative) (Details) $ in Thousands	1 Months Ended		12 Months Ended
	Mar. 31, 2020USD ($)	Feb. 28, 2018USD ($)item	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)
Commitments [Line Items]
Rent expense			$ 3,048	$ 0	$ 0
Master Services Agreement [Member]
Commitments [Line Items]
Commitment term		10 years
Number of agreement renewal options | item		3
Renewal option term		1 year
Percentage shortfall required if minimum commitment not met		25.00%
Purchase commitment amount		$ 1,000,000
Minimum [Member] | Master Services Agreement [Member]
Commitments [Line Items]
Purchase commitment amount	$ 975,000
Maximum [Member]
Commitments [Line Items]
Lease expiration			Dec. 31, 2029
Joint Venture [Member] | Master Services Agreement [Member]
Commitments [Line Items]
Commitment term		10 years

Commitments (Schedule of Future

Commitments (Schedule of Future Minimum Commitments) (Details) $ in Thousands	Mar. 31, 2020USD ($)
Commitments [Abstract]
Operating lease obligations	$ 141,010
Operating lease obligations, 2021	40,476
Operating lease obligations, 2022	34,750
Operating lease obligations, 2023	23,761
Operating lease obligations, 2024	15,393
Operating lease obligations, 2025	10,780
Operating lease obligations, Thereafter	15,850
Contingent consideration obligation	3,000
Contingent consideration obligation, 2021	3,000
Contingent consideration obligation, 2022
Contingent consideration obligation, 2023
Contingent consideration obligation, 2024
Contingent consideration obligation, 2025
Contingent consideration obligation, Thereafter
Purchase obligations and other	1,162,529
Purchase obligations and other, 2021	126,900
Purchase obligations and other, 2022	174,516
Purchase obligations and other, 2023	174,516
Purchase obligations and other, 2024	173,805
Purchase obligations and other, 2025	173,805
Purchase obligations and other, Thereafter	338,987
Total contractual obligations	1,306,539
Total contractual obligations, 2021	170,376
Total contractual obligations, 2022	209,266
Total contractual obligations, 2023	198,277
Total contractual obligations, 2024	189,198
Total contractual obligations, 2025	184,585
Total contractual obligations, Thereafter	354,837
Future minimum sublease receivable	$ 1,562

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details)	Jun. 26, 2019item$ / sharesshares	Mar. 31, 2020$ / sharesshares	Mar. 10, 2020$ / shares	Mar. 31, 2019$ / sharesshares
Class of Stock [Line Items]
Common Stock, shares authorized	9,000,000,001
Common Stock, par value | $ / shares	$ 0.001		$ 0.001
Common Class X [Member]
Class of Stock [Line Items]
Common Stock, shares authorized	1	0		1
Common Stock, par value | $ / shares	$ 0.001	$ 0.001		$ 0.001
Common Stock, shares outstanding		0		0
Common Stock [Member]
Class of Stock [Line Items]
Common Stock, shares authorized	9,000,000,000	9,000,000,000		252,800,000
Common Stock, par value | $ / shares	$ 0.001	$ 0.001		$ 0.001
Voting right of common stock share holdes, number of votes | item	1
Common Stock, shares outstanding		303,428,142		75,474,654

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2020USD ($)$ / sharesitem	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)
Related Party Transaction [Line Items]
Advances from related party	$ 625		$ 15,828
Repayment of advances to related party		$ 9,869
Ratio of Company outstanding shares to units of Joint Venture held by Company | item	1
Letter Agreement [Member]
Related Party Transaction [Line Items]
Net cash tax savings, percentage payment provided by agreement	100.00%
Letter Agreement [Member] | McKesson Corporation [Member]
Related Party Transaction [Line Items]
Maximum percentage ownership allowed to receive net cash tax savings payment	20.00%
Option Agreement [Member[
Related Party Transaction [Line Items]
Option exercise price | $ / shares	$ 1
Option Agreement [Member[ | McKesson Corporation [Member]
Related Party Transaction [Line Items]
Maximum percentage of ownership in the outstanding units of the Joint Venture allowed for option to acquire can be exercised	5.00%

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended
	Dec. 31, 2018	Mar. 31, 2020	Mar. 31, 2019
Fair Value [Line Items]
Freestanding derivative		$ 0	$ 81,264
Health Care Company [Member]
Fair Value [Line Items]
Shares purchased	$ 15,000
Related Company [Member]
Fair Value [Line Items]
Shares purchased	$ 500

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Mar. 31, 2019
Derivatives Fair Value [Line Items]
Interest rate cap agreements	$ (47,408)
Contingent consideration obligation	(3,000)
Freestanding derivative	0	$ 81,264
Total	(50,408)	81,264
Significant Other Observable Inputs (Level 2)
Derivatives Fair Value [Line Items]
Interest rate cap agreements	(47,408)
Total	(47,408)
Significant Unobservable Inputs (Level 3)
Derivatives Fair Value [Line Items]
Contingent consideration obligation	(3,000)
Freestanding derivative		81,264
Total	$ (3,000)	$ 81,264

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation of Fair Value Derivative Using Unobservable Inputs) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Fair Value Measurements [Abstract]
Balance at beginning of period	$ 81,264	$ 59,116
Increase in fair value based on ASC 505 equity-based compensation		20,135
Settlements due to exercise of awards	(5,077)	(1,297)
Change in fair value of equity-based awards	(33,409)	3,310
Settlement as component of Merger purchase price	(42,778)
Balance at end of period		$ 81,264

Fair Value Measurements (Carryi

Fair Value Measurements (Carrying Amount and Estimated Fair Value of Financial Instruments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Carrying [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	$ 410,405	$ 3,409
Accounts receivable	740,105
Investment in business purchase option	146,500
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	410,405	$ 3,409
Accounts receivable	740,105
Investment in business purchase option	146,500
Senior Notes due March 1, 2025 [Member] | Significant Other Observable Inputs (Level 2) | Carrying [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	997,772
Senior Notes due March 1, 2025 [Member] | Significant Other Observable Inputs (Level 2) | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	950,000
Senior Amortizing Notes due June 30, 2022 [Member] | Significant Other Observable Inputs (Level 2) | Carrying [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt component of tangible equity units	35,431
Senior Amortizing Notes due June 30, 2022 [Member] | Significant Other Observable Inputs (Level 2) | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt component of tangible equity units	34,806
Senior Credit Facilities [Member] | Significant Other Observable Inputs (Level 2) | Carrying [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	3,682,457
Senior Credit Facilities [Member] | Significant Other Observable Inputs (Level 2) | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	$ 3,452,687

Segment Reporting (Narrative) (

Segment Reporting (Narrative) (Details)	12 Months Ended
	Mar. 31, 2021segment	Mar. 31, 2020item
Number of reportable segments | item		3
Forecast [Member]
Number of reportable segments | segment	3

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Summary Of Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	$ 1,132,487	$ 1,176,572	$ 1,088,240
Unrealized gain (loss) on available for sale debt securities of the Joint Venture	1,045
Realized gain (loss) on available for sale debt securities of the Joint Venture	(1,045)
Change associated with foreign currency translation	(5,519)	(2,833)	1,242
Balance	3,285,447	1,132,487	1,176,572
Change associated with current period hedging, tax	607	2,139	623
Available For Sale Debt Security [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance
Unrealized gain (loss) on available for sale debt securities of the Joint Venture	1,045
Realized gain (loss) on available for sale debt securities of the Joint Venture	(1,045)
Change associated with foreign currency translation
Change associated with current period hedging
Reclassification into earnings
Balance
Foreign Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	(1,565)	1,268	26
Unrealized gain (loss) on available for sale debt securities of the Joint Venture
Realized gain (loss) on available for sale debt securities of the Joint Venture
Change associated with foreign currency translation	(5,519)	(2,833)	1,242
Change associated with current period hedging
Reclassification into earnings
Balance	(7,084)	(1,565)	1,268
Cash Flow Hedge [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	(1,691)	1,268	(338)
Unrealized gain (loss) on available for sale debt securities of the Joint Venture
Realized gain (loss) on available for sale debt securities of the Joint Venture
Change associated with foreign currency translation
Change associated with current period hedging	981	(1,671)	1,267
Reclassification into earnings		(1,778)	339
Balance	(288)	(1,691)	1,268
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	(3,256)	2,536	(312)
Unrealized gain (loss) on available for sale debt securities of the Joint Venture	1,045
Realized gain (loss) on available for sale debt securities of the Joint Venture	(1,045)
Change associated with foreign currency translation	(5,519)	(2,833)	1,242
Change associated with current period hedging	981	(1,671)	1,267
Reclassification into earnings		(1,778)	339
Balance	(7,372)	(3,256)	$ 2,536
ASU 2017-12 [Member] | Available For Sale Debt Security [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Cumulative effect of accounting change by the Joint Venture
ASU 2017-12 [Member] | Foreign Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Cumulative effect of accounting change by the Joint Venture
ASU 2017-12 [Member] | Cash Flow Hedge [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Cumulative effect of accounting change by the Joint Venture		490
ASU 2017-12 [Member] | Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Cumulative effect of accounting change by the Joint Venture		$ 490
ASU 2018-02 [Member] | Available For Sale Debt Security [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Cumulative effect of accounting change by the Joint Venture
ASU 2018-02 [Member] | Foreign Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Cumulative effect of accounting change by the Joint Venture
ASU 2018-02 [Member] | Cash Flow Hedge [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Cumulative effect of accounting change by the Joint Venture	422
ASU 2018-02 [Member] | Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Cumulative effect of accounting change by the Joint Venture	$ 422

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) - USD ($)	Jun. 01, 2020	May 01, 2020	Apr. 21, 2020	Mar. 10, 2020	Feb. 28, 2017
Subsequent Event [Line Items]
Purchace price				$ 4,035,743,000
Senior Notes [Member]
Subsequent Event [Line Items]
Debt instrument, face amount					$ 1,000,000,000
Stated interest rate					5.75%
Subsequent Event [Member] | Connected Analytics [Member]
Subsequent Event [Line Items]
Consideration		$ 55,000,000
Subsequent Event [Member] | eRx Network [Member]
Subsequent Event [Line Items]
Ownership interest purchased		100.00%
Purchace price		$ 212,900,000
Subsequent Event [Member] | PDX, Inc. [Member]
Subsequent Event [Line Items]
Ownership interest purchased	100.00%
Purchace price	$ 208,000,000
Subsequent Event [Member] | Unsecured Senior Notes Due 2025 [Member]
Subsequent Event [Line Items]
Debt instrument, face amount			$ 325,000,000
Stated interest rate			5.75%
Percentage of debt principal amount			100.00%
Maturity date			Dec. 31, 2025
Subsequent Event [Member] | Seller Note [Member] | Connected Analytics [Member]
Subsequent Event [Line Items]
Debt instrument, face amount		$ 25,000,000

Quarterly Financial Informati_3

Quarterly Financial Information (Schedule of Quarterly Financial Information) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Quarterly Financial Information [Abstract]
Total revenue	$ 196,792								$ 196,792
Income (loss) before income taxes	(1,009,571)	65,975	(107,555)	(39,701)	65,144	(17,468)	(25,374)	(22,302)	(1,090,851)	$ (70,607)	$ (58,666)
Net income (loss)	$ (866,881)	$ 50,735	$ (93,935)	$ (37,517)	$ 48,480	$ (12,388)	$ (18,591)	$ (17,501)	$ (947,597)	$ (52,012)	$ 60,955
Basic net income (loss) per share	$ (4.65)	$ 0.35	$ (0.66)	$ (0.50)	$ (0.05)	$ (0.16)	$ (0.25)	$ (0.23)	$ (6.92)	$ (0.69)	$ 0.81
Diluted net income (loss) per share	$ (4.65)	$ 0.35	$ (0.66)	$ (0.50)	$ (0.05)	$ (0.16)	$ (0.25)	$ (0.23)	$ (6.92)	$ (0.69)	$ 0.78